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ABSTRACT
The P2X7 receptor is a ligand-gated cation channel, which is expressed on a variety of
cell types, including human B cells. P2X7 activation induces a variety of downstream
events, including the shedding of the immunoglobulin E receptor, CD23. Cell surface
CD23 and soluble CD23 are important in the regulation of immunoglobulin E.
Furthermore, soluble CD23 functions as a proinflammatory mediator. Thus it is
important to elucidate the mechanisms involved in CD23 shedding. A disintegrin and
metalloprotease (ADAM) 10 constitutively sheds CD23 from the surface of cells but
whether P2X7 activates ADAM10, or other signalling processes to mediate CD23
shedding are unknown. Our laboratory has shown that P2X7 is expressed on human
RPMI 8226 multiple myeloma B cells and that P2X7 activation on these cells induces
the shedding of CD23. The primary aims of this thesis were: to confirm the presence of
and to further characterise P2X7 in RPMI 8226 cells; to examine the signalling
pathways involved in P2X7-induced CD23 shedding using this cell line as a model; to
determine, using RPMI 8226 cells, whether ADAM10 is involved in P2X7-induced
CD23 shedding; and finally to determine whether P2X7 activation induces CD23
shedding from primary human and murine B cells.
Messenger RNA (mRNA) expression of molecules was detected by reverse
transcriptase-polymerase chain reaction. P2X7, CD23 and CXCL16 expression was
detected by immunolabelling and measured by flow cytometry. Nucleotide-induced
ethidium+

uptake

(pore

formation)

was

measured

by

flow

cytometry

or

spectrofluorometry. Soluble CD23 and CXCL16 were measured by enzyme-linked
immunosorbent assay. ATP-induced currents were measured by electrophysiology.
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RPMI 8226 cells were shown to express mRNA for P2X7 and other P2X subtypes
(P2X1, P2X4 and P2X5). Functional P2X7 was present on RPMI 8226 cells, and the
new generation P2X7 antagonist AZ10606120, near-completely impaired both
P2X7-induced pore formation and CD23 shedding in these cells. This data confirmed
that the RPMI 8226 cell line is an adequate model to investigate the molecules and
processes involved in P2X7-induced CD23 shedding.
Several signalling pathways involved in other P2X7-induced responses including
reactive oxygen species formation, as well as changes in intracellular cation
concentrations, were not involved in P2X7-induced CD23 shedding from RPMI 8226
cells. However, the phospholipase (PLD)1 antagonist, CAY10593 (VU0155069)
impaired P2X7-induced CD23 shedding from RPMI 8226 cells. CAY10593 also
impaired pore formation in RPMI 8226 cells, P2X7-transfected human embryonic
kidney 293 cells and peripheral blood mononuclear cells. CAY10593 impaired
P2X7-induced pore formation in RPMI 8226 cells more potently than the PLD2
antagonist CAY10594 and the non-specific PLD antagonist halopemide. CAY10593
also inhibited P2X7-mediated inward currents. Notably, PLD1 was absent in RPMI
8226 cells. This data indicates that CAY10593 impairs human P2X7 independently of
PLD1 stimulation and highlights the importance of ensuring that compounds used in
signalling studies downstream of P2X7 activation do not affect the receptor itself.
RPMI 8226 cells were shown to express mRNA for ADAM10. The ADAM10
antagonist, GI254023X significantly impaired P2X7-induced CD23 shedding from
RPMI 8226 cells. ATP treatment of RPMI 8226 cells induced the rapid shedding of
another ADAM10 substrate, CXCL16. The P2X7 antagonists, AZ10606120 and KN-62
near completely impaired ATP-induced CXCL16 shedding from RPMI 8226 cells and
treatment of these cells with GI254023X significantly impaired P2X7-induced CXCL16
xxi

shedding. This data indicates that human P2X7 activation induces the rapid shedding of
CD23 and CXCL16, and that these processes are mediated by ADAM10.
ATP treatment of primary human and murine B cells also induced the rapid shedding of
CD23. Treatment of cells with AZ10606120, near-completely impaired ATP-induced
CD23 shedding from both human and murine B cells. ATP-induced CD23 shedding
was also impaired in B cells from P2X7 knockout mice. GI254023X impaired
P2X7-induced CD23 shedding from both human and murine B cells. This data indicates
that P2X7 activation induces the rapid shedding of CD23 from primary human and
murine B cells, and that this process is also mediated by ADAM10.
Overall, this study shows, for the first time that ADAM10 mediates P2X7-induced
CD23 and CXCL16 shedding from RPMI 8226 cells, as well as CD23 shedding from
primary human and murine B cells. Moreover, this study excludes a potential role for
various signalling molecules, including reactive oxygen species formation and the flux
of various cations in P2X7-induced CD23 shedding. Finally, this study shows that the
PLD1 antagonist, CAY10593, impairs P2X7 independently of PLD1.
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CHAPTER 1
Introduction
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1.1 CD23

1.1.1 Structure and features
CD23 is a 45 kDa, type II transmembrane glycoprotein that is composed of 321 amino
acids (Ludin et al. 1987, Suter et al. 1987). The glycoprotein consists of a large, C-type
lectin head domain that participates in immunoglobulin (Ig)E binding, followed by a
stalk region, which is important in CD23 oligomerisation, and a short N-terminal
cytoplasmic domain (Rosenwasser and Meng 2005, Acharya et al. 2010) (Figure 1.1).

Figure 1.1: The structure of membrane-bound CD23. Each CD23 molecule consists
of a C-type lectin head that binds immunoglobulin IgE and a coiled stalk region that
participates in CD23 oligomerisation to form trimeric CD23 at the cell surface. Adapted
from Gould and Sutton 2008.
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CD23 is often referred to as the low affinity IgE receptor (FcεRII) as it binds its main
ligand, IgE at a lower affinity compared to the high affinity IgE receptor (FcεRI)
(Rosenwasser and Meng 2005, Acharya et al. 2010). Two isoforms of CD23 have been
identified, CD23a and CD23b; these differ between species (human and murine), and in
tissue specific gene expression and regulation (Yokota et al. 1988). CD23a is expressed
constitutively in primary B cells and B cell lines (Yokota et al. 1988), whereas CD23b
is induced in various cell types and may be upregulated during viral infection (Wang et
al. 1991), and following stimulation by interleukin (IL)-4 (Defrance et al. 1987, Vercelli
et al. 1988, Yokota et al. 1988) and engagement of the co-stimulatory molecule CD40
on B cells (Gordon et al. 1991). These isoforms share a common C-terminal region, but
contain 6-7 differing amino acids in their N-terminal cytoplasmic domains in both
humans and mice, and are associated with different signalling pathways and
downstream effects in cells (Rosenwasser and Meng 2005, Acharya et al. 2010).

1.1.2 Distribution
CD23 is expressed on many cell types including B cells (Kikutani et al. 1989), T cells
(Armitage et al. 1989), monocytes and macrophages (Vercelli et al. 1988), neutrophils
(Yamaoka et al. 1996), eosinophils (Chihara et al. 1992), platelets (Klouche et al. 1997),
epidermal Langerhans cells (Bieber et al. 1989), follicular dendritic cells (Rieber et al.
1993), keratinocytes (Becherel et al. 1997), intestinal epithelial cells (Yu et al. 2003),
bone marrow stromal cells (Fourcade et al. 1992) and airway smooth muscle cells
(Hakonarson et al. 1999).
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1.1.3 Roles of membrane CD23
Membrane CD23 exists at the cell surface as a trimer (Kilmon et al. 2004) (Figure 1.1).
Its primary role as a membrane-bound receptor is negative feedback regulation of IgE
production (Yu et al. 1994, Cooper et al. 2012). In allergy, negative regulation of IgE
synthesis occurs by co-ligation of allergen-IgE complexes with IgE and CD23 on the
cell membrane (see review by Gould and Sutton 2008 for further detail). Membrane
CD23 is also mitogenic for normal B cells and B cell lines, which suggests CD23 may
be involved in autocrine control of B cell growth (Cairns and Gordon 1990).

Although IgE is the main ligand of membrane CD23, other ligands can also bind CD23,
including the complement receptor type 2 (CD21), major histocompatibility complex
(MHC) class II molecules and integrins. As membrane receptors, CD23 and CD21
interact to function as adhesion molecules in homotypic aggregation of human B cells
(Bjorck et al. 1993). In contrast to this, homotyptic aggregation of murine B cells is
independent of CD23 (Davey et al. 1995). Soluble CD21 also induces activation and
differentiation of human monocytes by binding membrane CD23 (Fremeaux-Bacchi et
al. 1998a). Furthermore, MHC II molecules can interact with the stalk region of CD23
(Kijimoto-Ochiai and Noguchi 2000), indicating CD23 functions as a co-stimulatory
adhesion molecule in antigen presentation by B cells (Flores-Romo et al. 1990).
Recombinant full-length CD23 incorporated into liposomes (Lecoanet-Henchoz et al.
1995) and a mouse CD23 fusion protein, ZZ-CD23 (Lecoanet-Henchoz et al. 1997)
interact with integrins αMβ2 (CD11b) and αXβ2 (CD11c) on human monocytes,
integrin-transfected COS-7 fibroblast-like cells (Lecoanet-Henchoz et al. 1995), murine
peritoneal macrophages and RAW264.7 macrophage cells (Lecoanet-Henchoz et al.
4

1997). This interaction is thought to regulate monocyte/macrophage activation
(Lecoanet-Henchoz et al. 1995, Lecoanet-Henchoz et al. 1997). Interactions of the
above ligands with soluble CD23 are also discussed in section 1.1.4.3.

1.1.4 Generation and roles of soluble CD23

1.1.4.1 Shedding of membrane CD23
Membrane CD23 is sensitive to proteolytic shedding that is mediated by membrane
metalloproteases of the a disintegrin and metalloprotease (ADAM) family (Weskamp et
al. 2006, Lemieux et al. 2007). After proteolytic cleavage, membrane CD23 may be
released from the cell as soluble CD23 into molecules of varying sizes including 37, 33,
25 (Letellier et al. 1990) and 16 kDa (Grenier-Brossette et al. 1992). ADAM10 is
thought to be the main metalloprotease responsible for constitutive CD23 shedding
(Weskamp et al. 2006, Lemieux et al. 2007) (Figure 1.2). Furthermore, murine B cells
lacking ADAM10 expression, display defective release of CD23 and a significant
reduction in soluble CD23 generation. This confirms ADAM10 is required for
constitutive CD23 cleavage in vivo (Gibb et al. 2010). It is thought that
ADAM-mediated cleavage occurs predominantly at the cell surface however, it has also
been shown that internalisation of membrane CD23 results in ADAM10-mediated
incorporation into exosomes, with cleavage occurring inside the exosome prior to
release of soluble CD23 from cells (Mathews et al. 2010). ADAM10 is also involved in
inducible

CD23

shedding,

including

phorbol-12-myristate-13-acetate

(PMA)-,
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Ca2+/ionomycin- (Weskamp et al. 2006, Le Gall et al. 2009) and lysophosphatidic acid(Lemieux et al. 2007) induced CD23 shedding.

Figure 1.2: Shedding of CD23. In the absence of IgE, ADAM10 cleaves CD23 and
releases soluble CD23 from the B cell membrane. From Gibb et al. 2010. Abbreviations:
IgE, Immunoglobulin E; sCD23, soluble CD23; ADAM10, a metalloprotease and disintegrin 10.

Several other ADAM members have been implicated in the release of CD23 from cells.
ADAM8, 15, and 28 have been associated with constitutive shedding of CD23 in
CD23-transfected, and ADAM and CD23 co-transfected human embryonic kidney
(HEK) 293 cells (Fourie et al. 2003). However, the involvement of these ADAMs has
been disputed with loss-of-function studies with ADAM-deficient cells, and
gain-of-function studies with overexpressed ADAMs failing to demonstrate
involvement of ADAM15 and ADAM28 (Weskamp et al. 2006). Furthermore, mice
lacking ADAM8 fail to show impaired CD23 shedding (Weskamp et al. 2006).
ADAM33 has also been implicated in CD23 shedding (Rosenwasser and Meng 2005),
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however the specific ADAM10 inhibitor GI254023X, impairs CD23 shedding in
primary B cells at a concentration that does not inhibit ADAM33 (Weskamp et al.
2006). Despite this, ADAM33 may play a minor role in this process in the absence of
ADAM10 (Weskamp et al. 2006). Matrix metalloprotease (MMP) 9, which is not an
ADAM family member, mediates Toll-like receptor-4-induced CD23 shedding in
human and murine lymphocytes (Jackson et al. 2009). However, the rate of shedding by
this mechanism is slower (Jackson et al. 2009) than that of other inducers of CD23
shedding (Weskamp et al. 2006, Lemieux et al. 2007, Le Gall et al. 2009).

1.1.4.2 Roles of soluble CD23 and IgE
Soluble CD23 binds IgE, acts as positive regulator of IgE synthesis and controls IgE
homeostasis (Cooper et al. 2012, Padro et al. 2013). In the soluble form, CD23 also
interacts with other ligands to induce biological effects, for example, soluble CD21 and
CD23 can form complexes, which inhibit soluble CD23-induced IgE synthesis in B
cells (Fremeaux-Bacchi et al. 1998b). The role of soluble CD23 and IgE production are
beyond the scope of this thesis but readers are referred to Gould and Sutton, (2008) for a
more extensive review.

1.1.4.3 Roles of soluble CD23 as a cytokine
Soluble CD23 has pleiotropic, cytokine-like effects on monocytes, B cells and T cells
(summarised in Table 1.1). Soluble CD23 is an important regulator of monocytes, for
example recombinant soluble CD23 promotes the proliferation of myeloid precursors in
the presence of IL-1α (Mossalayi et al. 1990a) and interacts with integrins CD11b and
7

CD11c, triggering an increase in nitric oxide and hydrogen peroxide, and the production
of proinflammatory cytokines including IL-1β, IL-6 and tumor necrosis factor (TNF)-α
(Lecoanet-Henchoz et al. 1995). The ligation of CD11b and CD11c by soluble CD23
also induces secretion of IL-8, macrophage inflammatory protein-1α and macrophage
inflammatory protein-1β from monocytes (Rezzonico et al. 2001). Secretion of
macrophage inflammatory proteins from monocytes may play an important role in the
recruitment of other cells that participate in the inflammatory response (Rezzonico et al.
2001).
Table 1.1: Biological effects of soluble CD23 on immune cells.

Cell Type

Biological Effect

Reference

Promotes differentiation of
myeloid cell precursors in the
presence of IL-1α

(Mossalayi et al. 1990a)

Drives cytokine release from
monocytes

(Hermann et al. 1999)
(Lecoanet-Henchoz et al. 1995)
(Rezzonico et al. 2001)
(Armant et al. 1995)

Attenuates apoptosis of B cell
precursors

(White et al. 1997)

Sustains growth of B cell
precursors

(Borland et al. 2007)

Monocytes

B cells

Promotes differentiation of
germinal centre centroblasts into
plasma cells in the presence of
IL-1α

T cells

Promotes differentiation in the
presence of IL-1α

(Liu et al. 1991)

(Mossalayi et al. 1990b)
(Bertho et al. 1991)

Abbreviations: IL, interleukin.
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Soluble CD23 also induces human monocytes to stimulate resting T cells, therefore
soluble CD23, when produced locally at a site of an immune response, may trigger an
inflammatory response via cytokine release and further amplify it via the stimulation of
non-antigen-specific T cells (Armant et al. 1995). Monocytes activated by soluble CD23
also express increased levels of molecules involved in B cell and T cell adhesion,
including the Toll-like receptor associated molecule CD14, the cell adhesion molecule
CD54, and the co-stimulatory molecules CD40, and CD80 (Armant et al. 1995).

Soluble CD23 promotes the survival of B cells (Liu et al. 1991, White et al. 1997) and
sustains the growth of human B cell precursors via interaction with the αVβ5 integrin
(Borland et al. 2007). The αVβ3 integrin or more commonly termed, vitronectin
receptor, and its associated protein CD47, may also function as a receptor for soluble
CD23 (Hermann et al. 1999). This interaction mediates proinflammatory cytokine
synthesis and may contribute to inflammatory processes involved in chronic disorders
such as rheumatoid arthritis (Hermann et al. 1999). In the presence of IL-1α, soluble
CD23 also promotes the differentiation of B cells (Liu et al. 1991) and T cells
(Mossalayi et al. 1990b, Bertho et al. 1991).

1.1.5 Soluble CD23 in disease
It is well-established that soluble CD23 plays a pivotal role in allergy and allergic
reactions (Gould and Sutton 2008). However, soluble CD23 also plays a role in a
variety of other diseases including autoimmune and inflammatory disorders. Elevated
soluble CD23 has been detected in the serum and saliva of patients with primary
9

Sjogren’s syndrome (Bansal et al. 1992, Takei et al. 1995) and in the serum of patients
with systemic lupus erythematosus (Bansal et al. 1992). The elevated level of soluble
CD23 in saliva has also been correlated with active sialectasis in Sjogren’s syndrome
(Takei et al. 1995) indicating soluble CD23 contributes to the pathology of this disease.
Soluble CD23 is elevated in patients with adult rheumatoid arthritis, which correlates
with disease status (Bansal et al. 1994) and in juvenile chronic arthritis (Massa et al.
1998). However, it remains unclear how soluble CD23 contributes to pathology of these
diseases. Elevated soluble CD23 has also been detected in patients with B cell-derived
chronic lymphocytic leukaemia (CLL) (Sarfati et al. 1988) and is used to predict time to
treatment in CLL patients (Meuleman et al. 2008). In this regard, soluble CD23 is a
surrogate marker for total CLL cell numbers.

1.2 CXCL16

1.2.1 Structure and features
Chemokines are cytokines that can induce chemotaxis of cells, and may be loosely
categorised as bearing homeostatic or inflammatory functions (Le et al. 2004).
Homeostatic chemokines are constitutively expressed and are involved in lymphocyte
and dendritic cell trafficking, as well as tissue organogenesis (Le et al. 2004).
Inflammatory chemokines are upregulated by proinflammatory stimuli and participate
in the innate and adaptive immune responses (Le et al. 2004). Many chemokines are
further classified on the basis of the arrangement of cysteine residues in their N-terminal
region, yielding the CXC, CC, C or CX3C classes of chemokines (Le et al. 2004). The
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four different chemokine classes usually attract different types of leukocytes; CC
chemokines attract mononuclear cells, eosinophils and basophils. Glu-Leu-Arg motif
(ELR)-positive CXC chemokines attract neutrophils, while ELR motif-negative CXC
chemokines attract lymphocytes. C chemokines attract T cells and CX3C chemokines
attract T cells, natural killer cells and monocytes (Le et al. 2004). Most chemokines are
in soluble forms, however some, namely CXCL16 and CX3CL1 (fractalkine) are
associated with glucosaminoglycan moieties on the cell surface and can be released by
metalloprotease cleavage (see section 1.2.4).

CXCL16 is a ligand for the CXC-chemokine receptor CXCR6 (Bonzo) (Matloubian et
al. 2000) and has functional characteristics of CXC chemokines (Wilbanks et al. 2001).
The molecule is expressed on the cell membrane as a multidomain molecule
(Matloubian et al. 2000). CXCL16 is much like the CX3CL1 chemokine in structure
(White and Greaves 2012), consisting of a chemokine domain, a glycosylated mucinlike stalk, single transmembrane helix and a short cytoplasmic tail (Bazan et al. 1997,
Wilbanks et al. 2001) (Figure 1.3). The amino acid sequence suggests a molecular
weight of approximately 24 kDa for membrane CXCL16, however glycosylation of the
mucin stalk gives the full-length protein a molecular weight of 60 kDa (Matloubian et
al. 2000).

11

Figure 1.3: The structure of membrane-bound CXCL16. CXCL16 consists of a
chemokine domain, a mucin-like stalk and a short cytoplasmic tail. Adapted from White
and Greaves 2012.

1.2.2 Distribution of CXCL16
CXCL16 is expressed on the surface of antigen presenting cells including subsets of B
cells, and monocytes and macrophages (Wilbanks et al. 2001). CXCL16 is also
expressed on dendritic cells (Tabata et al. 2005), aortic smooth muscle cells
(Chandrasekar et al. 2004), astrocytes, microglia, and neurons (Rosito et al. 2012). After
cytokine stimulation, CXCL16 may be expressed on several other cell types.
Interferon-γ and TNF-α induce CXCL16 expression on endothelial cells, smooth muscle
cells, fibroblasts (Abel et al. 2004), astroglia and glioma cells (Ludwig et al. 2005b).
IL-8 also induces CXCL16 expression on aortic smooth muscle cells (Chandrasekar et
al. 2005).

12

1.2.3 Roles of membrane CXCL16
Membrane CXCL16 predominantly functions as an adhesion receptor for cells
expressing CXCR6 (Shimaoka et al. 2004). Treatment with the broad spectrum
metalloprotease inhibitor, GM6001 enhances the adhesion of CXCL16-transfected
COS-7 fibroblast-like cells to CXCR6-expressing T cells by increasing cell surface
expression of CXCL16, and decreasing soluble CXCL16 (Shimaoka et al. 2004) (see
also section 1.2.4.1). Besides possessing adhesion activity, membrane CXCL16
functions as a scavenger receptor that binds phosphatidylserine (PS) and oxidised low
density lipoprotein (Shimaoka et al. 2000). Membrane CXCL16 also mediates cell
adhesion and phagocytosis of bacteria, and therefore may facilitate the uptake of various
pathogens during infection (Shimaoka et al. 2003, Gursel et al. 2006).

1.2.4 Generation and roles of soluble CXCL16

1.2.4.1 Shedding of membrane CXCL16
Metalloprotease cleavage of CXCL16 results in a soluble 35 kDa molecule (Matloubian
et al. 2000). Similar to soluble CD23, soluble CXCL16 is generated after proteolytic
cleavage of the membrane protein (Abel et al. 2004, Gough et al. 2004, Ludwig et al.
2005a, Hundhausen et al. 2007). Experiments using the ADAM10 inhibitor GI254023X
and the combined ADAM10/ADAM17 inhibitor GW280264X, (Abel et al. 2004), short
interfering RNA (siRNA) knockdown of ADAM10 and overexpression of ADAM10 in
cells (Gough et al. 2004) show ADAM10 is primarily responsible for the generation of
soluble CXCL16 and the regulation of cell surface CXCL16. In contrast, siRNA
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knockdown of ADAM17 in human mesangial cells impairs CXCL16 shedding and has
implicated ADAM17 in the constitutive shedding of CXCL16 (Schramme et al. 2008).
Thus while ADAM10 is the principal constitutive CXCL16 sheddase, it is possible that
ADAM17 may function as the main sheddase in certain conditions or cell types.

Using metalloprotease inhibitors, it has been shown that PMA-induced CXCL16
shedding is attributed to ADAM17 rather than ADAM10 (Abel et al. 2004, Ludwig et
al. 2005a, Hundhausen et al. 2007). However, siRNA knockdown of ADAM10 or
ADAM17 in human mesangial cells, impairs cytokine-induced shedding of CXCL16,
implying a role for both ADAM10 and ADAM17 in this process (Schramme et al.
2008). In contrast, Ca2+/ionomycin-induced shedding of CXCL16 is attributed to
ADAM10 rather than ADAM17 (Hundhausen et al. 2007). Thus, like constitutive
CXCL16 shedding, the ADAM responsible for inducible CXCL16 shedding may be
dependent on the conditions or cell types involved. Further studies are needed to deduce
the mechanism by which these ADAMs cleave CXCL16.

1.2.4.2 Roles of soluble CXCL16
A major role for soluble CXCL16 is the induction of chemotaxis of cells. Recombinant
soluble CXCL16 binds CXCR6-transfected L1-2 lymphoma B cells and induces Ca2+
flux and chemotaxis of these cells (Wilbanks et al. 2001). Soluble CXCL16 also
induces strong chemotactic responses in activated CD4+ and CD8+ T cells (Matloubian
et al. 2000). Besides chemotactic activity, recombinant human soluble CXCL16 also
acts as an angiogenic factor by inducing the proliferation, migration and tube formation
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of human umbilical vein endothelial cells (Zhuge et al. 2005). More recently, it has been
shown that recombinant soluble CXCL16 protects hippocampal neurons from
excitotoxic cell death and protects from oxygen glucose deprivation damage (Rosito et
al. 2012).

1.2.5 Soluble CXCL16 and disease
Like soluble CD23, soluble CXCL16 has also been implicated in several inflammatory
and autoimmune diseases, as well as acute coronary syndromes and cancer. Amounts of
CXCL16 in serum and cerebrospinal fluid are increased in patients with systemic lupus
erythematosus, multiple sclerosis and meningitis (le Blanc et al. 2006). CXCL16 is also
elevated in serum of patients with inflammatory bowel disease (Lehrke et al. 2008,
Diegelmann et al. 2010), and in the synovial fluid of rheumatoid arthritis patients (van
der Voort et al. 2005). Moreover, serum concentrations of CXCL16 reflect disease
activity, and may be a novel biomarker and potential predictor of multiple sclerosis
(Holmoy et al. 2013), colorectal cancer (Matsushita et al. 2012), atherosclerosis (Lehrke
et al. 2007), acute coronary syndromes (Sun et al. 2008, Jansson et al. 2009) and renal
injury in type 2 diabetes mellitus (Zhao et al. 2014).
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1.3 Purinergic signalling and purinergic receptors

1.3.1 Introduction
Purinergic transmitters and receptors have become an increasingly important focus in
physiology and pathophysiology since the elucidation of the role played by extracellular
adenosine 5’-triphosphate (ATP) in neurotransmission and neuromodulation (Burnstock
2007). Currently, it is well-known that extracellular nucleotides activate a network of
purinergic signalling cascades involving membrane receptors and ectoenzymes
(Burnstock 2007, Yegutkin 2008). ATP and other nucleotides such as adenosine,
adenosine 5’-diphosphate (ADP), uridine 5’-triphosphate (UTP) and uridine
5’-diphosphate (UDP)-glucose can be released into the extracellular environment by a
variety of conditions (Lazarowski et al. 2003). ATP can be released as a
neurotransmitter, autocrine and paracrine signalling molecule in excitatory tissues,
during infection, inflammation and other pathological conditions (Lazarowski et al.
2003). Once in the extracellular fluid, nucleosides and nucleotides activate two types of
purinergic receptors, termed P1 and P2 receptors respectively. P1 and P2 receptors are
characterised based on molecular structure, function and pharmacological profile. The
P1 receptor group comprises A1, A2A, A2B and A3 adenosine receptors; these receptors
are G protein-coupled and are predominantly selective for adenosine (Ralevic and
Burnstock 1998). The P2 receptor group is sub-divided into P2X and P2Y receptors
based on whether they are ligand-gated (P2X) or G protein-coupled (P2Y) and are
predominantly selective for ATP, although ADP, UTP and UDP-glucose also activate
some P2Y receptors (Khakh and North 2006) (Figure 1.4). P2X and P2Y activation
induces downstream signalling that affects many cellular processes. Although the
16

downstream functions of each P2 receptor remains to be fully elucidated, it is widely
accepted that purinergic signalling is involved in a large array of physiological
responses including neurotransmission, coagulation, inflammation, proliferation,
differentiation and cell death, and tissue regeneration (Burnstock 2007).

Figure 1.4: Extracellular nucleosides and nucleotides activate P1 and P2
purinergic receptors. Adenosine activates P1 receptors and ATP activates P2X
receptors, while several nucleotides including ATP, ADP, UTP and UDP-glucose
activate P2Y receptors. Adapted from Khakh and North 2006. Abbreviations: ATP,
adenosine 5’-triphosphate; ADP, adenosine 5’-diphosphate; UTP, uridine 5’-triphosphate; UDP, uridine
5’-diphosphate; AMP, adenosine monophosphate

1.3.2 P2Y receptors
P2Y receptors, like other G protein-coupled receptors, contain an intracellular
C-terminus, an extracellular N-terminus and seven transmembrane (TM1-7) α-helical
domains that form the ligand-binding site (Jacobson et al. 2012). P2Y receptors possess
a high level of sequence homology between transmembrane regions TM3, TM6 and
TM7, and structurally diverse intracellular loops and C-termini which influence the
17

degree of G protein coupling (Jacobson et al. 2012). Currently eight P2Y receptor
subtypes (P2Y1, 2, 4, 6, 11-14)

have been cloned, and these receptors may be

sub-divided based on coupling to specific G proteins (Jacobson and Boeynaems 2010).
P2Y1, 2, 4, 6, and 11 couple to Gq, to activate phospholipase C (PLC) β via adenylyl
cyclase, whereas P2Y12, 13, and 14 couple to Gi, to inhibit adenylyl cyclase. P2Y11 is
unique amongst the P2Y receptors in its ability to couple to both Gq and Gs (Jacobson
and Boeynaems 2010). P2Y receptors mediate a variety of downstream signalling
events including the stimulation of phospholipases A, C and D, mitogen-activated
protein kinase (MAPK), Rho-kinase and protein tyrosine kinase. The pharmacological
properties and tissue distribution varies between P2Y receptors (Burnstock and Knight
2004). Recently, the crystal structures of P2Y12 complexed with its agonist,
2-methylthio-adenosine-5’-diphosphate (Zhang et al. 2014a) and antagonist, AZD1283
(Zhang et al. 2014b) have been reported. These structural studies will provide insight
into the pharmacology of agonists and antagonists for P2Y12 and other P2Y receptors,
and further the development of drug candidates for P2Y receptors.

1.3.3 P2X receptors
P2X receptors are non-selective, ligand-gated cation channels, which upon activation
allow an influx of Ca2+ and Na+, and an efflux of K+ along an electrochemical gradient
(Jarvis and Khakh 2009). These receptors are unique structurally compared to other
ligand-gated channels such as the nicotinic acetylcholine and glutamate receptors
(Kaczmarek-Hajek et al. 2012). P2X receptors are trimers of subunits, each with two
transmembrane domains (TM1 and TM2), intracellular N- and C-termini and a large
extracellular loop per subunit (Kaczmarek-Hajek et al. 2012). Seven P2X receptors
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(P2X1-7) have been cloned and characterised, these possess a broad tissue distribution
and differing pharmacological properties (Burnstock and Knight 2004).

P2X structural and functional properties have predominantly been determined by cDNA
cloning however, the crystal structure of the zebrafish P2X4 receptor (Kawate et al.
2009) has provided a three dimensional resource available for further structural and
functional studies of P2X receptors (Figure 1.5). The P2X4 crystal structure has enabled
analysis and interpretation of previous structural and functional work, and will also
allow for studies using homology models of other P2X receptor subtypes from different
species (Young 2010). This advancement will contribute to further the understanding of
ligand binding, the structure of the open, closed and dilated channel, as well as ion
permeation, which are all important in structure-based drug design (Browne et al. 2010,
Jiang et al. 2013). The further elucidation of structure and function of P2X receptors
may be useful for new therapeutics for neuropathic pain and inflammation (Browne et
al. 2010, Jiang et al. 2013).

1.4 The P2X7 receptor

1.4.1 Structure and function
The human, mouse, rat, dog and rhesus macaque monkey P2X7 protein subunit consists
of 595 amino acids (Surprenant et al. 1996, Rassendren et al. 1997, Chessell et al.
1998b, Roman et al. 2009, Bradley et al. 2011b), while guinea-pig P2X7 consists of 594
amino acids (Fonfria et al. 2008). This introduction however, will predominantly focus
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on human and murine P2X7, the two species studied in this thesis. Computer modelling
suggests that P2X7 has a structure similar to that of other P2X receptors (Figure 1.5)

Figure 1.5: The structure of P2X receptors. A P2X7 subunit, shaped similarly to a
dolphin (left), and the chalice shaped trimeric receptor (right), is shown parallel to the
cell membrane. Each subunit is depicted in a different colour and represents the general
structure of P2X receptors. The structure of P2X7 is shown based on the crystal
structure of zebrafish P2X4. From Jiang 2012.

(Jiang 2012, Jiang et al. 2013). ATP activation of P2X7 induces the immediate opening
of a non-selective cation channel, which allows an influx of Ca2+ and Na+, and an efflux
of K+ across the cell membrane (Surprenant et al. 1996, Rassendren et al. 1997, Chessell
et al. 1998b). P2X7 is viewed historically as biologically unique in its ability to induce
pore formation upon prolonged (>30s) ATP activation (Burnstock 2007). However, it is
now known that activation of other P2X receptors including P2X2 (Virginio et al. 1999,
Chaumont and Khakh 2008), P2X4 (Seil et al. 2010) and P2X2/5 (Compan et al. 2012)
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can also induce permeabilisation of cells. P2X7 activation allows the uptake of organic
cations including N-methyl-D-glucamine+, ethidium+ and YO-PRO-12+ (Jiang et al.
2005, Cankurtaran-Sayar et al. 2009), and organic anions including Lucifer yellow and
calcein (Cankurtaran-Sayar et al. 2009). After P2X7 activation, organic cations and
anions are thought to enter the cell via different permeation pathways (CankurtaranSayar et al. 2009).

Originally, it was thought that the P2X7 channel dilated to a pore over prolonged
agonist application (North 2002). Later, it was shown that activated P2X7 interacts with
the hemichannel pannexin-1, which functions as the P2X7-induced pore (Pelegrin and
Surprenant 2006, Locovei et al. 2007). More recently however, studies have shown that
pannexin-1 is not the main pore pathway induced after P2X7 activation. Macrophages
from pannexin-1 knockout mice display ATP-induced YO-PRO-12+ uptake (Qu et al.
2011) and siRNA knockdown of pannexin-1 does not affect P2X7 responses, including
dye uptake in murine macrophages (Alberto et al. 2013). In support of this, it has been
shown that large organic dyes permeate the P2X7 receptor ion channel itself (Browne et
al. 2013).

1.4.2 Polymorphic and splice variants

1.4.2.1 Single nucleotide polymorphisms
The human P2RX7 gene is highly polymorphic and contains over 1500 single
nucleotide polymorphisms (SNPs). The majority of these are intronic and
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approximately 150 are non-synonymous (Sluyter and Stokes 2011). There are 20
characterised SNPs that alter P2X7 function, including the loss-of-function SNPs
V76A, R117W, G150R, E186K, L191P, R276H, R307Q, T357S, E496A and I568N
(Wiley et al. 2003, Gu et al. 2004, Roger et al. 2010, Stokes et al. 2010), and the
gain-of-function SNPs H155Y, H270R, and A348T (Cabrini et al. 2005, Roger et al.
2010, Stokes et al. 2010). The R307Q loss-of-function SNP was originally thought to
reduce P2X7 function by abolishing binding of ATP to P2X7 (Gu et al. 2004), however,
as Arg307 is involved in hydrogen bonding and salt bridge interactions, it has been
suggested that the R307Q SNP leads to a loss of these interactions (Jiang et al. 2013).
The I568N SNP prevents normal cell trafficking of P2X7, and thus cell surface
expression and function (Wiley et al. 2003). It remains to be determined how other
loss-of-function SNPs cause a loss of function effect. The gain-of-function SNP H155Y
affects P2X7 cell surface expression (Bradley et al. 2011a), while other gain-of-function
SNP effects remain to be determined. The Q460R SNP has minimal effect on P2X7
function itself, but is co-inherited with other gain-of-function SNPs in a haplotype
termed P2X7-4 (Stokes et al. 2010).

The murine P2XR7 gene has more than 1700 SNPs and similar to the human gene, are
mainly intronic. There are 10 reported non-synonomous SNPs only of which the
naturally occurring P451L has been characterised (Bartlett et al. 2014). This SNP was
originally identified in C57BL/6 mice (Adriouch et al. 2002). T cells from these mice
have lower sensitivity to ATP (Adriouch et al. 2002) and display significantly impaired
P2X7-induced cell death (Le Stunff et al. 2004) compared to T cells from wild-type
451P BALB/c mice. Furthermore, astrocytes from C57BL/6 mice have reduced P2X7
mediated pannexin-1 currents, ATP release and intracellular Ca2+ spread compared to
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astrocytes from BALB/c mice, which are wild-type at position 451 (Suadicani et al.
2009). The P451L SNP is also present in other mouse strains including the C57BL/10,
DBA/1 and DBA/2 strains (Adriouch et al. 2002). Other SNPs that have been identified
include the L11F, T221A and T283M SNPs in P2X7 cloned from the NTW8 murine
microglia cell line. Of these, only the T283M SNP exhibited low P2X7 function (Young
et al. 2006).

1.4.2.2 Splice variants
Human P2X7 has nine naturally occurring splice variants termed P2X7B-P2X7J. The
full-length 595 amino acid protein is termed P2XA (Cheewatrakoolpong et al. 2005,
Feng et al. 2006). Truncated variants P2X7B, C, E, and G have short C-termini, while
P2X7C-F are missing exons which code for the extracellular domain. P2X7G and H
have additional exons in the extracellular domain (Cheewatrakoolpong et al. 2005).
P2X7I leads to a null allele (Skarratt et al. 2005) and P2X7J is also a truncated variant,
which lacks exons from the extracellular loop to the C-terminus (Feng et al. 2006).
P2X7B can form functional channels but not pores and potentiates P2X7A-mediated
effects including dye uptake. P2X7B coexpression with P2XA, results in heteromeric
receptors that induce signalling pathways to stimulate cell growth (Adinolfi et al. 2010).
P2X7J cannot form pores but oligomerises with P2X7A, to prevent its trafficking to the
cell surface resulting in reduced P2X7 function (Feng et al. 2006).

In mice, three naturally occurring P2X7 splice variants have been identified, termed
P2X7K (Nicke et al. 2009), P2X713B and P2X713C (Masin et al. 2012). P2X7K has an
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alternate N-terminus and first transmembrane domain (Nicke et al. 2009). It is
functional with 8-fold higher sensitivity to the P2X7 agonist 2'(3')-O-(4benzoylbenzoyl)adenosine-5'-triphosphate

(BzATP)

(see

section

1.4.3),

slower

deactivation kinetics and increased tendency to form pores compared to P2X7A (Nicke
et al. 2009). P2X713B and P2X13C are C-terminal truncated variants with alternative
exons 13. When these variants are expressed in HEK 293 cells, they show low channel
function, cell expression and absent pore formation (Masin et al. 2012). P2X713B is
inefficiently trafficked and coassembles with P2X7A to inhibit P2X7 function (Masin et
al. 2012). P2X7K also escapes deletion in the GlaxoSmithKline P2X7 knockout mice
(Nicke et al. 2009) generated by Chessell and colleagues (Chessell et al. 2005), while
P2X13B and C escape deletion in the Pfizer P2X7 knockout mice (Masin et al. 2012)
generated by Solle and colleagues (Solle et al. 2001). Despite the discovery of human
and murine P2X7 SNPs and variants, the functional significance of these is poorly
understood.

1.4.3 Pharmacology
Human and murine P2X7 were first cloned from cDNA obtained from human
monocytes (Rassendren et al. 1997) and the NTW8 murine microglia cell line (Chessell
et al. 1998b) respectively. ATP is the natural ligand of P2X7, and requires higher
concentrations (half maximal effective concentration (EC50) of more than 100 µM) for
activation compared to other P2X receptors (North 2002). How such high
concentrations of extracellular ATP are achieved in vivo is often questioned. However,
comparison of P2X7-deficient mice and wild-type controls in a number of disease
models has highlighted a role for P2X7 and indirectly demonstrated that sufficient
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concentrations of extracellular ATP can be obtained in vivo under some conditions
(Labasi et al. 2002, Ke et al. 2003, Chessell et al. 2005, Beaucage et al. 2014). The
agonist order of potency for human P2X7 is BzATP >> ATP > 2-methylthio-adenosine5'-triphosphate > adenosine 5'-O-(3-thio) triphosphate (ATPγS) >> ADP (DonnellyRoberts et al. 2009). This order is similar for murine P2X7 however, 2-methylthioadenosine-5'-triphosphate and ATPγS are ineffective activators of this receptor
(Donnelly-Roberts et al. 2009). As BzATP is the most potent P2X7 agonist, it is often
confused as a selective agonist of P2X7. However, it is well known that BzATP can
activate other P2 receptors including P2X1 (Bianchi et al. 1999), P2X2 (Lynch et al.
1999), P2X3 (Bianchi et al. 1999), P2Y2 (Wildman et al. 2003) and P2Y11 (Communi
et al. 1999).

An ATP-independent pathway can also activate murine P2X7. ADP-ribosyltransferase
(ART) 2 in murine T cells, transfers an ADP-ribose group from nicotinamide adenine
dinucleotide (NAD) to activate P2X7 (Seman et al. 2003). Similar to ATP-induced
P2X7 activation, NAD-induced P2X7 activation causes Ca2+ flux, pore formation, PS
exposure, L-selectin (CD62L) shedding and apoptosis (Seman et al. 2003). As shown
by P2X7-induced PS exposure, lower concentrations of NAD are required to activate
P2X7 compared to ATP (EC50 of 2 uM vs 100 uM) (Seman et al. 2003). NAD-induced
activation of P2X7 does not occur in humans due to the inactivation of the ART2 gene
(Haag et al. 1994).

A number of P2X7 antagonists have been identified, these include the first generation
antagonists suramin, brilliant blue G (BBG), pyridoxal phosphate-6-azophenyl-2-425

disulphonic acid (PPADs), periodate-oxidised ATP (oATP) and KN-62. Of these, BBG
remains the most commonly used, particularly in in vivo studies (Bartlett et al. 2014).
BBG is generally considered a specific antagonist, especially at murine P2X7 (Jiang et
al. 2000). However, BBG, as well as suramin, both block pannexin-1 (Qiu and Dahl
2009). Suramin and PPADs are also well-known broad spectrum P2 receptor
antagonists (Kaczmarek-Hajek et al. 2012). Likewise oATP has been shown to inhibit
other P2X receptors (Evans et al. 1995) and KN-62 inhibits calmodulin-dependent
protein kinase, when used at concentrations 10-fold higher than that for P2X7 (Di
Virgilio 2003).

In more recent years, specific second generation antagonists of P2X7 have been
generated. These include A-438079, A839977, AZ10606120, AZ11645373 and
A740003 (Bartlett et al. 2014). Many studies tend to use new generation antagonists for
in vitro assays but continue to utilise first generation antagonists for in vivo studies
(Bartlett et al. 2014). Extracellular cations such as Na+, Ca2+ and Mg2+ are also known
to inhibit P2X7 function by binding to an unidentified inhibitory site or by reducing the
availability of the ATP4- species required for P2X7 activation (Wiley et al. 1992, Michel
et al. 1999). Therefore, these cations are often excluded from incubation media during
in vitro investigations to increase P2X7 function and aid measurements of receptor
function (Virginio et al. 1997).
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1.4.4 Distribution
P2X7 is expressed on a variety of cell lineages including hematopoietic cells,
osteoblasts, fibroblasts, endothelial cells, epithelial cells, and cells from the central and
peripheral nervous systems (Lenertz et al. 2011, Wiley et al. 2011). P2X7 was originally
thought to be expressed only on hematopoietic cells, and therefore its presence is well
established on these cell types (Wiley et al. 2011). Several studies show the presence of
P2X7 on human primary B cells (Gu et al. 2000, Gu et al. 2001) as well as malignant B
cells from patients with CLL (Wiley et al. 1992, Gu et al. 2000, Shemon et al. 2008).
While many studies show P2X7 expression on human B cells, a few studies show the
presence of P2X7 on murine B cells. In fact, some early studies suggest that P2X7 is not
expressed on murine B cells (Chused et al. 1996, Tsukimoto et al. 2006). In contrast,
others have shown that P2X7 activation induces the shedding of the TNF receptor,
CD27 from murine B cells (Moon et al. 2006). Therefore, it remains to be established if
murine B cells express functional P2X7.

1.4.5 Downstream events
P2X7 activation elicits a variety of downstream events including IL-1 cytokine family
member secretion, cell death and proliferation, transcription factor activation, reactive
oxygen species (ROS) formation and various membrane-related events.
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1.4.5.1 IL-1 cytokine family member secretion
P2X7 induces the secretion of cytokines belonging to the IL-1 family including IL-1β
(Ferrari et al. 1997a, Mehta et al. 2001, Brough et al. 2003, Pelegrin and Surprenant
2007), IL-18 (Mehta et al. 2001), IL-1α (Brough et al. 2003), IL-36α (Martin et al.
2009) and the IL-1 receptor antagonist (Wilson et al. 2004). P2X7-induced IL-1β
secretion is the most studied and relies on NLRP3 inflammasome activation and K+
efflux (Perregaux and Gabel 1994, Andrei et al. 2004, Munoz-Planillo et al. 2013).
Other signalling molecules involved in P2X7-induced IL-1β secretion include
Rho-kinases and caspases (Verhoef et al. 2003), as well as phospholipases A and C
(Andrei et al. 2004). Recently, prostaglandin release has been shown in conjunction
with IL-1β release following P2X7 activation in macrophages (Barbera-Cremades et al.
2012). P2X7-induced prostaglandin release involves activation of MAPKs including
c-Jun N-terminal kinase (JNK) and extracellular regulated kinases (ERK), as well as
activation of the enzyme cyclooxygenase-2 (Barbera-Cremades et al. 2012).

1.4.5.2 Cell death and proliferation
Classically, P2X7 activation is known to induce cell death by apoptosis, which involves
the activation of caspase-1, -3 and -8 (Ferrari et al. 1999) or JNK (Humphreys et al.
2000). Paradoxically, P2X7 is also involved in cell proliferation. In T cells, P2X7
activates the nuclear factor of activated T cells (NFAT) transcription factor to induce
T cell proliferation by secretion of the growth factor, IL-2 (Yip et al. 2009).
P2X7-induced cell proliferation has also been shown in microglia, however the
downstream effectors remain to be determined (Bianco et al. 2006, Monif et al. 2009).
The P2X7 splice variant, P2X7B, is thought to primarily promote cell proliferation,
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while P2X7A is considered the ‘death receptor’ (Adinolfi et al. 2010). P2X7 activation
also promotes survival and neuroprotection in neurons, which involves glycogen
synthase kinase-3 (GSK-3) (Ortega et al. 2009) and phosphatidyl-inositol-3-kinase
(PI3K) (Ortega et al. 2010).

1.4.5.3 Transcription factor activation
Several studies suggest that P2X7 activation influences gene expression due to the
regulation of several gene transcription factors. In addition to NFAT in T cells (Yip et
al. 2009), these include nuclear factor-κB in microglia (Ferrari et al. 1997b) and
osteoclasts (Korcok et al. 2004), cyclic adenosine monophosphate response element
binding protein activation (Gavala et al. 2008), FBJ murine osteosarcoma viral
oncogene homolog B/activation protein-1 in monocytes and osteoblasts (Gavala et al.
2010), and early growth response protein-1 in P2X7-transfected HEK 293 cells (Stefano
et al. 2007).

1.4.5.4 ROS formation
It is well established that P2X7 activation plays a role in the generation of ROS. P2X7
activation induces ROS generation via nicotinamide adenine dinucleotide phosphate
(NADPH) oxidase in macrophages (Lenertz et al. 2009), microglia (Bartlett et al. 2013),
submandibular glands (Seil et al. 2008) and erythroid cells (Wang and Sluyter 2013).
MAPK, ERK1/2 and protein kinase C (PKC) activation are involved in P2X7-induced
ROS production (Seil et al. 2008, Lenertz et al. 2009).
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1.4.5.5 Membrane-related events
P2X7 is involved in the regulation of phagocytosis. Transfection of P2X7 into nonphagocytic HEK 293 cells allows these cells to phagocytose latex beads or bacteria (Gu
et al. 2010, Wiley and Gu 2012). This process requires that P2X7 be complexed with
the non-muscle myosin IIA and does not require activation by ATP (Gu et al. 2010,
Wiley and Gu 2012). P2X7 activation induces the killing of mycobacterium
tuberculosis in macrophages, and requires the signalling molecule phospholipase D
(PLD) (Kusner and Adams 2000). P2X7 activation also induces lysosome secretion of
cathepsins B, K, L and S, which are released by Ca2+-dependent exocytosis from
monocytes and macrophages (Lopez-Castejon et al. 2010). Furthermore, P2X7
activation induces membrane blebbing, which involves MAPKs (Pfeiffer et al. 2004)
and Rho-kinases (Verhoef et al. 2003), and elicits other cell-membrane-related events
including microparticle release (Qu and Dubyak 2009) and the shedding of cell surface
molecules (see section 1.5).

1.4.6 Disease
P2X7 is implicated in a number of inflammatory and immune diseases including
rheumatoid arthritis (Portales-Cervantes et al. 2010), Sjogren’s syndrome (Lester et al.
2013), graft-versus-host disease (Wilhelm et al. 2010), multiple sclerosis (Yiangou et al.
2006), glomerulonephritis (Taylor et al. 2009b) and inflammatory pain (Chessell et al.
2005). Several studies report that P2X7 also plays a role in neurodegenerative diseases
including Alzheimer’s disease (Diaz-Hernandez et al. 2012), Huntington’s disease
(Diaz-Hernandez et al. 2009) and amyotrophic lateral sclerosis (Yiangou et al. 2006).
P2X7 also plays a role in cancer (Adinolfi et al. 2012) and infectious diseases (Miller et
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al. 2011a, Miller et al. 2011b). Furthermore, P2RX7 SNPs have been associated with
disorders. The Q460R SNP is associated with bipolar affective disorder (Barden et al.
2006), major depressive disorder (Lucae et al. 2006) and Sjogren’s syndrome (Lester et
al. 2013). The R307Q SNP is associated with low lumbar spine bone mineral density
(Gartland et al. 2012), while the A348T SNP is associated with a lower vertebral
fracture incidence in women ten years after menopause (Jorgensen et al. 2012). The
A348T SNP is also increased in frequency in Arabic rheumatoid arthritis patients (AlShukaili et al. 2011) and depressive disorder patients (Lucae et al. 2006).
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1.5 Nucleotide-induced shedding of cell surface molecules

1.5.1 Introduction
Ectodomain shedding is a vital post-translational modification which downregulates cell
surface expression of molecules and causes their release in a soluble form (Hayashida et
al. 2010). The soluble form may retain its original activity and induce functional
responses in an autocrine or paracrine manner (Hayashida et al. 2010). Ectodomain
shedding is exhibited by a diverse range of molecules including cytokines, growth
factors and cell adhesion molecules, and can be stimulated by a variety of mechanisms
(see Hayashida et al. 2010 for further review). Nucleotide or P2 receptor-induced
shedding is also exhibited by a variety of molecules including CD23 and CD62L
(Figure 1.6) and will be discussed in further detail below.
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Figure 1.6 Nucleotide-induced shedding of cell surface molecules. The nucleotides ATP and UTP activate P2X and P2Y receptors to
induce the shedding of cell surface molecules. ADAM10 is involved in nucleotide or P2X7-induced shedding of CD23, IL-6R, TIM-2,
BTC, and E-cadherin. Whether P2X7 activates ADAM10 to induce the shedding of CD23 and other molecules remains unknown.
ADAM17 is involved in P2X7-induced shedding of CD62L, ICAM-1, TNF-α and TGF-α. P2X7 activation also induces the shedding of
CD21, CD44, MHC I, CD27 and possibly NCAM. The involvement of other intracellular signalling molecules in the shedding of the above
molecules remains unclear. P2X7 activation also induces APP processing via an intracellular signalling cascade involving Rho-kinase,
ERK1/2, JNK, ERM and PI3K. However, an opposing role for P2X7 in APP processing is also suggested, whereby APP processing is
inhibited by GSK-3 after P2X7 activation. P2Y receptors are involved in the activation of mitochondrial ROS and DUOX-1, which activate
ADAM17 to shed TGF-α. Furthermore P2Y receptor activation is linked to the stimulation of ADAM10 and ADAM17, and several
downstream molecules, including PKC, PI3K and ERK1/2 which participate in HB-EGF and APP processing. P2Y receptor activation also
induces AREG and TNFR1 shedding, however the mechanisms remain undetermined. The focus of the current research is highlighted by
the dashed box. Abbreviations: ADAM, a disintegrin and metalloprotease; APP, amyloid precursor protein; AREG, amphiregulin; ATP, adenosine 5’-triphosphate;
CD21, complement receptor 2; CD23, IgE receptor; CD27, tumor necrosis factor receptor; CD44, hyaluronic acid receptor;

CD62L, L-selectin; CTF,

carboxyl-terminal fragment; DUOX, dual oxidase; E-cadherin, epithelial cadherin; ERK, extracellular signal-regulated kinase; ERM, ezrin radixin moesin; GSK,
glycogen synthase kinase; HB-EGF, heparin-binding-epidermal growth factor; ICAM, intercellular adhesion molecule; IL, interleukin; IL-6R, interleukin-6 receptor,
JNK, c-Jun N-terminal kinase; LPS, lipopolysaccharide; MHC, major histocompatibility complex; NCAM, neural cell adhesion molecule; PI3K, phosphatidylinositide
3-kinase; PKC, protein kinase C; ROS, reactive oxygen species; TIM, T cell immunoglobulin and mucin; TGF, transforming growth factor; TNF, tumor necrosis
factor; TNFR, tumor necrosis factor receptor; UTP, uridine 5’-triphosphate.
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Using protease inhibitors (Table 1.2), studies have shown a role for sheddases in
nucleotide-induced ectodomain shedding of molecules. Although, these inhibitors have
been useful in implicating a role for metalloproteases in this process, there is still a lack
of specific metalloprotease inhibitors available. GI254023X (Table 1.2) is a specific
ADAM10 inhibitor (Ludwig et al. 2005a), however it can also impair other ADAMs at
concentrations above 5 µM (Weskamp et al. 2006). Future development of more
specific metalloprotease antagonists will be beneficial to the study of mechanisms
involved in nucleotide-induced shedding.

1.5.2 CD23
As noted in section 1.1, CD23 is involved in the regulation of IgE levels (Gould and
Sutton 2008) and functions as an adhesion molecule. Moreover, in the soluble form,
CD23 also exerts cytokine-like activities (Acharya et al. 2010). ATP and
BzATP-induced CD23 shedding was first shown to occur from CLL lymphocytes (Gu
et al. 1998). The P2X7 antagonists, KN-62 and oxATP impair nucleotide-induced CD23
shedding from CLL cells, thus confirming a role for P2X7 in CD23 shedding (Gu et al.
1998). Since then, P2X7-induced CD23 shedding has been described for human
monocyte-derived dendritic cells (Sluyter and Wiley 2002), monocyte-derived
Langerhans cells (Georgiou et al. 2005) and RPMI 8226 multiple myeloma B cells
(Farrell 2008). Dendritic cells and Langerhans cells, from subjects who were
homozygous for the loss-of-function polymorphism E496A, exhibited attenuated
ATP-induced CD23 shedding (Sluyter and Wiley 2002, Georgiou et al. 2005) further
supporting a role for P2X7 in this process. Furthermore, BzATP induces CD23
shedding from CD23-transfected Chinese hamster ovary (CHO) cells (Le Gall et al.
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2009) and downregulates CD23 surface expression on murine B cells (Le Gall et al.
2010).

Table 1.2: Protease inhibitors used in studies of nucleotide-induced ectodomain
shedding.
Compound

Specificity

Reference

BB-2516

Broad spectrum
metalloprotease inhibitor

(Wada et al. 2003)

BB-3103

Broad spectrum
metalloprotease inhibitor

(Mirastschijski et al. 2002)

BB-94

Broad spectrum
metalloprotease inhibitor

(Davies et al. 1993)

E64

Non-selective cysteine
protease inhibitor

(Susa et al. 2004)

Decanoyl-RVKR-CMK

Non-selective convertase
inhibitor

(Denault et al. 1995)

GI254023X

ADAM10 inhibitor

(Ludwig et al. 2005a)

GM6001

Broad spectrum
metalloprotease inhibitor

(Grobelny et al. 1992)

GW280264X

ADAM10/ADAM17 inhibitor

(Ludwig et al. 2005a)

MG132

Proteasome inhibitor

(Palombella et al. 1994)

Phenanthroline

Broad spectrum
metalloprotease inhibitor

(Sellers and Woessner 1980)

TAPI-1

Broad spectrum
metalloprotease inhibitor

(Mullberg et al. 1995)

TAPI-2

Broad spectrum
metalloprotease inhibitor

(Arribas et al. 1996)

Ro 31-9790

Broad spectrum
metalloprotease inhibitor

(Steinmann-Niggli et al. 1997)

Abbreviations: ADAM, a disintegrin and metalloprotease
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While several studies show CD23 shedding is induced following P2X7 activation, a
lack of knowledge exists on the signalling pathways involved in this process. PMA
induces CD62L, but not CD23 shedding, and the hydroxamic acid-based protease
inhibitor of zinc-dependent MMPs, Ro 31-9790, inhibits P2X7-induced CD23 shedding
more potently than CD62L shedding (Gu et al. 1998). Therefore, it is thought that
P2X7-induced CD23 and CD62L shedding are regulated by different metalloproteases
(Gu et al. 1998). Furthermore, using BB-94, preliminary data from our laboratory
implies a role for metalloproteases in ATP-induced CD23 shedding from RPMI 8226
cells (Wang and Sluyter, personal communication). A role for ADAM10 in ATP- or
BzATP-induced CD23 shedding has been shown using the inhibitory prodomain
construct of ADAM10, A10-(23-213) (Lemieux et al. 2007) and in CD23-transfected
CHO cells and murine B cells using GI254023X (Le Gall et al. 2009, Le Gall et al.
2010). However, a direct role for P2X7 in ADAM10-mediated CD23 shedding was not
established in any of these studies.

1.5.3 CD62L
CD62L is a cell-adhesion molecule that consists of an extracellular, N-terminal lectin
domain, an epidermal growth factor (EGF) domain, two consensus repeat domains, a
transmembrane domain and a cytoplasmic tail (Smalley and Ley 2005). CD62L is
involved in constitutive trafficking of lymphocytes through lymphoid organs, and
rolling of leukocytes on inflamed vascular endothelium (Smalley and Ley 2005). Like
CD23, ATP was first shown to induce CD62L shedding from the cell surface of CLL
lymphocytes (Jamieson et al. 1996). The nucleotides adenosine, ADP and UTP do not
affect CD62L shedding, while oxATP inhibits both ATP and BzATP-induced CD62L
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shedding from these cells (Jamieson et al. 1996). Furthermore, KN-62 also inhibits
ATP-induced CD62L shedding from CLL lymphocytes, confirming a role for P2X7 in
this process (Gargett and Wiley 1997, Gu et al. 1998). Finally, BzATP-induced CD62L
shedding is drastically impaired in CLL cells expressing non-functional P2X7 (Gu et al.
2000).

Following the studies above, it was shown P2X7-induced CD62L shedding occurs from
human B cells and T cells (Sengstake et al. 2006) and subsets of these cells, including
CD4+ and CD8+ T cells (Elliott and Higgins 2004, Aswad and Dennert 2006, Sengstake
et al. 2006, Sluyter and Wiley 2014), and CD27- and CD27+ B cells (Sengstake et al.
2006). In murine T cells, NAD is able to induce CD62L shedding via the activation of
ART2 and P2X7 (see section 1.4.3) (Seman et al. 2003, Krebs et al. 2005). Furthermore,
ATP-induced CD62L shedding is almost absent from monocytes and lymphocytes
obtained from subjects containing the E496A loss-of-function polymorphism (Sluyter et
al. 2004, Sluyter and Wiley 2014), and from Pfizer P2X7 knockout mice (Labasi et al.
2002). In contrast, BzATP-induced CD62L shedding is more rapid in T cells from
GlaxoSmithKline P2X7 knockout mice (Taylor et al. 2009a), presumably due to the
presence of the escape variant P2X7K (Nicke et al. 2009, Schwarz et al. 2012).

A role for P2X7-induced CD62L shedding was implicated in T cell transendothelial
migration to the heart in a murine model of Duchenne muscular dystrophy (Cascabulho
et al. 2012). This study showed that BBG treatment of mdx/mdx mice allowed the
transendothelial migration of T cells to the heart by allowing sustained CD62L
expression (Cascabulho et al. 2012). This suggests that impaired P2X7-induced CD62L
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shedding may contribute to the pathology of Duchenne muscular dystrophy
(Cascabulho et al. 2012). In contrast to this study, Chen and colleagues showed that
oxATP does not affect the loss of CD62L during CLL lymphocyte transmigration (Chen
et al. 1999) suggesting P2X7 does not play a role in this process. This difference may be
due to different experimental conditions and may be dependent on cell types and species
involved. Overall, the above studies confirm a major role for P2X7 in CD62L shedding
from B and T cells, and monocytes.

Although a clear mechanism has not been attributed to P2X7-induced CD62L shedding,
metalloproteases were first implicated when it was shown that Ro 31-9790 inhibits
CD62L shedding (Gu et al. 1998). Now, ADAM17 is thought to be the principal
sheddase of CD62L in nucleotide-induced shedding from murine B cells and T cells (Le
Gall et al. 2009, Le Gall et al. 2010). However, in the absence of ADAM17, ADAM10
is able to shed CD62L after ATP treatment of these cells (Le Gall et al. 2009, Le Gall et
al. 2010). BzATP-stimulated CD62L shedding induced by ADAM17 is significantly
more rapid than shedding induced by ADAM10, corroborating a role for ADAM17 as
the principal sheddase (Le Gall et al. 2010).

The 4,4’-diisothiocyanatosilbene-2,2’-disulphonic acid, an inhibitor of PS translocation,
has implicated a role for non-apoptotic PS exposure in P2X7-induced CD62L shedding
from murine CD4+CD45RBlo T cells, a population of live cells with constitutive PS
exposure (Elliott et al. 2005). However, the precise mechanism remains undefined.
Other studies have shown that P2X7-induced CD62L shedding does not involve PKC
(Jamieson et al. 1996), PI3K or ERK1/2 (Foster et al. 2013). In contrast, Foster and
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colleagues show that rottlerin, an inhibitor of PKC, increases ATP-induced CD62L loss
from human CD4+ T cells (Foster et al. 2013). Furthermore, P2X7-mediated loss of
CD62L from human CD4+ T cells is enhanced by diphenyleneiodonium, which can
uncouple complex I of the mitochondrial respiratory chain to cause ROS formation
(Foster et al. 2013). P2X7-mediated loss is also enhanced by rotenone and antimycin A,
which uncouple complex I and III, respectively (Foster et al. 2013). While Foster and
colleagues did not directly show that this process involves ADAM17, ROS is able to
activate ADAM17 via oxidation of cysteine motifs, which are critical for CD62L
cleavage (Wang et al 2009). Furthermore, ROS production is involved in PMA-induced
ectodomain shedding of tumor necrosis factor receptor (TNFR) 2 (Zhang et al. 2001)
and ATP-induced shedding of transforming growth factor (TGF)-α (Myers et al. 2009)
(see section 1.5.9.2). Therefore, ROS may play a role in P2X7-induced activation of
ADAM17 (Foster et al. 2013).

1.5.4 CD21
Two main complement receptors have been described, complement receptor 1 (CD35)
and complement receptor 2 (CD21). In humans, different genes code these receptors,
whereas in mice they are alternative splice products of the same gene (Chen et al. 2000).
CD21 consists of tandem repeat motifs called short consensus repeats, which contain
the binding site for complement fragments. CD21 is predominantly expressed on
follicular dendritic cells and B cells, and binds complements iC3b, C3dg, C3d and C4d
(Chen et al. 2000). BzATP-induces CD21 shedding from human B cells, which is
inhibited in the presence of oxATP and KN-62, confirming a role for P2X7 in CD21
shedding (Sengstake et al. 2006). The mechanism by which this process occurs remains
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elusive, and to date, Sengstake and colleagues are the only group to show
P2X7-inducible release of CD21 (Sengstake et al. 2006). Constitutive CD21 shedding is
known to be a redox-regulated process, and can be induced by oxidising agent
pervanadate (Aichem et al. 2006). PKC, serine proteases and metalloproteases are
involved in this redox-regulated process (Aichem et al. 2006). CD21 shedding can also
be induced by ROS scavengers, such as N-acetylcysteine and glutathione, which can be
impaired by metalloprotease inhibitors (Aichem et al. 2006). It would be of interest to
determine whether P2X7-induced ROS formation and ADAM activation affect CD21
shedding.

1.5.5 CD44
CD44 is a type I transmembrane glycoprotein which consists of a short cytoplasmic tail,
a transmembrane domain, a glycosylated variable region and hyaluronic acid binding
domains (Petrey and de la Motte 2014). CD44 is expressed on several cell types
including leukocytes, neutrophils, macrophages, fibroblasts, epithelial and endothelial
cells (Petrey and de la Motte 2014). CD44 plays roles in tumour metastasis, lymphocyte
adhesion, T cell signalling, angiogenesis and inflammation (Petrey and de la Motte
2014). ATP induces CD44 shedding from murine P388D1 lymphoid neoplasm cells
(Lin et al. 2012). KN-62 and P2X7 short hairpin RNA inhibited ATP-induced cell
surface loss, as well as release of soluble CD44, which confirms a role for P2X7 in the
process. In contrast, ATP is unable to alter the expression of CD44 in CLL cells (Gu et
al. 1998). Therefore, P2X7-induced CD44 shedding may be cell or species specific.
While the mechanism involved in P2X7-induced CD44 shedding remains undefined,
ADAM10 (Anderegg et al. 2009), ADAM17 (Takamune et al. 2007), MMP 9 (Chetty et
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al. 2012) and MMP 14 (Kajita et al. 2001) are involved in constitutive CD44 shedding
and thus may play a role in nucleotide-induced CD44 shedding.

1.5.6 Epithelial-cadherin
Epithelial cadherin (E-cadherin) is a member of the classical cadherin family. It
contains a single pass transmembrane glycoprotein with five extracellular repeats that
bind E-cadherin molecules on opposing cells (Canel et al. 2013). E-cadherin mediates
cell-cell adhesion in epithelial tissues and loss of this molecule promotes epithelial
tumour metastasis (Canel et al. 2013). Melittin, the major component of bee venom
induces ADAM-dependent E-cadherin shedding from human HaCaT keratinocytes
(Sommer et al. 2012). Melittin also induces ATP release, ERK phosphorylation and
EGF receptor activation in these cells (Sommer et al. 2012). The P2 receptor antagonists
PPADS, Evans Blue and suramin suppress melittin-mediated ADAM activation
suggesting a contribution of P2 receptor activation to melittin-induced shedding
(Sommer et al. 2012). Furthermore, P2X7-transfected but not mock transfected
HEK 293 cells show increased melittin-induced phosphorylation of ERK, which can be
abrogated by apyrase, thus confirming a role for the ATP-P2X7 axis in this process
(Sommer et al. 2012). Melittin-induced E-cadherin shedding is inhibited by broad
spectrum metalloprotease inhibitor BB-2516, GI254023X and GW280264X (Sommer et
al. 2012). While P2X7 may play a role in this process, further evidence is needed to
establish a role for P2X7 or another P2 receptor in ADAM10-dependent E-cadherin
shedding in HaCaT keratinocytes.

42

1.5.7 Ig superfamily members
Nucleotides induce the loss of several molecules of the Ig superfamily including the
MHC class I, the IL-6 receptor (IL-6R), T cell immunoglobulin and mucin (TIM)-2,
neural cell adhesion molecule (NCAM) and the intercellular adhesion molecule
(ICAM)-1.

1.5.7.1 MHC molecules
MHC molecules are involved in initiating antigen-specific T cell immune responses
(Germain 1994). Typically, MHC class I presents intracellular antigen to CD8+ T cells,
while MHC class II presents extracellular antigen to CD4+ T cells (Germain 2002,
Pearce et al. 2004). MHC class I is composed of a single transmembrane heavy chain
(α1α2 and α3 domains) paired with β2 microglobulin (Maenaka and Jones 1999), and is
highly expressed on hematopoietic cells (Germain 1994). BzATP induces MHC class I
cell surface loss from lymphocytes obtained from NOD.E and C57BL/10 mice, but
whether this loss is due to shedding or internalisation remains unclear (Elliott and
Higgins 2004).

ATP also induces a loss of MHC class I from the cell surface of murine bone marrowderived macrophages. This effect is absent in macrophages from Pfizer P2X7 knockout
mice (Baroja-Mazo et al. 2013). Furthermore, ADP and adenosine do not seem to play a
role in this loss. Both A-438079 and A74003 impaired ATP-induced MHC I loss from
these cells (Baroja-Mazo et al. 2013), confirming a role for P2X7. Similar to
BzATP-induced MHC class I loss from lymphocytes (Elliott and Higgins 2004), it
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remains unclear whether ATP-induced loss of MHC class I is due to shedding or
internalisation (Baroja-Mazo et al. 2013). The protease inhibitor E64, proteasome
inhibitor MG132, GM6001, and zinc chelator TPEN do not impair ATP-induced loss of
MHC I from the cell surface of these cells (Baroja-Mazo et al. 2013) suggesting a
protease does not play a role in this process.

Establishing a mechanism for P2X7 in BzATP- and ATP-induced MHC class I loss may
be of interest particularly as P2X7 plays a role in biological processes involving other
human leukocyte antigen molecules. P2X7-induced microvesicle and exosome release
of MHC II has been shown to occur from macrophages (Qu and Dubyak 2009), while
ATP does not induce a loss of this molecule from the surface of CLL cells (Gu et al.
1998). Conversely, P2X7 plays a role in inhibiting soluble human leukocyte antigen-G
release from lipopolysaccharide (LPS)-activated peripheral blood mononuclear cells
(PBMCs) (Rizzo et al. 2009), suggesting a complex role for P2X7 in the release of
human leukocyte antigen molecules from cells.

1.5.7.2 IL-6R
IL-6 is a cytokine involved in homeostasis as well as immune responses, and is thus
secreted by both immune and non-immune cells (Chalaris et al. 2011). It induces the
proliferation and differentiation of T cells, macrophages and neutrophils, and can induce
fever in the presence of TNF-α and IL-1 (Chalaris et al. 2011). The IL-6R mediates the
biological activities of IL-6. The IL-6 and IL-6R complex is composed of a type I
transmembrane glycoprotein and a type I transmembrane signal transducer protein
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(glycoprotein130) (Chalaris et al. 2011). This complex binds to two molecules of
glycoprotein130 to induce downstream signalling involving the janus kinase-signal
transducer and activator of transcription, ERK and PI3K signalling pathways (Chalaris
et al. 2011). Furthermore, soluble IL-6R released by shedding, also binds IL-6 to
activate cells that do not express this receptor (Chalaris et al. 2011).

BzATP induces IL-6R shedding from wild-type murine splenic cells, but not from cells
obtained from Pfizer P2X7 knockout mice (Garbers et al. 2011). The serum level of the
IL-6R from these knockout mice is also reduced significantly compared to wild-type
mice, suggesting a role for P2X7 in IL-6R shedding. KN-62 inhibits both the
BzATP-induced cell surface loss of the IL-6R, as well as soluble IL-6R generation,
confirming a role for P2X7 in IL-6R shedding. GI254023X and GW280264X inhibit
BzATP-induced IL-6R shedding in P2X7 and IL-6R co-transfected NIH3T3 mouse
embryonic fibroblasts, and HEK 293 cells (Garbers et al. 2011) suggesting ADAM10 is
involved in this process. Furthermore, the ADAM10 prodomain, A10-(23-213) inhibits
BzATP-induced IL-6R shedding from wild-type murine T cells, and in T cells from
mice with dramatically reduced ADAM17 expression. Therefore, ADAM10 plays a
predominant role in P2X7-induced IL-6R shedding (Garbers et al. 2011). It remains
unclear how P2X7 activates ADAM10 to induce IL-6R shedding.

1.5.7.3 TIM-2
The TIM family consists of eight murine members (TIM1-8) and three human members
(TIM-1, TIM-3 and TIM-4) (Freeman et al. 2010). TIM molecules are type I cell
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surface glycoproteins, with an N-terminal linked immunoglobulin-like domain, a mucin
domain and a cytoplasmic region containing tyrosine phosphorylation motifs (Freeman
et al. 2010). TIM-2 is expressed on rodent Th2 cells and splenic B cells (Freeman et al.
2010). TIM-2 functions as a negative regulator of T cell activation and binds H-ferritin,
which leads to endocytosis of extracellular H-ferritin (Freeman et al. 2010). BzATP
induces TIM-2 shedding from murine splenic B cells, and P2X7 and TIM-2
co-transfected HEK 293 cells (Dewitz et al. 2014). Both GI254023X and GW280264X
inhibit BzATP-induced TIM-2 shedding, confirming a role for ADAM10 in this process
(Dewitz et al. 2014), however a direct role for P2X7 remains to be established.

1.5.7.4 NCAM
NCAMs consist of three major isoforms including NCAM120, NCAM140 and
NCAM180, which differ in intracellular length (Dallerac et al. 2013). NCAM
extracellular domains contain five Ig motifs and two fibronectin type III domains. These
molecules are involved in cell migration, cell survival, axon guidance and synaptic
targeting (Dallerac et al. 2013). ATP induces NCAM shedding from embryonic rat
hippocampal neurons, and the shedding of each of the three major isoforms from
NCAM-transfected L929 murine fibroblasts (Hubschmann et al. 2005). ATP at a
concentration of 2.5 mM is needed to induce significant shedding of NCAM180
(Hubschmann et al. 2005), indicating a possible role for P2X7 in ATP-induced NCAM
shedding. The broad spectrum metalloprotease inhibitors, BB-3103 and GM6001,
inhibit ATP-induced NCAM shedding from NCAM180-transfected L929 cells.
GM6001 also inhibits ATP-induced shedding of the major NCAM isoforms from
NCAM-transfected L929 cells (Hubschmann et al. 2005), confirming a role for
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metalloproteases in the process. Lysosomal, proteasomal, calpain, PI3K and PKC
inhibitors had no effect on ATP-induced NCAM shedding (Hubschmann et al. 2005).
Furthermore, the extracellular ATP binding site of NCAM is not required for
ATP-induced NCAM shedding, which further supports a role for a P2 receptor in this
process (Hubschmann et al. 2005). Given the high concentration of ATP required to
induce NCAM shedding, it is feasible that P2X7 may play a role in ATP-induced
NCAM shedding.

1.5.7.5 ICAM-1
ICAMs are transmembrane glycoproteins, and ligands for β2 integrins on leukocytes.
There are five ICAMs identified (ICAM-1-5), of which ICAM-1 is most studied (Hua
2013). ICAM-1 is involved in inflammatory cell trafficking, leukocyte effector
functions, adhesion of antigen presenting cells to T cells and signal transduction
pathways (Hua 2013). BzATP stimulates ICAM-1 shedding from ICAM-1 and P2X7
co-transfected murine embryonic fibroblasts (mEFs) (Le Gall et al. 2009). GI254023X
inhibits BzATP-induced shedding in ADAM17-knockout mEF cells, which express
endogenous ADAM10, but not in ADAM10-knockout mEF cells, which express
ADAM17. Furthermore, BzATP does not induce ICAM-1 shedding in ADAM10/17
double knockout cells (Le Gall et al. 2009). BB-2516, but not GI254023X, impairs
BzATP-induced ICAM-1 shedding in CHO cells, which express endogenous P2X7 and
both ADAMs (Le Gall et al. 2009). Overall, the data suggests that BzATP-induced
ICAM-1 shedding predominantly involves ADAM17. However, in the absence of
ADAM17, ADAM10 can also cleave ICAM-1 (Le Gall et al. 2009). Further studies are
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needed to corroborate a direct role for P2X7 in this process, given that CHO cells also
express P2Y receptors (Myers et al. 2009).

1.5.8 TNF-α and TNFRs
TNF-α is a proinflammatory cytokine that plays a critical role in immunity and chronic
inflammatory disease. The precursor form, transmembrane TNF-α binds TNF-α
receptors and induces cell signalling (Horiuchi et al. 2010). ADAM17 cleaves
transmembrane TNF-α to the soluble form, which mediates its biological activities
through TNFRs 1 and 2 (Horiuchi et al. 2010). The TNFR family, induce a variety of
biological activities including promotion of cell survival, cell differentiation and death
(So et al. 2006). These receptors are active in trimeric form on the cell surface and in
the soluble form after extracellular cleavage (So et al. 2006). This family of receptors
can be divided into two groups based on binding properties and amino acid sequences
of the cytoplasmic domains (So et al. 2006). These include TNFRs that contain a death
domain, such as TNFR1, which interacts with death domain proteins and leads to
apoptosis, while those that do not contain death domains associate with
TNF receptor-associated factors and lead to induction of proinflammatory activities (So
et al. 2006). Members of this family, including CD27, support activation, differentiation
and survival of B cells, T cells and dendritic cells (So et al. 2006). CD27 is a type I
transmembrane glycoprotein which is expressed on T cells (Camerini et al. 1991) and
B cells (Maurer et al. 1990). CD27 is involved in T cell activation (Agematsu et al.
1994) and B cell-B cell interactions (Maurer et al. 1990).
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1.5.8.1 TNF-α
BzATP induces the shedding of TNF-α from TNF-α and P2X7 co-transfected mEFs (Le
Gall et al. 2009). GI254023X impairs BzATP-induced shedding of TNF-α only in
ADAM17-knockdown

mEF

cells,

which

express

ADAM10,

but

not

in

ADAM10-knockdown mEF cells, which express ADAM17 (Le Gall et al. 2009). In
CHO cells, which endogenously express P2X7 and the ADAM proteases, GI254023X
does not impair BzATP-induced shedding, suggesting that ADAM10 contributes to the
shedding only in the absence of ADAM17 (Le Gall et al. 2009). The contribution of
P2X7 in this process remains to be established.

1.5.8.2 TNFR1
Recently, it was shown that the P2Y2 and P2Y4 agonist, UTP, induces the shedding of
soluble TNFR1 from human corneal epithelial cells (Sakimoto et al. 2014).
Furthermore, the eye drop diquafosol sodium, a P2Y2 agonist, increases soluble TNFR1
in tear fluids of patients with short break-up time dry eye (Sakimoto et al. 2014). A role
for downstream signalling molecules in UTP-induced TNFR1 shedding remains to be
determined. Rowlands and colleagues show that soluble TNF-α induces mitochondrial
Ca2+ oscillations while concomitantly, P2Y2 potentiates and prolongs these Ca2+
oscillations, which lead to ROS-dependent activation of ADAM17. Subsequently,
ADAM17 cleaves TNFR1 (Rowlands et al. 2011). Thus, it would be of interest to
determine the mechanism involved in direct nucleotide-induced TNFR1 shedding and
whether ADAM17 and mitochondrial Ca2+ oscillations are involved in this process.
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1.5.8.3 CD27
ATP induces a loss of surface CD27 from murine B and T cells (Moon et al. 2006).
Surface plasmon resonance shows that supernatants from ATP-treated splenocytes
display significant binding to immobilised anti-CD27 antibody (Moon et al. 2006)
indicating ATP-induced loss of CD27 is due to shedding. BzATP induces CD27
shedding more potently than ATP, and ATP induced CD27 shedding is impaired by
KN-62 confirming a role for P2X7 (Moon et al. 2006). Several antagonists targeting
signalling molecules including tyrosine kinases, PI3K, MEK-1 and p38 MAPK could
not impair P2X7-induced CD27 shedding. GM6001, almost completely impaired
P2X7-induced CD27 shedding suggesting a role for metalloproteases in this process
(Moon et al. 2006). However, the specific metalloproteases involved remain to be
determined.

1.5.9 Epidermal growth factor receptor ligands
Epidermal growth factor receptor (EGFR) activation involves the binding of growth
factor ligands EGF, heparin-binding EGF-like growth factor (HB-EGF), TGF-α,
amphiregulin, betacellulin, epiregulin and epigen (Schneider and Wolf 2008). The
EGFR ligands are type I transmembrane proteins that contain an N-terminal extension,
EGF module, a short juxtamembrane stalk, transmembrane domain and C-terminal
cytoplasmic tail (Schneider and Wolf 2008). Ectodomain shedding of these ligands
generates the soluble version, which binds and activates the EGFR (Schneider and Wolf
2008). EGFR ligands are involved in the modulation of cell proliferation, apoptosis and
migration in a variety of cancers and other diseases (Schneider and Wolf 2008). These
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ligands also play important roles in processes such as wound healing, tumorigenesis and
bone formation (Schneider and Wolf 2008).

1.5.9.1 HB-EGF
The first indication of nucleotide-induced HB-EGF release was indirectly shown using a
neutralising antibody against HB-EGF, which inhibited ATP-induced mitogenic effects
in guinea pig Muller glial cells (Milenkovic et al. 2003). It was postulated that
ATP-induced P2Y receptor activation leads to the release of HB-EGF from the cell,
which mediates transactivation of the EGF receptor (Milenkovic et al. 2003). Later,
direct evidence of nucleotide-induced HB-EGF shedding was shown using
ATPγS-treated HB-EGF-transfected SV-40 immortalised human corneal epithelial cells
(THCE) (Yin et al. 2007, Yin and Yu 2009). Wounding, which increases ATP in the
culture medium, as well as ADP, also induced HB-EGF shedding from THCE cells (Yin
et al. 2007, Yin and Yu 2009). The P2Y receptor inhibitor, reactive blue 2 inhibited
ATPγS-induced HB-EGF shedding confirming a role for a P2Y receptor in this process
(Yin et al. 2007). GM6001, GW280264X (Yin et al. 2007) and GI254023X (Yin and
Yu 2009) inhibited HB-EGF shedding from these cells. Furthermore, the MEK and
ERK1/2 inhibitors, PD98059 and U0126 respectively, also inhibited ATPγS- and
wound-induced HB-EGF shedding. Overall, these studies suggest that ADAM10,
ADAM17, MEK and ERK1/2 are involved in ATP-induced HB-EGF shedding from
THCE cells and that this process may be relevant during wound healing. ATPγS is
known to activate P2Y2 and partially P2Y4 (Ralevic and Burnstock 1998). It also
partially activates all P2X receptors except murine P2X7 (Kaczmarek-Hajek et al.
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2012). Therefore further pharmacological characterisation is required to determine
which P2 receptor is involved in HB-EGF shedding.

1.5.9.2 TGF-α
Several studies show that nucleotide treatment of cells induces TGF-α release. BzATP
induces the shedding of TGF-α from TGF-α-transfected CHO cells (Le Gall et al.
2009), and from TGF-α and P2X7 co-transfected mEFs (Le Gall et al. 2010). TGF-α
shedding from CHO cells is impaired by BB-2516 but not GI254023X, suggesting a
role for ADAM17 in the process (Le Gall et al. 2009). P2X7 seems to be involved in
TGF-α shedding, however further confirmation is required as P2Y receptors have also
been implicated in TGF-α shedding. Myers and colleagues have shown that both ATP
and UTP induce TGF-α shedding from TGF-α-transfected CHO cells (Myers et al.
2009). Based on UTP-induced shedding and P2Y2 mRNA expression in these cells, the
authors suggest a role for P2Y2 (Myers et al. 2009). The broad spectrum
metalloprotease inhibitor, TAPI-2 inhibits ATP-induced TGF-α shedding from CHO
cells, but, ATP does not induce TGF-α shedding from M2 CHO cells, which are
deficient in ADAM17 (Myers et al. 2009). ATP, ATPγS and UTP also induce the
release of endogenous TGF-α from EC-4 murine fibroblasts. ATP-induced TGF-α
shedding only occurs in EC-4 fibroblasts that express ADAM17 compared to
complimentary EC-2 fibroblasts, which are deficient in ADAM17 (Myers et al. 2009).
Therefore, ADAM17 is involved in nucleotide-induced TGF-α shedding.
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Ca2+ chelators, BAPTA-AM and EGTA suppress ATP-induced shedding of TGF-α
from CHO cells, indicating this process is regulated by both intracellular and
extracellular calcium (Myers et al. 2009). The ROS scavenger N-acetylcysteine, near
completely inhibits ATP-induced TGF-α shedding, while the mitochondrial complex I
inhibitor, rotenone impairs the majority of ATP-stimulated TGF-α shedding. Together,
the mitochondrial complex III inhibitor myxothiazol and rotenone inhibit ATP-induced
TGF-α shedding as effectively as N-acetylcysteine (Myers et al. 2009). Therefore,
mitochondrial ROS play major roles in nucleotide-induced TGF-α shedding (Myers et
al. 2009). However, as indicated elsewhere (section 1.5.3) rotenone can also induce
mitochondrial ROS formation, thus the role of ROS in ATP-induced shedding of
molecules require further investigation.

ATP also induces endogenous TGF-α shedding from the human bronchial epithelial
(HBE) 1 cell line, which is impaired by siRNA directed against the NADPH oxidase
homolog, dual oxidase 1 (Boots et al. 2009). Silencing of dual oxidase 1 impairs
ADAM17 activity, indicating a role for both molecules in ATP-induced TGF-α
shedding (Boots et al. 2009). Suramin inhibition of ATP-induced ADAM17 activation
implicates P2Y receptor activity in TGF-α shedding from these cells. (Boots et al.
2009). Melittin, which induces ATP secretion, also induces TGF-α shedding from
HaCaT keratinocytes, also suggesting a role for P2 receptors in this process (Sommer et
al. 2012). The ERK1/2 inhibitor, U0126 also impaired ATP-induced ADAM17 activity
in HBE1 cells (Boots et al. 2009) suggesting that ERK1/2 is involved in ATP-induced
stimulation of ADAM17. Collectively, the above studies suggest a role for both P2Y2
and P2X7 receptor activation in nucleotide-induced TGF-α shedding, but more evidence
is required to show a specific role for each receptor in this process.
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1.5.9.3 Amphiregulin
ATP and ATPγS induce amphiregulin shedding from human monocyte-derived
dendritic cells, which is enhanced in the presence of LPS (Bles et al. 2010). However,
ATP and ATPγS do not induce amphiregulin shedding from murine bone marrow
derived dendritic cells unless cells are pre-stimulated with LPS (Bles et al. 2010). UTP
also induces amphiregulin shedding from murine bone marrow-derived dendritic cells
in the presence of LPS (Bles et al. 2010) suggesting a role for P2Y2 in this process.
Moreover, suramin inhibits nucleotide-induced amphiregulin shedding from human
monocyte-derived dendritic cells (Bles et al. 2010) consistent with a role for P2Y
receptors in the process. However, further pharmacological evidence is required to
confirm a role for P2Y receptors in nucleotide-induced amphiregulin shedding.

1.5.9.4 Betacellulin
P2X7 is implicated in the shedding of betacellulin (Le Gall et al. 2009, Le Gall et al.
2010). BzATP induces betacellulin shedding from betacellulin-transfected CHO cells,
and betacellulin and P2X7 co-transfected mEFs (Le Gall et al. 2009). BzATP-induced
betacellulin shedding is impaired by BB-2516, GI254023X and dominant negative
ADAM10, which lacks the metalloprotease domain (Le Gall et al. 2009). When P2X7 is
co-expressed with betacellulin in ADAM17-knockdown mEFs, which express
endogenous ADAM10, GI254023X impairs BzATP-induced betacellulin shedding.
However, in ADAM10-knockdown mEFs, which express endogenous ADAM17,
BzATP does not induce betacellulin shedding (Le Gall et al. 2009). Collectively this
suggests ADAM10 is the dominant metalloprotease involved in BzATP-induced
betacellulin shedding.
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Given that multiple P2 receptors are implicated in EGFR ligand shedding, it will be of
value to determine the specific mechanisms and conditions required for each receptor in
these processes.

1.5.10 Amyloid precursor protein
Amyloid-β peptide (Aβ) accumulation is a major pathological hallmark of Alzheimer’s
disease (Haass et al. 2012). Amyloid precursor protein (APP) is a type I membrane
protein with an intracellular C-terminus and an extracellular N-terminus (Haass et al.
2012). APP can be cleaved by two alternate proteolytic pathways, termed the
amyloidogenic and anti-amyloidogenic pathways (Figure 1.7). In the amyloidogenic
pathway, APP is cleaved by the β-secretase and then the γ-secretase to generate Aβ.
(Haass et al. 2012). Specifically, the β-secretase first cleaves the APP ectodomain to
generate the soluble fragment, soluble amyloid precursor protein β (sAPPβ) and the
β-carboxyl-terminal fragment (β-CTF) in the transmembrane domain. β-CTF itself is
then subsequently cleaved by γ-secretase to generate Aβ, which is found in extracellular
fluids (Haass et al. 2012). In contrast, the anti-amyloidogenic pathway involves
α-secretase activity, which cleaves APP in the middle of the Aβ domain and results in
the secretion of soluble amyloid precursor protein α (sAPPα) and the generation of
membrane α-carboxyl-terminal fragment (α-CTF). α-CTF is then cleaved by γ-secretase
to generate the truncated Aβ peptide termed p3 (Haass et al. 2012). Several ADAM
metalloproteases including ADAM9, ADAM10, ADAM17 and ADAM19 can function
as α-secretases. It is thought these pathways compete with each other, as enhancing
α-secretase activity in animal models of Alzheimer’s disease lowers Aβ generation
(Haass et al. 2012).
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Figure 1.7: APP processing pathways. The amyloidogenic pathway (left) is (1)
initiated with the cleavage of APP by β-secretase (2) to generate sAPPβ and β-CTF. (3)
β-CTF

is

subsequently

cleaved

by

γ-secretase

(4)

to

generate

Aβ.

The

anti-amyloidogenic pathway (right) is (1) initiated with the cleavage of APP by
α-secretase (2) to generate sAPPα and α-CTF. (3) α-CTF is subsequently cleaved by
γ-secretase (4) to generate truncated Aβ peptide termed p3 (adapted from Haas et al.
2012). Abbreviations: APP, amyloid precursor protein; sAPPβ, soluble amyloid precursor protein β;
β-CTF, β-carboxyl-terminal fragment; sAPPα, soluble amyloid precursor protein α; α-CTF,
α-carboxyl-terminal fragment

Both P2Y2 and P2X7 activation are involved in the release of sAPPα from cells. P2Y2
was first implicated in this process using P2Y2-transfected human 1321N1 astrocytoma
cells (Camden et al. 2005). UTP-induced shedding of sAPPα from 1321N1 cells is
dependent on the presence of extracellular Ca2+, and partially on ERK1/2 (Camden et al.
2005). The metalloprotease inhibitors phenanthroline and TAPI-2, as well as the
pro-protein convertase inhibitor, decanoyl-RVKR-CMK ketone, inhibit UTP-induced
sAPPα shedding (Camden et al. 2005), implying a role for metalloproteases in the
process. siRNA silencing of ADAM10 and ADAM17 reduced UTP-induced sAPPα
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shedding, and when silenced simultaneously, near completely suppressed shedding
(Camden et al. 2005). This indicates that both ADAM10 and ADAM17 are involved in
P2Y2-induced sAPPα shedding.

UTP-induced sAPPα shedding is enhanced after pre-treatment with IL-1β in rat primary
cortical neurons, which endogenously express P2Y2 (Kong et al. 2009). In agreement
with Camden and colleagues, TAPI-2 near-completely inhibits, while U0126 partially
inhibits UTP-induced sAPPα shedding. Conflicting with Camden and colleagues, who
found that UTP-induced sAPPα shedding is independent of PKC activation (Camden et
al. 2005), Kong and colleagues found that the PKC inhibitor, GF109203, partially
inhibits UTP-induced sAPPα shedding (Kong et al. 2009). The PI3K inhibitor,
LY294002 also significantly inhibits UTP-induced sAPPα shedding (Kong et al. 2009).
These studies indicate that ADAM10/17 and PI3K regulate P2Y2-induced sAPPα
shedding, which is enhanced in the presence of IL-1β, and involves both PKC and
ERK1/2 (Camden et al. 2005, Kong et al. 2009). However, these studies do not show
direct activation of P2Y2 and therefore cannot discount the effect of other P2 receptors.
In particular, P2Y4 which is also activated by UTP and may be involved in
UTP-induced APP processing from primary rat cortical astrocytes (Tran 2011).

ATP and BzATP also induce the shedding of sAPPα from human APP-transfected
murine Neuro2a neuroblastoma cells (Delarasse et al. 2011). P2X7 antagonists,
A-438079 and BBG, as well as P2X7 siRNA inhibit BzATP-induced shedding of
sAPPα from these cells. BzATP also induces sAPPα shedding from SK-N-BE human
neuroblastoma cells which express endogenous P2X7 and APP (Delarasse et al. 2011).
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The P2X7 antagonists, oATP and A-438079 also impair BzATP-induced sAPPα
shedding from these cells (Delarasse et al. 2011). Collectively, this data suggests that
P2X7 activation induces sAPPα release from neuroblastoma cells. Furthermore, BzATP
fails to induce sAPPα shedding from astrocytes and neural progenitor cells from Pfizer
P2X7 knockout mice (Delarasse et al. 2011), confirming a role for P2X7 in this process.
TAPI-2 and GM6001 inhibit BzATP-induced sAPPα shedding from Neuro2a cells
establishing a role for metalloproteases. However, siRNA silencing of ADAM 9, 10 and
17 does not inhibit P2X7-induced shedding of sAPPα from these cells (Delarasse et al.
2011), suggesting the involvement of an alternate α-secretase in P2X7-induced
shedding. Furthermore, U0126 and the JNK inhibitor, SP600125, as well as siRNA
against intracellular signalling complex, ezrin radixin and moesin (ERM) impair
P2X7-induced sAPPα shedding from APP-transfected Neuro2a cells (Delarasse et al.
2011, Darmellah et al. 2012). The Rho-kinase inhibitor, fasudil, and the PI3K inhibitors,
LY294002 and wortmannin also impair P2X7-induced sAPPα shedding from these cells
(Darmellah et al. 2012). The PI3K inhibitors do not impair ERM phosphorylation,
suggesting PI3K is activated downstream of the ERM (Darmellah et al. 2012). Overall,
P2X7-induced shedding of sAPPα from neural cells depends on Rho kinase, MAP
kinase, ERM phosphorylation, PI3K and involves metalloprotease action.

In contrast to the above data, Diaz-Hernandez and colleagues show an opposing role for
P2X7 in APP processing. P2X7 antagonists, BBG and A-438079 inhibit GSK-3 by
increasing ser9/ser21 phosphorylation, which subsequently increases the α-secretase
product, α-CTF in Neuro2a cells (Diaz-Hernandez et al. 2012). Whereas, BzATP
treatment of Neuro2a cells decreases α-CTF and activates GSK-3 by decreasing
ser9/ser21 phosphorylation. This α-CTF product decreases when Neuro2a cells are
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treated with broad spectrum metalloprotease inhibitor TAPI-1 (Diaz-Hernandez et al.
2012). Similar effects were also observed in P2X7-transfected HEK 293 cells (DiazHernandez et al. 2012). Furthermore, in vivo antagonism of P2X7 by BBG in a murine
model of early onset familial Alzheimer’s disease inhibits GSK-3 and the development
of Aβ plaques via regulation of α-secretase activity (Diaz-Hernandez et al. 2012). This
work is corroborated by Leon-Otegui and colleagues who also show BzATP decreases
α-CTF in Neuro2a cells and BBG reverts this inhibition, thus proposing a role for P2X7
in the inhibition of α-secretase activity (Leon-Otegui et al. 2011). Diaz-Hernandez and
colleagues critique the use of higher BzATP concentrations by Delarasse and
colleagues, and suggest a role for P2Y2 in their system. Indeed, Leon-Otegui and
colleagues show that BzATP used at a concentration above 100 µM increases α-CTF
and thus α-secretase activity via P2Y2 (Leon-Otegui et al. 2011). It is unclear which
P2X7 mechanism prevails in APP processing and thus further studies are warranted.
Interestingly, it has been shown that Aβ can promote the caspase-mediated cleavage of
P2X4 (Varma et al. 2009), suggesting a complex role for P2 receptors in the
amyloidogenic and anti-amyloidogenic pathways.

1.6 Summary and aims of current research
Nucleotide induced P2 receptors activate several signalling pathways which result in the
shedding of membrane molecules (Figure 1.6). P2X7 is involved in the shedding of
several different membrane molecules including CD23. P2X7 and soluble CD23 play a
key role in inflammatory and immune diseases, but how both molecules contribute to
these diseases has not been determined. Moreover, the role of P2X7 in ATP-induced
CD23 shedding is limited to malignant B cells and dendritic cells derived in culture,
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thus whether this process occurs in primary B cells remains unknown. Furthermore, the
mechanism by which P2X7 induces CD23 shedding from cells, particularly B cells
remains elusive. Currently, it is known that the ADAM10 metalloprotease constitutively
sheds CD23 from the cell surface, but whether P2X7 activates ADAM10 and/or other
downstream signalling molecules to induce the shedding of CD23 has not been
elucidated. Therefore the aims of the current research are to:
1. Confirm the presence of and to further characterise P2X7 on RPMI 8226
multiple myeloma B cells;
2. Examine the signalling pathways involved in P2X7-induced CD23 shedding
using RPMI 8226 cells as a model;
3. Examine whether ROS are involved in P2X7-induced CD23 shedding from
RPMI 8226 cells;
4. Determine, using RPMI 8226 cells, whether ADAM10 is involved in
P2X7-induced CD23 shedding and;
5. Determine whether P2X7 activation induces CD23 shedding from primary
human and murine B cells.
Elucidating the mechanisms involved in P2X7-induced CD23 shedding and identifying
the cell types associated with this process may reveal potential novel therapeutic targets
for autoimmune and inflammatory disorders.
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CHAPTER 2
Materials and methods
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2.1 Reagents
RPMI-1640 medium (containing 10 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic
acid (HEPES)), L-glutamine, GlutaMAX, DMEM:F12 medium (containing 10 mM
HEPES)

penicillin/streptomycin,

probenecid,

G418,

dichlorodihydrofluorescein

diacetate (H2DCFDA), mitoSOX™ Red and YO-PRO-1 iodide solution were from Life
Technologies (Grand Island, NY). Foetal bovine serum was from either Lonza (Basal,
Switzerland) or Bovogen Biologicals (East Keilor, Australia). Agarose and
HyperLadderTM I molecular weight markers were from Bioline (Alexandria, Australia).
Adenosine

5’-triphosphate

(ATP),

2'(3')-O-(4-benzoylbenzoyl)adenosine-5'-

triphosphate, adenosine 5’-diphosphate, uridine 5’-triphosphate, paraformaldehyde,
colchicine,

N-methyl-D-glucamine,

1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-

tetraacetic acid (BAPTA-AM), imipramine, poly-D-lysine, hydrogen peroxide,
rotenone,

high

grade

bovine

serum

albumin

(BSA),

2,2′-azino-bis(3-

ethylbenzothiazoline-6-sulfonic acid and red blood cell lysis buffer were from
Sigma-Aldrich (St. Louis, MO). Sodium chloride (NaCl), potassium chloride (KCl),
D-glucose, HEPES, calcium chloride (CaCl2), sucrose, BSA, ethylene glycol tetraacetic
acid (EGTA), dimethyl sulphoxide, Tween-20 and ethidium bromide were from
Amresco (Solon, OH). Magnesium chloride (MgCl2) was from Chem-Supply (Gillman,
Australia). AZ10606120, AZ11645373, A-438079, SB216763 and BB-94 were from
Tocris Bioscience (Ellisville, MO). Choline chloride (choline Cl) and ammonium
chloride were from Univar (Downers Grove, IL). Rottlerin, SB202190, SB203580,
U0126 and SP600125 were from Merck Chemicals (Darmstadt, Germany). AG-126,
GF109203X, D609, Fasudil, Y-27632, AACOCF3 and 7-aminoactinomycin D (7AAD)
were from Enzo Life Sciences (Plymouth Meeting, PA). LY294002 and GM6001 were
from Calbiochem (Darmstadt, Germany). GI254023X was kindly provided by
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GlaxoSmithKline (Stevenage, United Kingdom). KN-62 was from Alexis Biochemicals
(Lausen, Switzerland). CAY10593 (VU0155069), CAY10594, halopemide and
diphenyleneiodonium were from Cayman Chemical Company (Ann Arbor, MI). Ficoll
PaqueTM PLUS was from GE Healthcare Bio-Sciences AB (Uppsala, Sweden).

2.2 Antibodies
Purified anti-human P2X7 monoclonal antibody (mAb) (clone L4) and isotype control
(clone WMD7) conjugated to Alexa Fluor® 647 (Life Technologies) was kindly
provided by Dr. Ronald Sluyter (University of Wollongong, Wollongong, Australia).
Phycoerythrin (PE) and allophycocyanin (APC)-conjugated murine anti-human CD23
(clone EBVCS2) and isotype control (clone P3.6.2.8.1) mAbs, APC-conjugated murine
anti-human CD19 (clone HIB19), fluorescein isothiocyanate (FITC)-conjugated rat
anti-murine CD23 (clone B3B4), FITC-conjugated isotype control (clone eBR2a),
APC-conjugated rat anti-murine CD19 (clone eBio1D3) and PE-conjugated murine
anti-human Toll-like receptor 9 (TLR-9) (clone eB72-1665) mAbs were from
eBioscience (San Diego, CA). Rabbit anti-human CXCL16 and control IgG antibodies
(Ab) were from Peprotech (Rocky Hill, NJ), and FITC-conjugated sheep anti-rabbit Ab
was from Silenus Laboratories (Hawthorn, Australia).
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2.3 Cells
2.3.1 Cell lines
Human RPMI 8226 multiple myeloma B cells and human A431 skin epithelial
carcinoma cells (European Collection of Cell Cultures, Porton Down, UK) were
maintained in complete RPMI-1640 medium (RPMI-1640 medium containing 10%
(v/v) foetal bovine serum and 2 mM GlutaMAX or L-glutamine) at 37ºC and 95%
air/5% CO2. Murine erythroleukaemia cells (MEL) cells were kindly provided by Dr.
Sally Eaton (University of Sydney, Sydney, Australia) and maintained as above. Human
embryonic kidney (HEK) 293 cells (American Type Culture Collection, Rockville, MD)
stably expressing human P2X7 were maintained by Dr. Leanne Stokes (University of
Sydney, Penrith, Australia), in complete DMEM:F12 medium (DMEM:F12 medium
containing 10% foetal bovine serum, 100 U/ml penicillin, 100 μg/ml streptomycin,
2 mM L-glutamine and 800 µg/ml G418). Cell lines were routinely checked for
mycoplasma using the MycoAlertTM Mycoplasma Detection Kit (Lonza) and were
consistently negative for mycoplasma.

2.3.2 Human peripheral blood mononuclear cells
All experiments involving human blood were approved by the University of
Wollongong Human Ethics Committee. Human peripheral blood was collected into
VACUETTE® lithium heparin tubes (Greiner Bio-One, Frickenhausen, Germany) and
diluted with an equal volume of incomplete RPMI 1640 medium or phosphate-buffered
saline (PBS). Peripheral blood mononuclear cells (PBMCs) were separated by density
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gradient centrifugation over Ficoll-PaqueTM PLUS (560 x g for 30 min) and washed
once in incomplete RPMI 1640 medium or twice in NaCl medium (145 mM NaCl,
5 mM KCl, 5 mM D-glucose, 10 mM HEPES, pH 7.4) (450 x g for 10 min).

2.3.3 Murine splenic cells
All experiments involving mice were approved by the University of Wollongong
Animal Ethics Committee. C57BL/6 and DBA/1 mice were from Animal Resources
Centre (Perth, Australia) or Australian BioResources (Moss Vale, Australia). P2X7
knockout mice (Solle et al. 2001) backcrossed onto a C57BL/6 background (Tran et al.
2010), were bred at the Centenary Institute (Sydney, Australia) by Dr. Bernadette
Saunders or the University of Wollongong (Wollongong, Australia) by Vanessa Sluyter.
Mice were euthanised by CO2 and spleens collected in ice-cold PBS. Spleens were
teased apart using a needle and forceps in ice-cold PBS, and cells were filtered through
a 70 µm nylon cell strainer (BD, San Jose, CA). Splenic cells were then washed in
ice-cold PBS (400 x g for 5 min) and the pellet resuspended in red blood cell lysis
buffer. Red blood cells were lysed for 3 min at room temperature with agitation and the
remaining leukocytes were washed once with ice-cold DMEM/F12 medium. Cells were
then washed twice in NaCl medium.
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2.4 Detection of specific messenger RNA expression by
reverse transcriptase-polymerase chain reaction
Total RNA was isolated from cells using the RNeasy Mini Kit (Qiagen, Hilden,
Germany) according to the manufacturer’s instructions. Primers to P2X1-6 (Wareham et
al. 2009), phospholipase D (PLD)1 (designed using OligoPerfectTM Designer, Life
Technologies) PLD2 (Scott et al. 2009) (Table 2.1) and a disintegrin and
metalloprotease (ADAM) 10 (Verrier et al. 2004) were obtained from GeneWorks
(Hindmarsh, Australia). Primers to P2X7 (Skarratt et al. 2005) (Table 2.1) were
obtained from Sigma-Genosys (Castle Hill, Australia).

Table 2.1: Primer pairs used to detect mRNA of P2X receptors, PLD isoforms and
ADAM10.
Molecule

Forward (5’-3’)

Reverse (5’-3’)

P2X1

CGTCATCGGGTGGGTGTTTCTCTA

AGGGCGCGGGATGTCGTCA

P2X2

GGGCCCCGAGAGCTCCATCATC

GCAGGCAGGTCCAGGTCACAGTCC

P2X3

ACTGGCCGCTGCGTGAACTACA

CACGTCGAAGCGGATGCCAAAAG

P2X4

CGGCACCCACAGCAACGGAGTCT

TGTATCGAGGCGGCGGAAGGAGTA

P2X5

GGCCCCAAGAACCACTACTGC

CCTCGGCCTCCTGGGAACTGTCT

P2X6

AGCCCCTACTGTCCCGTGTTCC

GCCTTGGCCTCCTCATACTTTGTC

P2X7

GGATGGTGAACCAGCAGCTA

AAGCCACTGTACTGCCCTTC

PLD1

TCATGTGTCATCCACCGTCT

GGCGTGGAGTACCTGTCAAT

PLD2

GGCGATGAGATTGTGGACA

CTGGAAGAAGTCATCACAGA

ADAM10

GCAGAATCATGATGACTACTGTTTG

TATAGCCACAATCACATTCTTCACC

Abbreviations: ADAM10, A disintegrin and metalloprotease 10; mRNA, messenger RNA; PLD,
Phospholipase D
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Reverse transcriptase-polymerase chain reaction (RT-PCR) amplification of P2X
receptor mRNA was performed using SuperscriptTM III One-Step RT-PCR System
Platinum Taq DNA polymerase (Life Technologies) according to the manufacturer’s
instructions using a Mastercycler Pro S (Eppendorf, North Ryde, Australia). Polymerase
chain reaction (PCR) cycling conditions for P2X1-7 were 54°C for 30 min, 95°C for 2
min, 30 cycles of 95°C for 15 s, 58°C (P2X1 primer pair), 59°C (P2X2 primer pair),
58°C (P2X3 primer pair), 58°C (P2X4 primer pair), 55°C (P2X5 primer pair), 58°C
(P2X6 primer pair) or 55°C (P2X7 primer pair) for 30 s, and 72°C for 1 min, followed
by a final step of 72°C for 5 min. RT-PCR amplification of PLD1, PLD2 and ADAM10
was performed using the MyTaq One-Step RT-PCR Kit (Bioline) according to the
manufacturer’s instructions. PCR cycling conditions for PLD were 45°C for 20 min,
94°C for 2 min, 30 cycles of 94°C for 30 s, 54°C (PLD1 primer pair) or 57°C (PLD2
primer pair) for 1 min, and 72°C for 1 min, and a final step of 72°C for 5 min. PCR
cycling conditions for ADAM10 were 45°C for 20 min, 30 cycles of 94°C for 10 s,
49°C for 1 min 30 s and 72°C for 1 min, and a final step of 72°C for 10 min. Amplicons
were separated on a 2% (w/v) agarose gel by electrophoresis using the Mini-SubTM Cell
GT System tank (BioRad, Hercules, CA). Amplicons were visualised using ethidium
bromide and the Gel Logic 2200 Pro Imaging System (Carestream Health, Rochester,
NY). Amplicon size was determined using the HyperLadderTM I molecular weight
markers.

2.5 P2X receptor sequencing
Total RNA was isolated as in Section 2.4. RT-PCR was performed using the
SuperscriptTM III One-Step RT-PCR System Platinum Taq DNA polymerase for P2X5
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or the MyTaq One-Step RT-PCR Kit for P2X7 according to the manufacturer’s
instructions. Primer pairs used for P2X5 complementary DNA (cDNA) are shown in
Table 2.1. Primer pairs (GeneWorks) specific for four overlapping regions of full-length
P2X7 cDNA including parts of the untranslated 5′ and 3′ ends are shown in Table 2.2.
The PCR cycling conditions for P2X5 were as in Section 2.4. The PCR cycling
conditions for P2X7 were 45 °C for 20 min, 95 °C for 1 min, 40 cycles of 95 °C for 10
s, 63 °C (primer pair 1), 59 °C (primer pair 2), 62 °C (primer pair 3) or 61 °C (primer
pair 4) for 10 s, and 72 °C for 30 s, and a final step of 72 °C for 5 min. Amplicons were
ran on 2% (w/v) agarose gels and visualised by ethidium bromide staining (as above,
Section 2.4), and then excised and purified using the Wizard SV Gel and PCR Clean-Up
System (Promega, Madison, WI) according to the manufacturer’s instructions. Purified
amplicons were sequenced using the above primers with the BigDye Terminator v3.1
Cycle Sequencing Kit (Applied Biosystems, Carlsbad, CA) and an Applied Biosystems
3130xl Genetic Analyzer by Margaret Phillips (University of Wollongong). PCR
cycling conditions for sequencing were 95 °C for 2 min, and then 25 cycles of 96 °C for
30 s, 55 °C for 15 s and 60 °C for 4 min. Results were analysed using Clustal W (Larkin
et al. 2007) for P2X5 and Geneious (Biomatters, Auckland, New Zealand) for P2X7.

Table 2.2: Primer pairs used to sequence full-length P2X7 cDNA.
Primer pairs

Forward (5’-3’)

Reverse (5’-3’)

1

TGGCCCTGTCAGGAAGAGTA

CACCAGGCAGAGACTTCACA

2

TTGTAAAAAGGGATGGATGGA

AAATATGGGAGCGACAGCAG

3

TACATCGGCTCAACCCTCTC

GAACAGCTCTGAGGTGGTGA

4

GTCTGGTGCCAGTGTGGAA

ACTCCCGACCTCAGGTGAT
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2.6 Detection of P2X7 expression by flow cytometry
Cell surface and total P2X7 expression was examined in fresh cells, or fixed and
permeabilised cells, by immunofluorescent labelling and flow cytometry. For the
detection of cell-surface P2X7, fresh RPMI 8226 cells (1 x 106 cells/ml) were washed
once in PBS. For the detection of total P2X7 (cell surface and intracellular), RPMI 8226
cells were fixed and permeabilised using the Intracellular Fixation and Permeabilisation
Buffer Set (eBioscience) according to manufacturer’s instructions. Briefly, RPMI 8226
cells were fixed with 0.2% (w/v) paraformaldehyde in PBS for 20 min and centrifuged
(400 x g for 5 min). Fixed cells were permeabilised with 0.1% (w/v) saponin in PBS.
Fresh, or fixed and permeabilised cells were then incubated with Alexa-Fluor® 647conjugated anti-P2X7 or isotype control mAb for 20 min at room temperature; 7AAD
was included with fresh cells to exclude dead cells. The mean fluorescence intensity
(MFI) of P2X7 expression was determined using a LSR II flow cytometer (BD) (using
band-pass filters of 660/20 for Alexa-Fluor® 647 and 695/40 for 7AAD). Analysis was
performed using FlowJo software (Tree Star, Ashland, OR).

2.7 Measurement of P2X7-induced pore formation by flow
cytometry

2.7.1 Cell lines and human PBMCs
P2X7-mediated pore formation was assessed using a fixed-time assay as described
(Constantinescu et al. 2010). Cell lines or human PBMCs suspended in NaCl medium
(1 x 106 cells/ml) were incubated with 25 μM ethidium+ in the absence or presence of
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ATP (as indicated) at 37 °C. In some experiments, cells were resuspended in either
NaCl medium containing 1.5 mM CaCl2 and 1 mM MgCl2, sucrose medium (280 mM
sucrose, 5 mM KCl, 10 mM N-methyl-D-glucamine, 5 mM D-glucose, 10 mM HEPES,
pH 7.4), KCl medium (150 mM KCl, 5 mM D-glucose, 10 mM HEPES, pH 7.4), or
choline Cl medium (150 mM choline Cl, 5 mM KCl, 5 mM D-glucose, 10 mM HEPES,
pH 7.4) and incubated with 25 μM ethidium+ in the absence or presence of ATP (as
indicated) for 5 min at 37 °C. In other experiments, cells in NaCl medium were
preincubated in the absence or presence of antagonist (as indicated), and then with
25 μM ethidium+ in the absence or presence of ATP (as indicated) for 5 min at 37°C.
All ATP incubations were stopped by addition of an equal volume of ice-cold
MgCl2 medium (NaCl medium containing 20 mM MgCl2) and centrifugation
(300 x g for 5 min). Cells were washed once with NaCl medium. PBMCs were then
incubated with APC-conjugated anti-human CD19 mAb for 20 min at 4°C and washed
once with NaCl medium. The MFI of ethidium+ uptake was determined using flow
cytometry (using a 575/26 nm band-pass filter for ethidium+ or 660/20 nm for APC) and
FlowJo software. For PBMCs, lymphocytes and monocytes were gated by forward and
side scatter, and B cells and T cells on CD19+ and CD19- lymphocytes, respectively.

2.7.2 Murine cells
P2X7-induced pore formation into murine splenic cells was assessed by flow cytometric
measurements of ATP-induced YO-PRO-12+ uptake as described (Jalilian et al. 2012).
Splenic cells suspended in NaCl medium (1 x 106 cells/ml) were preincubated in the
absence or presence of 10 µM AZ10606120 (as indicated), and then with 1 µM
YO-PRO-12+ in the absence or presence of ATP (as indicated) for 15 min at 37°C.
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Incubations were stopped by addition of an equal volume of ice-cold MgCl2 medium
and centrifugation (350 x g for 3 min). Cells were washed once with NaCl medium.
Cells were labelled with APC-conjugated anti-murine CD19 mAb and 7AAD for 20
min at 4°C and washed once with NaCl medium. The MFI of YO-PRO-12+ uptake into
CD19+ cells was determined using flow cytometry (using band-pass filters of 515/20 nm
for YO-PRO-12+, 660/20 nm for APC and 695/40 for 7AAD) and FlowJo software.

2.8 Measurement of P2X7-induced CD23 and CXCL16 loss by
flow cytometry

2.8.1 RPMI 8226 cells
Nucleotide-induced CD23 and CXCL16 loss from RPMI 8226 cells was assessed by
flow cytometric measurements of cell surface CD23 or CXCL16 expression as
described (Farrell 2008). RPMI 8226 cells in NaCl medium (1 x 106 cells/ml) were
incubated in the absence or presence of nucleotide (as indicated) at 37ºC. In some
experiments, cells suspended in NaCl medium were preincubated in the absence or
presence of antagonist (as indicated), and then in the absence or presence of 1 mM ATP
at 37ºC. In other experiments, cells were suspended in either choline Cl medium, KCl
medium or NaCl medium containing either 0.1 mM EGTA or 50 µM BAPTA-AM for 5
min, and then in the absence or presence of 1 mM ATP for 7 min at 37ºC. All
nucleotide incubations were stopped by addition of an equal volume of ice-cold MgCl2
medium and centrifugation (300 x g for 5 min). Cells were washed once with NaCl
medium and incubated with PE- or APC-conjugated anti-human CD23 or isotype
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control mAb for 30 min at room temperature. Alternatively, cells were washed once
with NaCl medium and incubated with anti-CXCL16 or IgG control Ab for 30 min at
room temperature, washed twice and incubated with a FITC-conjugated anti-rabbit IgG
Ab for 30 min at room temperature. The MFI of cell surface CD23 or CXCL16
expression was measured using flow cytometry (using band-pass filters of 515/20 nm
for FITC, 575/26 nm for PE and 660/20 nm for APC) and FlowJo software.

2.8.2 PBMCs and splenic cells
Nucleotide-induced shedding of CD23 from PBMCs or splenic cells was assessed in a
similar manner to that for RPMI 8226 cells (Section 2.8.1). Briefly, cells suspended in
NaCl medium (1 x 106 cells/ml), were incubated in the absence or presence of
nucleotide (as indicated) for up to 30 min at 37ºC. In some experiments, cells in NaCl
medium were pre-incubated at 37°C for 15 min in the absence or presence of antagonist,
and then in the absence or presence of 1 mM ATP (as indicated). Incubations with
nucleotide were stopped by addition of an equal volume of ice-cold MgCl2 medium and
centrifugation (350 x g for 3 min). Cells were then washed once with NaCl medium and
incubated with species-specific fluorochrome-conjugated anti-CD23 (or isotype control)
mAb, anti-CD19 mAb and 7AAD for 30 min at 4ºC. The MFI of cell-surface CD23
expression on viable CD19+7AAD- cells was determined using flow cytometry (using
band-pass filters of 515/20 nm for FITC or 575/26 for PE, 660/20 nm for APC and
695/40 nm for 7AAD) and FlowJo software.
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2.9 Detection of TLR-9 and CD23 by flow cytometry
Cell surface and total TLR-9 and CD23 expression in RPMI 8226 and splenic cells was
measured as previously described (Schmid et al. 1991). Splenic cells were washed once
with NaCl medium (1 x 106 cells/ml) and labelled with APC-conjugated anti-murine
CD19 or, isotype control mAb, and 7AAD for 30 min at 4ºC. Cells were then fixed by
suspension in ice-cold 0.25% (w/v) paraformaldehyde in PBS for 1 hour at 4°C. RPMI
8226 cells or splenic cells were then either washed once (RPMI 8226 cells: 300 x g for
5 min or splenic cells: 350 x g for 3 min) in cold PBS (fixed) or in 0.2% (v/v) Tween-20
in PBS (fixed and permeabilised) and labelled with PE-conjugated anti human-TLR-9
or isotype control mAb, or FITC-conjugated anti-murine CD23 or isotype control mAb,
respectively, for 30 min at 4°C. The MFI of cell surface and total (cell surface and
intracellular) TLR-9 or CD23 expression on RPMI 8226 cells or CD19+ splenic cells
respectively, was determined using flow cytometry (using band-pass filters 515/20 nm
for FITC, 575/26 for PE, 660/20 nm for APC and 695/40 nm for 7AAD) and FlowJo
software.

2.10 Measurement of soluble CD23 and CXCL16 by enzymelinked immunosorbent assay

2.10.1 Soluble CD23
RPMI 8226 cells, PBMCs or splenic cells suspended in NaCl medium containing 0.1%
(w/v) BSA (RPMI 8226 cells: as indicated, PBMCs and splenic cells: 5 x 106 cells/ml)
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were incubated in the absence or presence of 1 mM ATP for 20 min at 37°C.
Incubations were stopped by centrifugation (11,000 x g for 10 s). Cell-free supernatants
were stored at -80°C until required. Soluble CD23 was quantified using the Human
CD23/FcεRII Quantikine enzyme-linked immunosorbent assay (ELISA) Kit or the
Mouse CD23/FcεRII DuoSet ELISA Development Kit (both R&D Systems,
Minneapolis, MN), according to the manufacturer’s instructions.

2.10.2 Soluble CXCL16
RPMI 8226 cells suspended in NaCl medium containing 0.1% BSA (w/v) (1 x 107
cells/ml) were incubated in the absence or presence of 1 mM ATP for 10 min at 37°C.
Incubations were stopped by centrifugation (11,000 x g for 10 s). Cell-free supernatants
were stored at -80 °C until required. Soluble CXCL16 was quantified using the Human
CXCL16 Mini ELISA Development Kit (Peprotech) according to the manufacturer's
instructions. High grade BSA was used to prepare assay diluent and blocking buffer,
and 2,2′-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid was used as a substrate.

2.11

Measurement

of

P2X7

channel

activity

by

electrophysiology
P2X7 channel activity in P2X7-transfected HEK 293 cells was kindly assessed by Dr.
Leanne Stokes using electrophysiological measurements of ATP-induced currents as
described (Stokes et al. 2010). Briefly, whole-cell patch-clamp recordings were
performed at room temperature using an EPC10 amplifier and Patchmaster acquisition
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software (HEKA, Lambrecht, Germany). ATP and CAY10593 were delivered using the
RSC-160 fast-flow system (Bio-Logic Science Instruments, Claix, France). Membrane
potential was clamped at -60 mV in all experiments. External solution was 145 mM
NaCl, 5 mM KCl, 2 mM CaCl2, 1 mM MgCl2, 13 mM D-glucose, 10 mM HEPES, and
internal solution was 145 mM NaCl, 10 mM HEPES, 10 mM EGTA. Both solutions
were adjusted to pH 7.3 with 5 M NaOH and were 300-310 mOsm/L.

2.12 Measurement of P2X7-induced pore formation using a
fluorescent plate reader
Ethidium+ uptake assays on human P2X7-transfected HEK 293 cells were kindly
performed by Dr. Leanne Stokes using a fluorescent plate reader (Optima FLUOSTAR,
BMG Labtech, Offenburg, Germany). Cells (5 x 104 cells/well) were incubated
overnight in a 96-well poly-D-lysine coated plate. Ethidium+ (25 µM) was added in low
divalent solution (145 mM NaCl, 5 mM KCl, 0.2 mM CaCl2, 13 mM D-glucose, 10 mM
HEPES, pH 7.3). Cells were preincubated with CAY10593 for 15 min at 37°C before
measurements started. ATP was injected after 40 second measurements commenced.
Fluorescence was measured using a 485 nm excitation filter and a 520 nm emission
filter block. Gain was set at the beginning of the experiment to 30% required value and
fluorescence measurements were taken every 10 s.

2.13 Measurement of reactive oxygen species formation
Reactive oxygen species (ROS) formation was measured as previously described
(Foster et al. 2013, Wang and Sluyter 2013). RPMI 8226 cells in NaCl medium
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(1 x 106 cells/ml) were loaded with the broad spectrum ROS indicator, 5 μM
H2DCFDA, for 5 min or with the mitochondrial superoxide indicator, 2.5 μM
mitoSOX™ Red for 30 min at 37 °C. Cells were centrifuged (300 x g for 5 min) and
washed once with NaCl medium. H2DCFDA or mitoSOX™ Red-loaded cells in NaCl
medium were incubated in the absence or presence of 1 mM ATP or ROS-inducing
compounds (as indicated) at 37°C. Incubations were stopped by addition of an equal
volume of ice-cold MgCl2 medium and centrifugation (300 x g for 5 min). Cells were
then were washed once with NaCl medium. The MFI of dichlorofluorescein
fluorescence (ROS formation) or mitoSOX Red (superoxide generation) was measured
using flow cytometry (using bandpass filters of 515/20 nm for dichlorofluorescein and
575/26 nm for mitoSOX™ Red) and FlowJo software.

2.14 Presentation of data and statistics
Data is presented as mean ± standard deviation. Differences between multiple groups
was analysed by the one-way analysis of variance using Tukey’s multiple comparison
test. Differences between two groups was analysed by an unpaired Student’s t-test,
except for human PBMC ELISA data for which a paired Student’s t-test was used.
Statistical analyses were performed using GraphPad Prism 5 (Windows version 5.01;
GraphPad Software, San Diego, CA) with P < 0.05 considered significant.
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CHAPTER 3
Characterisation of the
P2X7 receptor in human
multiple myeloma
RPMI 8226 B cells
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3.1 Introduction
The P2X7 receptor is a trimeric ligand-gated cation channel belonging to the family of
P2X receptors (Jiang 2012). Activation of P2X7 by adenosine 5’-triphosphate (ATP)
causes a flux of Ca2+, Na+ and K+, as well as the uptake of organic cations including the
fluorescent dye, ethidium+ (Jiang et al. 2005, Cankurtaran-Sayar et al. 2009). The
relative function of P2X7 is also increased in the absence of extracellular Ca2+, Mg2+
and Na+ ions (Jarvis and Khakh 2009). P2X7 is present on haemopoietic cells, including
human primary B cells and malignant B cells from patients with chronic lymphocytic
leukaemia (CLL) (Gu et al. 2000). P2X7 is also expressed on the human acute
monocytic leukaemic cell line, THP-1 but these cells require treatment with
inflammatory mediators to induce P2X7 expression (Humphreys and Dubyak 1998)
before use. Examples of other human cell lines which express P2X7 are limited.
Therefore, there is a lack of suitable human models to study P2X7 that is constitutively
expressed on human cell lines. Preliminary data from our laboratory indicates that the
human multiple myeloma B cell line, RPMI 8226 expresses functional P2X7 (Farrell
2008, Pupovac 2009). This same cell line also expresses the low affinity IgE receptor,
CD23 (Genty et al. 2004). Other preliminary data from our laboratory indicates that
P2X7 activation induces rapid CD23 shedding from RPMI 8226 cells (Farrell 2008).
Collectively, this suggests that RPMI 8226 cells may serve as a model cell line to study
the mechanisms involved in P2X7-induced CD23 shedding. Therefore, this chapter
aims to confirm the presence of and to further characterise P2X7 in RPMI 8226 cells.
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3.2 Results

3.2.1 RPMI 8226 cells express P2X1, P2X4, P2X5 and P2X7 messenger
RNA
To confirm the presence of P2X7 in RPMI 8226 cells and to examine the presence of
other P2X subtypes, RNA was isolated from these cells and analysed by reverse
transcriptase-polymerase chain reaction (RT-PCR). RT-PCR revealed strong expression
of P2X7, as well as P2X4 and P2X5 (Figure 3.1). Weak expression of P2X1 was also
observed but was not readily apparent when captured as an electronic image (Figure
3.1). The respective amplicons corresponded to the predicted sizes of P2X1 (400 base
pairs (bp)), P2X4 (433 bp) and P2X7 (544 bp). In contrast the amplicon for P2X5 was
501 bp, approximately 71 bp larger than the predicted size (430 bp). Sequence analysis
of the P2X5 amplicon revealed an extra 66 bp (Figure 3.2). This insert is located
between exon 9 and exon 10 of the P2RX5 gene (Figure 3.2). P2X2, P2X3 and P2X6
were absent from RPMI 8226 cells (Figure 3.1).

Figure 3.1: RPMI 8226 cells express P2X1, P2X4, P2X5 and P2X7 messenger RNA.
RNA was isolated from RPMI 8226 cells and analysed by RT-PCR using primers to
P2X1-7. RNA substituted with H2O was used as a negative control. PCR products were
visualised using ethidium bromide. Representative result of three experiments is shown.
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Figure 3.2: P2X5 complementary DNA (cDNA) from RPMI 8226 cells contains a
66 nucleotide bp insert. RNA was isolated from RPMI 8226 cells and RT-PCR
performed using primers to P2X5. The amplicon was excised from a 2% agarose gel
after electrophoresis separation then purified and sequenced. Representative sequence
from three separate sequencing reactions is shown.

3.2.2 RPMI 8226 cells express cell surface but not intracellular P2X7
Previous data from our group demonstrates surface expression of P2X7 on RPMI 8226
cells (Farrell 2008, Pupovac 2009, Gadeock 2010). To determine if P2X7 was confined
to the surface of RPMI 8226 cells or was also present intracellularly, cell surface or total
(surface and intracellular) P2X7 was examined in fresh cells, or fixed and permeabilised
cells, respectively by immunofluorescent labelling. Expression of P2X7 was similar in
both fresh cells, and fixed and permeabilised cells (22.6 ± 0.1 versus 20.2 ± 4.1 mean
fluorescence intensity (MFI) of P2X7 expression respectively, n = 3, P = 0.3499; Figure
3.3).
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Figure 3.3: RPMI 8226 cells express cell surface but not intracellular P2X7. (A)
Fresh cells or (B) fixed and permeabilised cells were labelled with Alexa Fluor® 647conjugated anti-P2X7 (black line) or isotype control (grey fill) monoclonal antibody
(mAb), and the relative P2X7 expression (MFI) determined by flow cytometry (right
panels). (A) 7-aminoactinomycin D was included with fresh cells to exclude dead cells,
and were gated first by forward scatter (FSC) and side scatter (SSC) (left panel),
followed by 7-aminoactinomycin D negative cells as shown (centre panel). (B) Fixed
and permeabilised cells were gated by FSC and SSC as shown (left panel).
Representative results from three experiments are shown.

3.2.3 ATP induces ethidium+ uptake into RPMI 8226 cells in a
time-dependent manner
Previous data from our group demonstrates that 5 min incubation with ATP induces
ethidium+ uptake into RPMI 8226 cells (Farrell 2008, Pupovac 2009, Gadeock 2010).
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To determine whether ATP induces ethidium+ uptake in a time-dependent manner, cells
were incubated with ATP for up to 9 min and ethidium+ uptake measured by flow
cytometry. ATP-induced ethidium+ uptake into RPMI 8226 cells linearly, in a
time-dependent fashion (Figure 3.4). Ethidium+ uptake in the absence of ATP was
minimal over 9 min (results not shown).

Figure 3.4: ATP induces ethidium+ uptake into RPMI 8226 cells in a
time-dependent manner. (A, B) RPMI 8226 cells in NaCl medium were incubated
with 25 μM ethidium+ in the absence (basal) or presence of 1 mM ATP at 37ºC for up to
9 min (as indicated). Incubations were stopped by addition of MgCl2 medium and
centrifugation, and the MFI of ethidium+ uptake determined by flow cytometry. (A)
Basal or ATP-treated cells were gated by the same gate against FSC and SSC as shown,
and histograms represent basal (grey fill) and ATP-induced (black line) ethidium+
uptake in RPMI 8226 cells at 5 min. (B) Results are mean ± standard deviation (SD)
(n = 3).
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3.2.4 Ca2+ and Mg2+ inhibit ATP-induced ethidium+ uptake into
RPMI 8226 cells
The above data (Figure 3.4) and our preliminary data (Farrell 2008, Pupovac 2009,
Gadeock 2010) were obtained in medium nominally free of Ca2+ and Mg2+. To
determine the effect of extracellular divalent cations on P2X7 function in RPMI 8226
cells, cells were incubated with increasing concentrations of ATP in the absence or
presence of physiological concentrations of Ca2+ and Mg2+, and ethidium+ uptake
measured by flow cytometry. In the absence of extracellular Ca2+ and Mg2+, ATP
induced ethidium+ uptake in a concentration-dependent manner, with maximal uptake
occurring at 0.5 mM ATP, and with an approximate half maximal effective
concentration (EC50) of 116 ± 15 µM (Figure 3.5). In the presence of extracellular Ca2+
and Mg2+, ATP also induced ethidium+ uptake in a concentration-dependent manner,
but the amount of uptake was lower with near-maximal uptake occurring at 5 mM ATP,
and with an EC50 of 1 ± 0.4 mM (Figure 3.5).

3.2.5 ATP-induced ethidium+ uptake into RPMI 8226 cells is enhanced
in sucrose and KCl medium compared to NaCl medium
Na+ in cell media is known to inhibit P2X7 function (Wiley et al. 1992, Michel et al.
1999). To assess whether the absence of Na+ alters the potency of ATP against P2X7 in
RPMI 8226 cells, cells were incubated in sucrose, KCl or NaCl medium in the presence
of increasing concentrations of ATP. Similar to above (Figure 3.5), ATP induced
ethidium+ uptake into RPMI 8226 cells suspended in NaCl medium in a
concentration-dependent manner and with an EC50 of 99 ± 20 μM (Figure 3.6). In
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contrast, the EC50 values for ATP-induced ethidium+ uptake into RPMI 8226 cells
suspended in either sucrose or KCl medium, both nominally free of Na+, were lower
(3 ± 3 or 18 ± 8 μM, respectively) compared to the EC50 for ATP in NaCl medium
(Figure 3.6).

Figure 3.5: Ca2+ and Mg2+ impair ATP-induced ethidium+ uptake into RPMI 8226
cells. RPMI 8226 cells in NaCl medium or NaCl medium containing 1.5 mM CaCl2 and
1 mM MgCl2 were incubated with 25 μM ethidium+ in the absence (basal) or presence
of varying ATP concentrations (as indicated) at 37°C for 5 min. Incubations were
stopped by addition of MgCl2 medium and centrifugation, and the MFI of ethidium+
uptake determined by flow cytometry. Ethidium+ uptake is expressed as percent
maximum response compared to 0.5 mM ATP. Results are mean ± SD (n = 3).
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Figure 3.6: ATP-induced ethidium+ uptake into RPMI 8226 cells is enhanced in
sucrose and KCl medium compared to NaCl medium. RPMI 8226 cells in sucrose,
KCl or NaCl medium were incubated with 25 μM ethidium+ in the presence of varying
amounts of ATP (as indicated) at 37°C for 5 min. Incubations were stopped by MgCl2
solution and centrifugation, and the MFI of ethidium+ uptake determined by flow
cytometry. Ethidium+ uptake is expressed as percent maximum response compared to
1 mM ATP for each corresponding medium. Results are mean ± SD (n = 9).

3.2.6 P2X7 antagonists impair ATP-induced ethidium+ uptake into
RPMI 8226 cells in a concentration-dependent manner
Specific P2X7 antagonists including AZ10606120 (Michel et al. 2008), AZ11645373
(Stokes et al. 2006) and A-438079 (Nelson et al. 2006) have been characterised using
cells expressing recombinant P2X7. However these antagonists have been far less
studied on cells expressing endogenous (or native) P2X7. Therefore, to test these
specific P2X7 antagonists on endogenously expressed P2X7, RPMI 8226 cells were
preincubated in the absence or presence of increasing concentrations of AZ10606120,
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AZ11645373 or A-438079, and the ATP-induced ethidium+ uptake was measured by
flow cytometry. AZ10606120, AZ11645373 and A-438079 impaired ATP-induced
ethidium+ uptake in a concentration-dependent manner, with maximal inhibition
occurring at 100 nM, 300 nM and 10 µM, and with a half maximal inhibitory
concentrations (IC50s) of 11 ± 1 nM, 27 ± 3 nM and 900 ± 100 nM, respectively (Figure
3.7).

3.2.7 Probenecid, but not colchicine impairs ATP-induced ethidium+
uptake into RPMI 8226 cells
The pannexin-1 antagonist, probenecid and the microtubule destabiliser, colchicine
impair P2X7-induced dye uptake into cells (Silverman et al. 2009, Marques-da-Silva et
al. 2011). Therefore, to determine whether these compounds impair P2X7-induced
ethidium+ uptake in RPMI 8226 cells, cells were preincubated in the absence or
presence of either compound at concentrations previously shown to block
P2X7-induced dye uptake (Silverman et al. 2009, Marques-da-Silva et al. 2011), and
ATP-induced ethidium+ uptake was measured by flow cytometry. Probenecid impaired
ATP-induced ethidium+ uptake by 42 ± 5% (Figure 3.8), whereas colchicine did not
affect ATP-induced ethidium+ uptake (Figure 3.8). In the absence of ATP, neither
compound altered basal ethidium+ uptake (Figure 3.8).
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Figure 3.7: P2X7 antagonists impair ATP-induced ethidium+ uptake into RPMI
8226 cells in a concentration-dependent manner. RPMI 8226 cells in NaCl medium
were preincubated at 37°C for 15 min in the absence or presence of varying
concentrations of antagonist (as indicated). Cells were then incubated with 25 µM
ethidium+ in the absence or presence of 1 mM ATP at 37°C for 5 min. Incubations were
stopped by addition of MgCl2 medium and centrifugation, and the MFI of ethidium+
uptake determined by flow cytometry. Results are the mean percent of ATP-induced
ethidium+ uptake in the absence of antagonist ± SD (n = 3).

3.2.8 RPMI 8226 cells contain several single nucleotide polymorphisms
in the P2RX7 gene
Human P2RX7 is highly polymorphic, with a number of single nucleotide
polymorphisms (SNPs) coding for loss or gain of function (Sluyter and Stokes 2011).
Therefore, to determine if RPMI 8226 cells encode P2RX7 SNPs, full-length P2X7
cDNA was amplified by RT-PCR and sequenced. The P2RX7 gene of RPMI 8226 cells
was homozygous for three non-synonymous SNPs (Figure 3.9; Table 3.1), and two
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synonymous SNPs (Table 3.1). Of note, these cells contained the A348T
gain-of-function SNP (Cabrini et al. 2005, Roger et al. 2010, Stokes et al. 2010), and the
H521Q SNP, which reduces the sensitivity of the receptor to inhibition by extracellular
Ca2+ (Roger et al. 2010) (Figure 3.9; Table 3.1). RPMI 8226 were wild-type at other
nucleotide positions in the P2RX7 gene (results not shown).

Figure 3.8: Probenecid, but not colchicine, impairs ATP-induced ethidium+ uptake
into RPMI 8226 cells. RPMI 8226 cells in NaCl were preincubated in the absence or
presence of (A) 2.5 mM probenecid for 15 min or (B) 50 µM colchicine for 1 hour.
Cells were then incubated with 25 µM ethidium+ in the absence (basal) or presence of
1 mM ATP at 37°C for 5 min. Incubations were stopped by addition of MgCl2 medium
and centrifugation, and the MFI of ethidium+ uptake determined by flow cytometry.
Results are mean ± SD (n = 3).
††

**

P < 0.01 compared to corresponding basal control,

P < 0.01 compared to ATP alone.
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Figure 3.9: RPMI 8226 cells contain three non-synonymous SNPs in the P2RX7
gene. Full-length P2X7 cDNA from RPMI 8226 cells was amplified by RT-PCR and
sequenced using primers spanning full-length P2X7 cDNA to identify SNPs.
Representative sequences from two separate reactions are shown.

3.2.9 ATP induces CD23 loss from RPMI 8226 cells in a timedependent manner
Previous data from our group demonstrates that ATP induces CD23 loss from the cell
surface of RPMI 8226 cells (Farrell 2008). To confirm that P2X7 activation induces
CD23 loss from RPMI 8226 cells, cells were incubated with 1 mM ATP for up to 30
min and cell surface CD23 expression measured by flow cytometry. As expected, ATP
induced the rapid loss of cell surface CD23 in a time-dependent manner with a t1/2 of
approximately 7 min (Figure 3.10).
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Table 3.1: RPMI 8226 cells contain several SNPs in the P2RX7 gene.

dbSNP rs#
cluster IDa

Base changeb

Amino acid
change

Effect on
function

rs28360448

GTG>GTA

V154V

Synonymousc

rs1718119

GCT>ACT

A348T

Gain

rs28360459

GCG>GTG

A433V

Unknown

rs2230913

CAC>CAG

H521Q

Neutrald

rs1621388

CCG>CCA

P582P

Synonymous

a

http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?locusId=5027.

b

Full length P2X7 cDNA from RPMI 8226 cells was amplified by RT-PCR and

sequenced to identify SNPs. Representative sequences from two separate reactions are
shown.
c

Synonymous mutations are predicted to have neutral effect on function.

d

Neutral effect; however the mutant receptor displays reduced sensitivity to inhibition

by extracellular Ca2+ (Roger et al. 2010).
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Figure 3.10: ATP induces CD23 loss from RPMI 8226 cells in a time-dependent
manner. (A, B) RPMI 8226 cells in NaCl medium were incubated for up to 30 min (as
indicated) at 37°C in the absence (basal) or presence of 1 mM ATP. Incubations were
stopped by addition of MgCl2 medium and centrifugation. Cells were then labelled with
phycoerythrin (PE)-conjugated anti-CD23 or isotype control mAb, and the MFI of cell
surface CD23 expression determined by flow cytometry. (A) Cells incubated in the
absence (Basal) or presence of ATP were gated against FSC and SSC as shown (top
panel). Representative histograms show CD23 (black line) or isotype control mAb
binding (grey fill) on RPMI 8226 cells incubated in the absence (basal) or presence of
1 mM ATP for 30 min (bottom panel). (B) Results are mean ± SD (n = 3).

3.2.10 ATP induces CD23 loss from RPMI 8226 cells in a
concentration-dependent manner
To further characterise ATP-induced CD23 loss from RPMI 8226 cells, cells were
incubated in the presence of increasing concentrations of ATP and cell surface CD23
measured by flow cytometry. ATP induced a loss of CD23 in a concentration-dependent
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manner, with maximal loss occurring at 1 mM ATP, and with an EC50 of 74 ± 12 µM
(Figure 3.11).

Figure 3.11: ATP induces CD23 loss from RPMI 8226 cells in a concentrationdependent manner. RPMI 8226 cells in NaCl medium were incubated with increasing
concentrations of ATP (as indicated) at 37°C for 7 min. Incubations were stopped by
addition of MgCl2 medium and centrifugation. Cells were then labelled with
PE-conjugated anti-CD23 or isotype control mAb, and the MFI of cell surface CD23
expression determined by flow cytometry. CD23 expression is expressed as percentage
of CD23 expression in the absence of ATP. Results are mean ± SD (n = 3); where error
bars are absent SD is too small to be seen.

3.2.11 AZ10606120 impairs ATP-induced CD23 loss from RPMI 8226
cells
To confirm that ATP-induced CD23 loss is mediated by P2X7, RPMI 8226 cells were
preincubated in the absence or presence of 100 nM AZ10606120 and then with ATP
and cell surface CD23 measured by flow cytometry. As above (Figure 3.10 and 3.11),
ATP induced a loss of CD23 from the surface of RPMI 8226 cells (Figure 3.12).
AZ10606120 impaired ATP-induced CD23 loss by 88 ± 9% compared to ATP-induced
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CD23 loss in the absence of AZ10606120 (Figure 3.12). In the absence of ATP,
AZ10606120 did not significantly alter cell surface CD23 expression (Figure 3.12).

Figure 3.12: AZ10606120 impairs ATP-induced CD23 loss from RPMI 8226 cells.
RPMI 8226 cells in NaCl medium were preincubated at 37°C for 15 min in the absence
or presence of 100 nM AZ10606120, and then in the absence (basal) or presence of
1 mM ATP for 7 min at 37°C. Incubations were stopped by addition of MgCl2 medium
and centrifugation. Cells were then labelled with PE-conjugated anti-CD23 or isotype
control mAb, and the MFI of cell surface CD23 expression determined by flow
cytometry. Results are mean ± SD (n = 3); **P < 0.01 compared to corresponding basal
control, and ††P < 0.01 compared to ATP alone.

3.2.12 ATP induces CD23 shedding from RPMI 8226 cells
To confirm that the ATP-induced loss of cell surface CD23 was due to CD23 shedding,
RPMI 8226 cells were incubated with ATP, and the amount of soluble CD23 in cell-free
supernatants measured by enzyme-linked immunosorbent assay (ELISA). Incubation of
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cells with 1 mM ATP resulted in a significantly higher release of soluble CD23
compared to cells incubated in the absence of ATP (Figure 3.13).

Figure 3.13: ATP induces CD23 shedding from RPMI 8226 cells. RPMI 8226 cells
in NaCl medium (5 x 106 cells/ml) were incubated in the absence (basal) or presence of
1 mM ATP for 20 min, incubations were stopped by centrifugation and the amount of
soluble CD23 in cell-free supernatants determined by ELISA. Results are mean ± SD (n
= 3); **P < 0.01 compared to basal control.

3.3 Discussion
Preliminary data in our laboratory indicated that the human RPMI 8226 multiple
myeloma B cell line expresses functional P2X7. Using immunofluorescent labelling and
immunoblotting our group has previously shown the presence of P2X7 in RPMI 8226
cells (Farrell 2008, Pupovac 2009, Gadeock 2010). Moreover, flow cytometric
measurements have demonstrated that ATP and the most potent P2X7 antagonist
BzATP, can induce ethidium+ uptake into, and CD23 shedding from RPMI 8226 cells,
and that these processes could be impaired by the P2X7 antagonists, KN-62 and
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A-438079 (Farrell 2008, Pupovac 2009, Gadeock 2010). This chapter confirms that
RPMI 8226 cells express functional P2X7 and makes a number of new observations.
First, RT-PCR and immunolabelling confirmed that P2X7 was present in RPMI 8226
cells.

Second,

ATP

induced

ethidium+

uptake

in

a

time-dependent

and

concentration-dependent fashion with an EC50 (~116 µM), similar to ATP-induced
cation fluxes mediated by recombinant P2X7 (Rassendren et al. 1997). Third,
ATP-induced ethidium+ uptake was reduced in the presence of extracellular Ca2+ and
Mg2+, and increased with removal of Na+ ions which is characteristic of P2X7 in other
cell types (Wiley et al. 1992, Michel et al. 1999). Fourth, the P2X7 antagonists
A-438079, AZ10606120 and AZ11645373 impaired ATP-induced ethidium+ in a
concentration-dependent manner. The rank order of potency AZ10606120 >
AZ11645373 > A-438079 obtained in this study corresponds to previous published
values of heterologous P2X7 (IC50 of ~1.4 nM, 10-90 nM and ~300 nM respectively)
(Nelson et al. 2006, Stokes et al. 2006, Michel et al. 2008).

Preliminary data in our laboratory indicated that P2X7 activation induces the shedding
of CD23 from RPMI 8226 cells (Farrell 2008). This chapter also confirms that P2X7
activation induces CD23 shedding from these cells. First, ATP induced a loss of CD23
from RPMI 8226 cells in a time-dependent manner, with a t1/2 (~7 min) similar to that
obtained by Farrell (2008). Second, new observations showed that ATP induced a loss
of CD23 in a concentration-dependent manner, with an EC50 (~74 µM) similar to ATPinduced ethidium+ uptake (Figure 3.5) and to ATP-induced CD23 shedding from CLL
cells (Gu et al. 1998). Third, the new generation antagonist, AZ10606120, nearcompletely impaired ATP-induced CD23 loss from RPMI 8226 cells similar to that
observed by Farrell (2008), who showed that A-438079 and KN-62 near-completely
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prevented ATP-induced CD23 shedding from these cells. Finally, using a human CD23
ELISA, the ATP-induced CD23 loss from RPMI 8226 cells was demonstrated to be due
to shedding; similar amounts of ATP-induced soluble CD23 were observed by Farrell
(2008). Other studies have also showed the rapid shedding of CD23 (< 30 min) from
CLL cells (Gu et al. 1998) and human monocyte-derived dendritic cells (Sluyter and
Wiley 2002, Georgiou et al. 2005). Thus, combined this data reinforces a role for P2X7
activation in the rapid shedding of CD23 from human leukocytes and supports the use
of RPMI 8226 cells to investigate this process further.

Probenecid, but not colchicine, impaired ATP-induced ethidium+ uptake into RPMI
8226 cells. Probenecid is commonly used as a pannexin-1 inhibitor (Silverman et al.
2009), however it has long been recognised that probenecid blocks other molecules (Di
Virgilio et al. 1990). More recently, probenecid has been shown to impair P2X7 directly
(Bhaskaracharya et al. 2014). Whether probenecid inhibits ATP-induced ethidium+
uptake in RPMI 8226 cells by blocking pannexin-1 or by blocking P2X7 directly
remains unknown. Microarray studies show that pannexin-1 gene is overexpressed in
some human multiple myeloma cell lines (Largo et al. 2006), however whether RPMI
8226 cells express pannexin-1 protein is unknown. The microtubule destabiliser,
colchicine, impairs ATP-induced YO-PRO-12+ uptake in Xenopus oocytes and human
embryonic kidney 293 cells expressing human P2X7, and ethidium+ uptake in murine
peritoneal macrophages (Marques-da-Silva et al. 2011). In contrast, colchicine, used at
the same concentration (50 µM) does not impair ATP-induced ethidium+ uptake in
RPMI 8226 cells. Colchicine used at concentrations below 50 µM impairs ATP-induced
IL-1β release in murine microglial MG6 cells (Takenouchi et al. 2008) but not in human
monocytic THP-1 cells (Martinon et al. 2006) suggesting that the effect of colchicine
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may be cell specific. Marques-da-Silva and colleagues reported that colchicine
concentrations used by Martinon and colleagues were ineffective at inhibiting
ATP-induced cell permeabilisation in their experiments (Marques-da-Silva et al. 2011).
Therefore it is possible that colchicine concentrations greater than 50 µM are required to
impair ATP-induced ethidium+ uptake in RPMI 8226 cells.

In addition to P2X7 transcripts, RT-PCR revealed the strong expression of P2X4 and
P2X5 transcripts, as well as the weak expression of P2X1 transcripts in RPMI 8226
cells. Prior to this study, the expression of P2X subtypes in RPMI 8226 cells was
unknown. The pattern of P2X mRNA expression in RPMI 8226 cells is similar to that
described for Epstein-Barr virus-infected human B cells, which express relatively high
amounts of P2X4 and P2X5, and lower amounts of P2X1 and P2X7, but little or no
P2X2, P2X3 or P2X6 (Lee et al. 2006). Whether P2X1, P2X4 and P2X5 mRNA are
translated to protein or lead to functional P2X channels in these cells or in RPMI 8226
cells remains unknown. However, immunofluorescent labelling demonstrated the
presence of P2X1 and P2X4, as well as P2X7, but not P2X5, in human CLL B cells
(Sluyter et al. 2001) suggesting that other P2X subtypes, apart from P2X7, may also
form functional P2X channels in RPMI 8226 cells and other cells of the B cell lineage.
Data from this chapter also showed that the P2X5 cDNA transcript contained an extra
66 nucleotide bp suggesting the presence of a potential P2X5 variant in RPMI 8226
cells. This sequence is located between exon 9 and 10 in the P2RX5 gene. Further
experiments are required to determine whether this variant encodes a functional
receptor. Future experiments will need to examine the size of P2X5 protein in RPMI
8226 cells by Western blotting and determine whether this receptor is functional using
electrophysiology. This however, was beyond the scope of this thesis. It is well known
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that the most prevalent P2X5 isoform (P2X5a) occurs in humans as a non-functional
variant due to a SNP in the 3’ splice site of exon 10 (Bo et al. 2003, Kotnis et al. 2010).
Therefore, it would be of interest to determine if RPMI 8226 cells encode this SNP,
however due to the partial sequence of exon 10 obtained in the current study this
appears unlikely.

The results in this chapter revealed for the first time that RPMI 8226 cells are
homozygous for the gain-of-function A348T SNP, as well as the A433V and H521Q
SNPs (Figure 3.14). Although not formally demonstrated, A433V may also act as an
additional gain-of-function SNP in these cells as the opposite amino acid exchange at
position 76 of P2X7 (V76A) causes a loss of function (Roger et al. 2010, Stokes et al.
2010). Others have shown that H521Q impairs ATP-induced inward currents but not
ethidium+ uptake (Roger et al. 2010). Moreover, this same group showed that H521Q
reduced the sensitivity of P2X7 to inhibition by extracellular Ca2+ (Roger et al. 2010).
In contrast, maximal ATP-induced ethidium+ uptake was only partly lower in RPMI
8226 cells suspended in NaCl medium containing Ca2+/Mg2+ compared to cells in NaCl
medium nominally free of Ca2+/Mg2+ (Figure 3.5). However, this data is complicated by
the presence of Mg2+ (in the medium used), which is known to impair P2X7 by binding
to H130 and H201 (Acuna-Castillo et al. 2007) and by reducing the amount of
extracellular ATP4-, the presumed ligand of P2X7 (Jiang 2009).

This chapter confirms that RPMI 8226 cells express functional P2X7 and that its
activation results in the rapid shedding of CD23, supporting the use of these cells as a
model to study the mechanisms involved in P2X7-induced CD23 shedding. Moreover,
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this chapter demonstrates new features regarding P2X7 in RPMI 8226 cells including its
sensitivity to extracellular Ca2+, Mg2+ and Na+, to three more recently developed P2X7
antagonists, and to probenecid, as well as presence of the non-synonymous SNPs,
A348T, A433V and H521Q in these cells.

Figure 3.14: A schematic of the P2X7 subunit showing the SNPs identified in
RPMI 8226 cells. The P2RX7 gene in RPMI 8226 cells contains two synonymous
SNPs, V154V and P582P, and three non-synonymous SNPs, A348T, A433V, and
H521Q.
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CHAPTER 4

CAY10593 (VU0155069)
inhibits human P2X7
independently of
phospholipase D1
stimulation
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4.1 Introduction
Prolonged exposure of P2X7 to extracellular adenosine 5’-triphosphate (ATP) opens a
second permeability state or pore that allows the uptake of organic cations including
fluorescent dyes such as ethidium+ (Wiley et al. 1998, Cankurtaran-Sayar et al. 2009).
Whether this second permeability state is attributed to intrinsic channel dilation (Yan et
al. 2010), the pannexin-1 channel (Pelegrin and Surprenant 2006) or an alternate but
unknown uptake pathway (Schachter et al. 2008, Cankurtaran-Sayar et al. 2009,
Marques-da-Silva et al. 2011) remains controversial. Recently it has been shown that
large organic dyes can directly permeate P2X7 (Browne et al. 2013). Moreover, our
understanding of this permeability state is further complicated with some (DonnellyRoberts et al. 2004, Faria et al. 2005, Bianco et al. 2009) but not other (da Cruz et al.
2006, Michel et al. 2006, Wang and Sluyter 2013) studies showing that P2X7-induced
dye uptake involves the p38 mitogen-activated protein kinase (MAPK).

Regardless of the true identity of the P2X7 pore and the mechanism by which it opens,
P2X7 activation stimulates multiple signalling pathways via molecules such as MAPK,
protein kinase C (PKC), mitogen/extracellular regulated kinase 1/2 (MEK1/2),
c-Jun N-terminal kinase (JNK), rho-kinase, phosphoinositide 3-kinase (PI3K), glycogen
synthase kinase (GSK)-3 and phospholipase A2 (PLA2), C (PLC) and D (PLD). These
signalling pathways induce various cellular events including inflammatory mediator
release, reactive oxygen and nitrogen species formation, and cell proliferation or death
(Lenertz et al. 2011, Wiley et al. 2011). P2X7 activation also induces the shedding of
cell surface molecules including CD23 (Gu et al. 1998, Sluyter and Wiley 2002,
Georgiou et al. 2005). Furthermore, data from our laboratory shows that P2X7
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activation induces CD23 shedding from RPMI 8226 cells (Farrell 2008; Chapter 3).
However, the intracellular signalling pathways that mediate this process are unknown.

PLD catalyses the hydrolysis of phosphatidylcholine to phosphatidic acid and choline,
which subsequently participate in various cellular events (McDermott et al. 2004). Two
isoforms of mammalian PLD have been described, PLD1 and PLD2 (McDermott et al.
2004). P2X7 activation can stimulate PLD in B cells (Gargett et al. 1996, Shemon et al.
2007) and macrophages (el-Moatassim and Dubyak 1993, Humphreys and Dubyak
1996). P2X7-induced PLD stimulation in macrophages plays a role in the killing of
intracellular mycobacteria (Kusner and Adams 2000, Fairbairn et al. 2001) and the
generation of microvesicles capable of further macrophage activation (Thomas and
Salter 2010). In contrast, the role of P2X7-induced PLD stimulation in B cells remains
unknown. This chapter aims to examine the signalling pathways involved in
P2X7-induced CD23 shedding using RPMI 8226 cells as model.

4.2 Results

4.2.1 ATP-induced CD23 shedding from RPMI 8226 cells is not
prevented by changes in intracellular cation concentrations
To assess a potential role for changes in intracellular cation concentrations in
P2X7-induced CD23 shedding, ATP-induced CD23 shedding from RPMI 8226 cells
was compared between cells suspended in NaCl medium (control) to cells suspended in
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either choline Cl medium, KCl medium, or in NaCl medium containing ethylene glycol
tetraacetic acid (EGTA) or 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid
(BAPTA-AM), which prevent Na+ influx, K+ efflux, Ca2+ influx or intracellular Ca2+
increases, respectively. ATP-induced CD23 shedding was assessed using flow
cytometry as described in Chapter 3. As observed in Chapter 3, ATP induced CD23
shedding from RPMI 8226 cells in NaCl medium (Figure 4.1A-D). ATP-induced CD23
shedding was potentiated from cells suspended in either choline Cl or KCl medium
compared to cells in NaCl medium (Figure 4.1A, B). In contrast, ATP-induced CD23
shedding was similar from cells suspended in NaCl medium containing 100 µM EGTA
or 50 µM BAPTA-AM compared to cells in NaCl medium (Figure 4.1C, D).

4.2.2 PLD antagonists but not other enzyme antagonists inhibit
P2X7-induced CD23 shedding from RPMI 8226 cells
To determine the involvement of intracellular signalling pathways in P2X7-induced
CD23 shedding, cells were preincubated in the presence of antagonists of various
enzymes or their corresponding diluent control, and the ATP-induced CD23 shedding
assessed using flow cytometry as above. Antagonist concentrations were based on
previously published concentrations (Table 4.1). Most of the enzyme antagonists failed
to significantly impair ATP-induced CD23 shedding (Table 4.1). Of note, the PLD1
antagonist CAY10593 (VU0155069), and to a lesser extent, the PLD2 antagonist
CAY10594 and the non-selective PLD antagonist halopemide (all at 10 µM)
significantly impaired ATP-induced CD23 shedding (Table 4.1; Figure 4.2). In the
absence of ATP, the PLD antagonists did not significantly alter cell surface expression
of CD23 compared to control treated cells (Figure 4.2).
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Figure 4.1: ATP-induced CD23 shedding from RPMI 8226 cells is not prevented by
changes in intracellular cation concentrations. (A-D) RPMI 8226 cells in NaCl
medium (control), in (A) choline Cl medium, (B) KCl medium, or in (C, D) NaCl
medium containing (C) 0.1 mM EGTA or (D) 50 µM BAPTA-AM were preincubated at
37°C for (A-C) 5 min or (D) 30 min. (A-D) Cells were then incubated in the absence
(basal) or presence of 1 mM ATP at 37°C for 7 min. Incubations were stopped by
addition of MgCl2 medium and centrifugation. Cells were labelled with phycoerythrin
(PE)-conjugated anti-CD23 or isotype control monoclonal antibody (mAb), and the
mean fluorescence intensity (MFI) of cell surface CD23 expression determined by flow
cytometry. Results are mean ± standard deviation (SD) (n = 3); *P < 0.05 and **P < 0.01
compared to basal control, and ††P < 0.01 compared to ATP control.
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Table 4.1: PLD antagonists impair ATP-induced CD23 shedding from RPMI 8226
cells.

a

Percent inhibition
of ATP-induced
CD23 lossb

Reference

Compound (µM)

Target

GF109203X (10)

PKC α, β

2 (3)

(Shemon et al. 2007)

Rottlerin (20)

PKC δ, θ

13 (6)

(Shemon et al. 2007)

SB202190 (20)

p38 MAPK

7 (7)

(Noguchi et al. 2008)

SB203580 (20)

p38 MAPK

10 (6)

(Noguchi et al. 2008)

AG126 (50)

p42 MAPK

0 (0)

(Verhoef et al. 2005)

U0126 (10)

MEK1/2

6 (7)

(Pfeiffer et al. 2004)

SP600125 (20)

JNK

2 (2)

(Noguchi et al. 2008)

Fasudil (10)

Rho-kinase

0 (0)

(Verhoef et al. 2003)

Y-27632 (10)

Rho-kinase

1 (2)

(Verhoef et al. 2003)

LY294002 (10)

PI3K

0 (1)

(Pfeiffer et al. 2004)

SB216763 (3)

GSK-3

3 (3)

(Ortega et al. 2009)

AACOCF3 (40)

iPLA2, cPLA2

0 (0)

(Andrei et al. 2004)

D609 (100)

PLC

0 (0)

CAY10593 (10)

PLD1

43 (4)**

CAY10594 (10)

PLD2

19 (6) **

Halopemide (10)

PLD

6 (7)*

(Andrei et al. 2004)
(Thomas and Salter
2010)
(Thomas and Salter
2010)
(Scott et al. 2009)

Imipramine (10)

aSmase

8 (5)

(Bianco et al. 2009)

Probenecid (2500)

Pannexin-1

3 (3)

(Silverman et al. 2009)

Carbenoxolone (50)

Pannexin-1

0 (0)

(Silverman et al. 2009)

NH4Cl (10000)

Endosomes

8 (3)

(Mathews et al. 2010)

Abbreviations: aSmase, acid sphingomyelinase; JNK, c-Jun N-terminal kinase; MAPK, mitogenactivated protein kinase; MEK 1/2, mitogen-activated kinase/ERK kinase 1/2; NADPH, nicotinamide
adenine dinucleotide phosphate; NH4Cl, ammonium chloride; PKC, protein kinase C; PLA2,
phospholipase A2; PLC, phospholipase C; PLD, phospholipase D.
b

RPMI 8226 cells in NaCl medium were preincubated at 37°C in the presence of

compound (as indicated) or corresponding diluents, for 15 min (or 30 min for
LY294002 or NH4Cl, or 1 h for SB216763 or Imipramine) and then in the absence or
presence of 1 mM ATP at 37°C for 7 min. Incubations were stopped by addition of
MgCl2 medium and centrifugation. Cells were labelled with PE- or allophycocyanin
(APC)-conjugated anti-CD23 or isotype control mAb, and the MFI of cell surface CD23
expression determined by flow cytometry. Results are the mean percent inhibition of
ATP-induced CD23 loss ± SD (n = 3).

*

P < 0.05 and

**

P < 0.01 compared to ATP

alone.
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Figure 4.2: PLD antagonists impair ATP-induced CD23 shedding from RPMI 8226
cells. (A-C) RPMI 8226 cells in NaCl medium were preincubated at 37°C for 15 min in
the presence of dimethyl sulphoxide (DMSO), or 10 µM (A) CAY10593, (B)
CAY10594 or (C) halopemide. Cells were then incubated in the absence (basal) or
presence of 1 mM ATP at 37°C for 7 min. Incubations were stopped by addition of
MgCl2 medium and centrifugation. Cells were then labelled with PE-conjugated
anti-CD23 or isotype control mAb, and the MFI of cell surface CD23 expression
determined by flow cytometry. Results are mean ± SD (n = 3); **P < 0.01 compared to
corresponding DMSO control, and †P < 0.05 and

††

P < 0.01 compared to ATP with

DMSO.

4.2.3 PLD antagonists impair ATP-induced ethidium+ uptake into
RPMI 8226 cells
The above data (Table 4.1; Figure 4.2) indicates that the PLD antagonists can inhibit
P2X7-induced CD23 shedding. Therefore, the mode of action by which these
compounds impaired P2X7-induced CD23 shedding was investigated. Since previous
studies have highlighted that some enzyme antagonists directly block P2X7 (Shemon et
al. 2004, Shemon et al. 2008), the current study first investigated whether PLD
antagonists impaired ATP-induced CD23 shedding by blocking P2X7 activation. Thus,
RPMI 8226 cells were preincubated in the presence of DMSO, CAY10593, CAY10594
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or halopemide (each at 10 µM), and the ATP-induced ethidium+ uptake was measured
by flow cytometry. The PLD antagonists significantly inhibited ATP-induced ethidium+
uptake by 56 ± 4%, 20 ± 6% and 15 ± 5%, respectively compared to ATP-induced
ethidium+ uptake in cells preincubated with DMSO (Figure 4.3). In the absence of ATP,
these antagonists did not significantly alter basal ethidium+ uptake (Figure 4.3).

Figure 4.3: PLD antagonists impair ATP-induced ethidium+ uptake into
RPMI 8226 cells. RPMI 8226 cells in NaCl medium were preincubated at 37°C for 15
min in the presence of DMSO, or 10 µM CAY10593, CAY10594 or halopemide. Cells
were then incubated with 25 µM ethidium+ in the absence (basal) or presence of 1 mM
ATP at 37°C for 5 min. Incubations were stopped by addition of MgCl2 medium and
centrifugation, and the MFI of ethidium+ uptake determined by flow cytometry. Results
are mean ± SD (n = 3);

**

P < 0.01 compared to DMSO control, and

††

P < 0.01

compared to ATP with DMSO.
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4.2.4 PLD antagonists impair ATP-induced ethidium+ uptake into
RPMI 8226 cells in a concentration-dependent manner
The above data (Figure 4.3) suggests that the inhibitory action of the PLD antagonists
on P2X7-induced CD23 shedding is due to impaired P2X7 activation. Therefore, to
further characterise the effect of the above three PLD antagonists on P2X7 activation,
cells were preincubated in the presence of increasing concentrations of each antagonist
and the ATP-induced ethidium+ uptake measured, using 120 µM ATP which is
approximate to the half maximal effective concentration (EC50) for ATP in this process
(see Chapter 3). CAY10593 inhibited ATP-induced ethidium+ uptake in a
concentration-dependent manner, with maximal inhibition occurring near 10 µM and a
half maximal inhibitory concentration (IC50) of 2.0 ± 0.5 µM (Figure 4.4). At the
highest concentration used (10 µM), CAY10594 and halopemide inhibited
ATP-induced ethidium+ uptake by less than 29% on average and the IC50 values for
these antagonists could not be reliably determined due to this low amount of inhibition
(Figure 4.4). Thus, the mode of action by which CAY10593 impairs P2X7 was studied
further.
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Figure 4.4: PLD antagonists impair ATP-induced ethidium+ uptake into
RPMI 8226 cells in a concentration-dependent manner. RPMI 8226 cells in NaCl
medium were preincubated at 37°C for 15 min in the presence of DMSO or varying
concentrations of antagonist (as indicated). Cells were then incubated with 25 µM
ethidium+ in the absence or presence of 120 µM ATP at 37°C for 5 min. Incubations
were stopped by addition of MgCl2 medium and centrifugation, and the MFI of
ethidium+ uptake determined by flow cytometry. Results are the mean percent of
ATP-induced ethidium+ uptake in the absence of antagonist ± SD (n = 3).

4.2.5 CAY10593 impairs ATP-induced ethidium+ uptake into RPMI
8226 cells in a non-competitive-like manner
To determine whether CAY10593 inhibits P2X7-induced pore formation in a
competitive or non-competitive manner, RPMI 8226 cells were preincubated in the
presence of DMSO, or 2 or 10 µM CAY10593, and then the ethidium+ uptake was
measured in the presence of increasing concentrations of ATP. In the absence of
CAY10593, ATP induced ethidium+ uptake in a concentration-dependent manner with
maximal uptake occurring at 0.5 mM ATP and with an EC50 of 116 ± 31 µM (Figure
4.5). In the presence of 2 µM CAY10593, the mean maximum ATP response was
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reduced by 17% and with a slight increase in the EC50 to 154 ± 26 µM (Figure 4.5). In
the presence of 10 µM CAY10593, the mean maximum ATP response was reduced by
60% and with a larger increase in the EC50 to 256 ± 22 µM (Figure 4.5).

Figure 4.5: CAY10593 impairs ATP-induced ethidium+ uptake into RPMI 8226
cells in a non-competitive-like manner. RPMI 8226 cells in NaCl medium were
preincubated at 37°C for 15 min in the presence of DMSO, or 2 µM or 10 µM
CAY10593. Cells were then incubated with 25 µM ethidium+ in the absence or presence
of varying concentrations of ATP at 37°C for 5 min. Incubations were stopped by
addition of MgCl2 medium and centrifugation, and the MFI of ethidium+ uptake
determined by flow cytometry. Results are the mean percent of maximum ATP
(0.5 mM)-induced ethidium+ uptake ± SD (n = 3).
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4.2.6 PLD1 is not required for ATP-induced ethidium+ uptake into
RPMI 8226 cells
Collectively, the above results show that the PLD1 specific antagonist CAY10593 can
impair P2X7-induced pore formation. Therefore, to determine whether this effect is due
to inhibition of PLD1 or direct inhibition of P2X7 itself, a series of experiments were
performed. First, the presence of PLD1 and PLD2 in RPMI 8226 cells was examined by
RT-PCR. The human skin epithelial carcinoma cell line, A431, which expresses both
PLD isoforms (Min et al. 2001), was used as a positive control. RT-PCR revealed the
presence of PLD1 (666 bp) in A431 cells but not in RPMI 8226 cells, despite the
presence of PLD2 (561 bp) in both cell lines (Fig. 4.6A). Next, choline Cl medium has
previously been shown to prevent P2X7-induced PLD stimulation (el-Moatassim and
Dubyak 1993, Fernando et al. 1999). Therefore, RPMI 8226 cells were suspended in
either choline Cl or NaCl medium and the ATP-induced ethidium+ uptake measured.
ATP-induced ethidium+ uptake was potentiated in cells incubated in choline Cl
compared to NaCl medium (Figure 4.6B). Finally, in the presence of a primary alcohol,
PLD catalyses a transphosphatidylation reaction to form a phosphatidyl alcohol product,
which does not serve as a substrate for PLD-mediated signal transduction (Morris et al.
1997). Therefore, RPMI 8226 cells were preincubated in the presence of the primary
alcohol, 0.27% (v/v) 1-butanol, or the secondary alcohol, 0.27% (v/v) 2-butanol as a
negative control, and the ATP-induced ethidium+ uptake measured. ATP-induced
ethidium+ uptake into cells treated with 1-butanol was also increased compared to cells
treated with 2-butanol (Figure 4.6C). In the absence of ATP, ethidium+ uptake into cells
in choline Cl or NaCl media in the presence of either alcohol was similar (Figure 4.6B,
C).
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Figure 4.6: PLD1 is not required for ATP-induced ethidium+ uptake into
RPMI 8226 cells. (A) RNA was isolated from A431 (positive control) and RPMI 8226
cells, and then analysed by RT-PCR using primers for PLD1 and PLD2. RNA
substituted with H2O was used as a negative control. PCR products were visualised by
agarose gel electrophoresis and ethidium bromide staining. A representative result from
three experiments is shown. (B, C) RPMI 8226 cells were preincubated at 37°C for 5
min in (B) choline Cl or NaCl medium, or (C) NaCl medium in the presence of 0.27%
(v/v) 2-butanol (negative control) or 1-butanol. (B, C) Cells were then incubated with
25 µM ethidium+ in the absence (basal) or presence of 1 mM ATP at 37°C for 5 min.
Incubations were stopped by addition of MgCl2 medium and centrifugation, and the
MFI of ethidium+ uptake determined by flow cytometry. Results are the mean ± SD
(n = 3); *P < 0.05 and
††

**

P < 0.01 compared to corresponding basal control, and

P < 0.01 compared to (B) ATP in NaCl medium or (C) ATP with 2-butanol.
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4.2.7 CAY10593 impairs ATP-induced inward currents and pore
formation in human P2X7-transfected human embryonic kidney 293
cells
The above results (Figure 4.6) indicate that PLD signalling is not required for
P2X7-induced pore formation and that CAY10593 directly impairs P2X7. Therefore,
the effect of CAY10593 on P2X7 channel activity in human P2X7-transfected human
embryonic kidney (HEK) 293 cells was assessed by electrophysiology. In the absence
of 10 µM CAY10593, ATP induced an inward current typical of P2X7 (Figure 4.7A).
Removal of extracellular ATP, and subsequent 3-5 min incubation with 10 µM
CAY10593 followed by ATP, reduced the ATP-induced inward current to 29.5 ± 2.6 %
of control (Figure 4.7A). To confirm that CAY10593 impairs P2X7 pore formation in
these cells, P2X7-transfected HEK 293 cells were preincubated with CAY10593 for 15
min at 37°C and ATP-induced ethidium+ uptake was measured. CAY10593 impaired
ATP-induced ethidium+ uptake into P2X7-transfected HEK 293 cells by 72% (Figure
4.7B).

4.2.8 CAY10593 impairs ATP-induced ethidium+ uptake into primary
human peripheral blood mononuclear cells
To determine if CAY10593 inhibits P2X7-induced pore formation in primary cells,
peripheral blood mononuclear cells (PBMCs) from a human donor were preincubated in
the presence of DMSO or 10 µM CAY10593 and ethidium+ uptake was measured in the
absence or presence of ATP. CAY10593 inhibited ATP-induced ethidium+ uptake into
B cells, T cells and monocytes by 66 ± 5%, 76 ± 3% and 80 ± 4%, respectively (Figure
113

4.8). In the absence of ATP, CAY10593 did not significantly alter ethidium+ uptake
compared to DMSO treated cells (Figure 4.8). Similar amounts of inhibition (77 ± 15%,
91 ± 6% and 76 ± 12%) were observed in B cells, T cells and monocytes, respectively
from a second donor (figure not shown).

Figure 4.7: CAY10593 impairs ATP-induced inward currents and pore formation
in human P2X7-transfected HEK 293 cells. (A) Inward currents were elicited using
1 mM ATP in low divalent NaCl solution. ATP was added for 5 seconds (black bar)
before and after treatment with 10 µM CAY10593 (3-5 minutes). ATP was added in the
continued presence of CAY10593 (single representative trace of 4 to 7 cells is shown).
(B) P2X7-transfected HEK 293 cells in low divalent NaCl solution containing 25 µM
ethidium+ were preincubated in the presence of DMSO or CAY10593 for 15 min at
37°C. ATP (1 mM) was injected after 40 s. Fluorescence was measured every 10 s using
a plate reader (representative result from three experiments shown).
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Figure 4.8: CAY10593 impairs ATP-induced ethidium+ uptake into primary
human PBMCs. (A, B) PBMCs in NaCl medium were preincubated for 15 min in the
presence of DMSO or 10 µM CAY10593. Cells were then incubated with 25 µM
ethidium+ in the absence or presence of 1 mM ATP at 37°C for 5 min. Incubations were
stopped by addition of MgCl2 medium and centrifugation, and washed once with NaCl
medium. Cells were then labelled with APC-conjugated anti-CD19 mAb. The MFI of
ethidium+ uptake into B cells, T cells and monocytes was determined by flow
cytometry. (A) (top panel) Basal or ATP-treated lymphocytes (l) or monocytes (m) were
gated by forward scatter (FSC) and side scatter (SSC). CD19+ B cells (b) or CD19T cells (t) were further gated as shown (bottom panel). (B) Representative histograms
show basal (grey fill) and ATP-induced (solid line) ethidium+ uptake (top panel).
Results are the mean ATP-induced ethidium+ uptake ± SD (n = 3); **P < 0.01 compared
to corresponding DMSO.
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4.2.9 CAY10593 impairs human but not murine P2X7-induced pore
formation
The murine erythroleukemia (MEL) cell line expresses P2X7 (Constantinescu et al.
2010, Wang and Sluyter 2013). Therefore, to test whether CAY10593 inhibits murine
P2X7, MEL cells were preincubated with 10 µM CAY10593 and ATP-induced
ethidium+ uptake was measured by flow cytometry (Figure 4.9A). The RPMI 8226 cell
line was used as a positive control. CAY10593 impaired ATP-induced ethidium+ uptake
into MEL cells by only 2 ± 3% (Figure 4.9B). Furthermore, in the absence of ATP,
CAY10593 significantly impaired ethidium+ uptake in DMSO treated MEL cells.
Therefore, CAY10593 did not impair the net ATP-induced ethidium+ uptake. As
expected, CAY10593 significantly impaired ATP-induced ethidium+ uptake by 62 ± 2%
in RPMI 8226 cells (Figure 4.9B). In contrast, in the absence of ATP, CAY10593 did
not significantly alter ethidium+ uptake in DMSO treated RPMI 8226 cells (Figure
4.9B).
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Figure 4.9: CAY10593 impairs human but not murine P2X7-induced pore
formation. (A, B) MEL cells or (B) RPMI 8226 cells in NaCl medium were
preincubated for 15 min in the presence of DMSO or 10 µM CAY10593. Cells were
then incubated with 25 µM ethidium+ in the absence or presence of 1 mM ATP at 37°C
for 5 min. Incubations were stopped by addition of MgCl2 medium and centrifugation
and the MFI of ethidium+ uptake measured by flow cytometry. (A) Basal or
ATP-treated MEL cells were gated by FSC and SSC. Representative histograms show
basal (grey fill) and ATP-induced (solid line) ethidium+ uptake. (B) Results are mean ±
SD (n = 3);

**

P < 0.01 compared to DMSO control, and

††

P < 0.01 compared to ATP

with DMSO.

4.3 Discussion
This chapter demonstrates that the PLD1 antagonist, CAY10593 directly impairs human
P2X7 activation. Preliminary investigations demonstrated that CAY10593 impaired
ATP-induced CD23 shedding. However, CAY10593 also impaired ATP-induced
ethidium+ uptake into RPMI 8226 cells in a concentration-dependent manner, and with
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an IC50 similar to that of the P2X7 antagonist, A-438079 as observed previously by
Nelson et al. (2006) and in Chapter 3. Unlike A-438079, however, which blocks P2X7
in a competitive manner (Nelson et al. 2006), CAY10593 impaired P2X7 in a
non-competitive-like manner. CAY10593 also impaired ATP-induced ethidium+ uptake
into P2X7-transfected HEK 293 cells, and primary human B cells, T cells and
monocytes.

Data from this chapter also shows that CAY10593 impairs P2X7 activation
independently of PLD1 stimulation. First, CAY10593 was far more effective at
inhibiting P2X7-induced pore formation than halopemide, which both impair cellular
PLD1 with similar efficacies (Scott et al. 2009). Second, the IC50 value of CAY10593
for inhibition of P2X7-induced pore formation was two logs greater than that observed
for the inhibition of phorbol 12-myristate 13-acetate-induced PLD1 stimulation in the
non-small-cell lung cancer cell line, Calu-1 (Scott et al. 2009) (2 μM vs. 11 nM,
respectively). Third, PLD1 mRNA was absent in RPMI 8226 cells, indicating that these
cells do not contain this PLD isoform. Fourth, the primary alcohol, 1-butanol, which
prevents PLD-mediated signalling (Morris et al. 1997), did not impair P2X7-induced
pore formation. In fact, 1-butanol potentiated this process, similar to a previous study in
which incubation with 1-butanol increased P2X7-induced pore formation and cytolysis
in murine macrophages compared to controls (Le Stunff and Raymond 2007). The
authors of this previous study concluded that phosphatidic acid production, resulting
from PLD stimulation, delays P2X7-induced pore formation and cytolysis. Thus, it is
possible that PLD-induced phosphatidic acid production may also delay P2X7-induced
pore formation in human cells. Fifth and similar to the effect of 1-butanol,
P2X7-induced pore formation and CD23 shedding were not impaired in choline Cl
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medium, which prevents P2X7-induced PLD stimulation in murine macrophages (elMoatassim and Dubyak 1993) and human chronic lymphocytic leukemic lymphocytes
(Fernando et al. 1999). Sixth, CAY10593 also impaired P2X7 channel activity, a
function of P2X7 not directly linked to the activation of intracellular signalling
molecules (Pelegrin 2011). Finally, it is unlikely that CAY10593 impairs P2X7 activity
via a PLD2-dependent mechanism despite the presence of PLD2 mRNA in RPMI 8226
cells; the PLD2 inhibitor, CAY10594, was far less effective at impairing ATP-induced
ethidium+ uptake and CD23 shedding compared to CAY10593. Combined this data
highlights the importance of ensuring that antagonists used in intracellular signalling
studies downstream of P2X7 activation do not directly affect P2X7 itself. In this regard,
CAY10593 has been used at 50 µM to support a role for PLD in the generation of
P2X7-induced microvesicles capable of activating macrophages (Thomas and Salter
2010). However, data from this chapter suggests that CAY10593 may have also acted
on P2X7 itself in this previous study. Conversely, this data in combination with that of
Scott and colleagues (Scott et al. 2009) indicates that the use of CAY10593 at nM
concentrations is of potential value in determining if PLD1 is involved in signalling
pathways downstream of P2X7 activation.

As noted above CAY10593 impaired P2X7-induced pore formation more efficaciously
than CAY10594 or halopemide. Moreover, CAY10593 blocked P2X7-induced CD23
shedding to a greater extent than CAY10594 or halopemide. CAY10593 was originally
synthesised via the modification of the 1-(piperidin-4-yl)-1H-benzo[d]imidazol-2(3H)one analogue halopemide, but unlike halopemide, CAY10593 contains a chiral
(S)-methyl group which prompts PLD1 preferring pharmacology (Scott et al. 2009),
CAY10594, which has a 1-phenyl-1,3,8-triazaspiro[4,5]decan-4-one scaffold instead of
119

a 1-(piperidin-4-yl)-1H-benzo[d]imidazol-2(3H)-one scaffold, also lacks a chiral
(S)-methyl group (Scott et al. 2009). Therefore, this structural group may be of
importance in the interaction of CAY10593 with P2X7. The scaffold or structural
groups of CAY10593 may provide useful leads in the development of new P2X7
antagonists. In this regard, the study of analogues of the P2X7 antagonist KN-62, which
is also an inhibitor of Ca2+/calmodulin-dependent protein kinase II, has provided
valuable insight into moieties which interact with P2X7 and the design of new P2X7
antagonists (Romagnoli et al. 2005).

CAY10593 failed to impair ATP-induced ethidium+ uptake into MEL cells, indicating
that this antagonist does not act on murine P2X7. In this regard, P2X7 antagonists also
show species selectivity, for example KN-62 impairs human and murine P2X7 but not
rat P2X7 (Humphreys et al. 1998). However, CAY10593 reduced basal ethidium+
uptake into MEL cells but not into RPMI 8226 cells, suggesting that this compound
affects the membrane permeability of MEL cells to ethidium+. In human umbilical vein
endothelial cells, siRNA silencing of PLD2 decreases basal permeability of these cells
to horseradish peroxidase flux (Zeiller et al. 2009). Further, this same study also found
that PLD2 regulates permeability through cytoskeleton reorganisation (Zeiller et al.
2009). Therefore it is possible that basal ethidium+ permeability in MEL cells may be
dependent on PLD1 activity. It would be valuable to determine if the PLD2 antagonist,
CAY10594 or the broad spectrum PLD antagonist, halopemide, also modify basal
ethidium+ uptake into these cells.
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It is unknown if P2X7-induced CD23 shedding results from changes in intracellular
cation concentrations, stimulation of signalling pathways downstream of P2X7
activation or by a direct physical interaction of P2X7 itself. The current chapter reports
data exploring the first two of these three potential mechanisms. In this study, we show
that P2X7-induced CD23 shedding does not require changes in intracellular Na+, K+ or
Ca2+ concentrations. Changes in intracellular cation concentrations are crucial for some
P2X7-mediated downstream processes. For example, P2X7-induced interleukin (IL)-1β
processing and release is dependent on K+ efflux from human monocytes (Andrei et al.
2004, Sluyter et al. 2004), murine and human macrophages (Perregaux and Gabel 1994,
Ferrari et al. 1997a, Kahlenberg and Dubyak 2004) and murine microglia (Sanz and Di
Virgilio 2000). Moreover, P2X7-induced secretion of IL-1β is dependent on the influx
of extracellular Ca2+ and a sustained increase in intracellular Ca2+ in human monocytes
(Gudipaty et al. 2003, Andrei et al. 2004), murine macrophages and P2X7-transfected
HEK 293 cells (Gudipaty et al. 2003). Finally, P2X7-induced rapid phosphatidylserine
exposure on murine thymocytes is dependent on Na+ influx (Courageot et al. 2004). In
contrast to these studies, we found that neither K+ efflux, Na+ influx, Ca2+ influx nor an
increase in intracellular Ca2+ is essential for P2X7-induced CD23 shedding from RPMI
8226 cells. Of note, choline Cl and KCl medium potentiated ATP-induced CD23
shedding compared to NaCl medium, which is likely due to the omission of
extracellular Na+, a cation known to inhibit P2X7 activity (Wiley et al. 1992, Michel et
al. 1999), as well as the possible inhibition of phosphatidic acid production by choline
as discussed above.

The data in this chapter also shows that several signalling pathways downstream of
P2X7 activation, including PKC, MAPK, MEK1/2, JNK, Rho kinase, PI3K, GSK-3,
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PLA, PLC and aSmase (Table 4.1) are unlikely to be involved in P2X7-induced CD23
shedding. Furthermore, pannexin-1, as well as cell membrane-related structures
including endosomes are also unlikely to be involved (Table 4.1). However, it should be
noted that the compounds used to target these enzymes and molecules were only used at
a single concentration, and thus the involvement of these or other signalling pathways in
P2X7-induced CD23 shedding cannot be excluded.

In conclusion, this chapter demonstrates the PLD1 antagonist, CAY10593, impairs
human P2X7 independently of PLD1 stimulation. This chapter highlights the
importance of ensuring that antagonists used in intracellular signalling studies
downstream of P2X7 activation do not directly affect P2X7 itself. Moreover, this study
suggests that CAY10593 may serve in studies of P2X7-induced PLD1 stimulation when
used at nM concentrations, as well as a future lead compound in the development of
P2X7 antagonists.
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CHAPTER 5
The effect of reactive
oxygen species on
P2X7-induced CD23
shedding from RPMI 8226
cells
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5.1 Introduction
It is well established that P2X7 activation induces reactive oxygen species (ROS)
generation via the activation of nicotinamide adenine dinucleotide phosphate (NADPH)
oxidase in several cell types (Noguchi et al. 2008, Seil et al. 2008, Lenertz et al. 2009,
Bartlett et al. 2013, Wang and Sluyter 2013), however little is known about the role of
P2X7 and ROS in B cells. Furthermore, ROS generation is involved in
nucleotide-induced shedding of cell membrane molecules such as transforming growth
factor-α (Boots et al. 2009, Myers et al. 2009), but whether ROS is involved in P2X7induced CD23 shedding also remains unknown. Several molecules that are involved in
P2X7-induced downstream events were not implicated in P2X7-induced CD23
shedding from RPMI 8226 cells (Chapter 4). During the course of these investigations,
Foster and colleagues published a study showing mitochondrial superoxide, generated
via

the

pharmacological

modulation

of

mitochondrial

enzymes,

enhanced

P2X7-mediated loss of CD62L from human T cells (Foster et al. 2013). Furthermore,
this study (Foster et al. 2013) and a previous study (Wang et al. 2009) show that
hydrogen peroxide (H2O2), a form of ROS, downregulates cell surface CD62L. The aim
of this chapter was to investigate the effect of the ROS H2O2, and rotenone (which
uncouples mitochondrial complex I and leads to the enhancement of mitochondrial
superoxide) (Foster et al. 2013) and diphenyleneiodonium (DPI) (an inhibitor of flavone
containing enzymes) (Foster et al. 2013) on P2X7-induced CD23 shedding from
RPMI 8226 cells.

124

5.2 Results

5.2.1 H2O2 but not DPI or rotenone enhance ATP-induced CD23 loss
from RPMI 8226 cells
To determine whether H2O2, DPI or rotenone affect P2X7-induced CD23 shedding,
RPMI 8226 cells were preincubated in the absence or presence of 100 µM H2O2, or in
the presence of dimethyl sulphoxide (DMSO), 100 µM DPI or 5 µM rotenone and then
with 1 mM adenosine 5’-triphosphate (ATP), and cell surface CD23 expression
measured by flow cytometry as described in Chapter 3. As observed in Chapters 3 and
4, ATP induced a loss of CD23 from the cell surface of RPMI 8226 cells (Figure 5.1AC). H2O2 significantly enhanced ATP-induced CD23 loss approximately 2-fold
compared to ATP-induced CD23 shedding alone (Figure 5.1A). In contrast, DPI and
rotenone did not affect ATP-induced CD23 loss (Figure 5.1B, C). In the absence of
ATP, H2O2 and rotenone but not DPI caused a small but significant amount of basal
CD23 loss (Figure 5.1A-C).
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Figure 5.1: H2O2 but not DPI or rotenone enhance ATP-induced CD23 loss from
RPMI 8226 cells. RPMI 8226 cells in NaCl medium were preincubated at 37°C in the
absence or presence of (A) 100 µM H2O2 for 15 min, or in the presence of (B,C)
DMSO, (B) 100 µM DPI for 1 h, or (C) 5 µM rotenone for 30 min. Cells were then
incubated in the absence (basal) or presence of 1 mM ATP at 37°C for 7 min.
Incubations were stopped by addition of MgCl2 medium and centrifugation. Cells were
labelled with phycoerythrin (PE)-conjugated anti-CD23 or isotype control monoclonal
antibody (mAb), and the mean fluorescence intensity (MFI) of cell surface CD23
expression determined by flow cytometry. Results are mean ± standard deviation (SD)
(n = 3); *P < 0.05 and **P < 0.01 compared to corresponding basal or DMSO control,
and ††P < 0.01 compared to ATP alone.

5.2.2 ATP, DPI and rotenone induce ROS formation in RPMI 8226
cells
To determine if DPI and rotenone could induce ROS formation in RPMI 8226 cells,
cells

were

loaded

with

the

broad

spectrum

ROS

indicator

5

µM

dichlorodihydrofluorescein diacetate (H2DCFDA) or the superoxide indicator 2.5 µM
mitoSOX Red. Cells were then incubated in the absence or presence of 100 µM DPI or
5

µM

rotenone

and

ROS

formation

was

detected

by

measuring

dichlorodihydrofluorescein (DCF) or mitoSOX Red fluorescence using flow cytometry.
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Since ATP can induce ROS formation in several cell types (Seil et al. 2008, Lenertz et
al. 2009, Bartlett et al. 2013, Wang and Sluyter 2013), 1 mM ATP was used as a
comparison. ATP induced approximately a 7-fold increase in DCF fluorescence
compared to cells incubated without ATP (Figure 5.2A). DPI and rotenone induced
approximately a 2-fold and 6-fold increase in DCF fluorescence respectively compared
to cells incubated with DMSO (Figure 5.2B, C). In contrast to DCF fluorescence, ATP
did not induce mitoSOX Red fluorescence compared to cells incubated without ATP
(Figure 5.2D). However, DPI induced approximately a 2-fold increase compared to
DMSO, while rotenone induced a small, but significant increase in mitoSOX Red
fluorescence compared to DMSO (Figure 5.2E, F). Collectively, these results show that
DPI and rotenone can induce ROS formation in RPMI 8226 cells (Figure 5.2), but only
H2O2 can increase ATP-induced CD23 loss (Figure 5.1). Therefore the effects of H2O2
on CD23 loss were assessed further.

5.2.3 H2O2 enhances ATP-induced CD23 loss from RPMI 8226 cells in
a time-dependent manner
H2O2 induces the rapid shedding (<15 min) of CD62L from human T cells in a
time-dependent manner (Foster et al. 2013). Therefore to determine whether H2O2
enhances ATP-induced CD23 loss in a time-dependent manner, RPMI 8226 cells were
preincubated with 100 µM H2O2 and then with ATP for up to 7 min and cell surface
CD23 measured by flow cytometry. H2O2 enhanced ATP-induced CD23 loss compared
to cells incubated with ATP alone at each time point measured from 1-7 min (Figure
5.3). In contrast, preincubation with H2O2 had no significant effect on CD23 expression
at 0 min (Figure 5.3).
127

Figure 5.2: ATP, DPI and rotenone induce ROS formation in RPMI 8226 cells. (AF) RPMI 8226 cells in NaCl medium were loaded with (A-C) 5 µM H2DCFDA for 5
min or (D-F) 2.5 µM mitoSOX Red for 30 min at 37°C and washed once with NaCl
medium. (A-F) Cells were then incubated at 37°C in the absence (basal) or presence of
(A, D) 1 mM ATP for 20 min, or in the presence of (B, C, E, F) DMSO, (B, E) 100 µM
DPI for 1 h or (C, F) 5 µM rotenone for 30 min. Incubations were stopped by addition
of MgCl2 medium and centrifugation. The MFI of DCF or mitoSOX Red fluorescence
was measured by flow cytometry. Results are mean ± SD; (A, F, n = 3; B-E, n = 6);
*

P < 0.05 and **P < 0.01 compared to corresponding basal or DMSO control.
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Figure 5.3: H2O2 enhances ATP-induced CD23 loss from RPMI 8226 cells in a
time-dependent manner. RPMI 8226 cells were preincubated at 37°C for 15 min in the
absence or presence of 100 µM H2O2 and then with 1 mM ATP at 37°C for up to 7 min
(as indicated). Incubations were stopped by addition of MgCl2 medium and
centrifugation. Cells were labelled with PE-conjugated anti-CD23 or isotype control
mAb, and the MFI of cell surface CD23 expression determined by flow cytometry.
Results are mean ± SD (n = 3); *P < 0.05 and

**

P < 0.01 compared to corresponding

ATP alone.

5.2.4 P2X7 activation is not involved in H2O2-induced enhancement of
ATP-induced CD23 loss from RPMI 8226 cells
To determine if P2X7 activation is involved in H2O2-induced enhancement of
ATP-induced CD23 loss, RPMI 8226 cells were preincubated in the absence or
presence of 100 nM AZ10606120, or in the absence or presence of 100 nM
AZ10606120 with 100 µM H2O2. Cells were then incubated in the absence or presence
of ATP, and cell surface CD23 measured by flow cytometry. As observed above (Figure
5.1 and 5.3), ATP induced a loss of CD23 compared to basal control, which was
enhanced by H2O2 (Figure 5.4). Also as expected, the P2X7 antagonist, AZ10606120
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impaired ATP-induced CD23 loss by 97 ± 5% compared to ATP-induced CD23 loss in
the absence of AZ10606120 (Figure 5.4). However, in the presence of H2O2,
AZ10606120 impaired ATP-induced CD23 loss by only 69 ± 9% compared to
ATP-induced CD23 loss in the absence of AZ10606120 (Figure 5.4). In the absence of
ATP, AZ106016120 did not significantly alter cell surface CD23 expression in the
absence or presence of H2O2 (Figure 5.4). Thus, the incomplete inhibition of ATPinduced CD23 loss in the presence of H2O2 by AZ10606120 suggests that P2X7
activation is not involved in the enhanced ATP-induced CD23 loss by H2O2.

Figure 5.4: P2X7 activation is not involved in H2O2-induced enhancement of
ATP-induced CD23 loss from RPMI 8226 cells. RPMI 8226 cells were preincubated
at 37°C in the absence or presence of 100 nM AZ10606120 for 15 min (control), or in
the absence or presence of 100 nM AZ10606120 for 15 min, followed by absence (left)
or presence (right) of 100 µM H2O2 for 15 min. Cells were then incubated in the
absence (basal) or presence of ATP at 37°C for 7 min. Incubations were stopped by
addition of MgCl2 medium and centrifugation. Cells were labelled with PE-conjugated
anti-CD23 or isotype control mAb, and the MFI of cell surface CD23 expression
determined by flow cytometry. Results are mean ± SD (n = 3); *P < 0.05 and **P < 0.01
compared to corresponding basal control, and

††

P < 0.01 compared to corresponding

ATP in the absence of AZ10606120.
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5.2.5 H2O2 does not affect ATP-induced ethidium+ uptake nor
AZ10606120 inhibition of ATP-induced ethidium+ uptake into
RPMI 8226 cells.
To examine if H2O2 affects P2X7 activation, RPMI 8226 cells were preincubated in the
absence or presence of 100 nM AZ10606120 alone, or with 100 µM H2O2 in the
absence or presence of 100 nM AZ10606120. Cells were then incubated with ATP, and
ethidium+ uptake measured by flow cytometry. As previously observed (Chapters 3 and
4), ATP-induced significant ethidium+ uptake compared to basal control (Figure 5.5).
AZ10606120 impaired ATP-induced ethidium+ uptake by 100 ± 0% compared to
ATP-induced ethidium+ uptake in the absence of AZ10606120 (Figure 5.5). In the
presence of H2O2, ATP induced similar amounts of ethidium+ uptake compared to basal
control, and this was impaired by AZ10606120 with the same efficacy as the
AZ10606120-mediated inhibition of ATP-induced ethidium+ uptake in the absence of
H2O2 (Figure 5.5). AZ106016120 did not significantly alter basal ethidium+ uptake in
the absence or presence of H2O2 (Figure 5.5).
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Figure 5.5: H2O2 does not affect ATP-induced ethidium+ uptake nor AZ10606120
inhibition of ATP-induced ethidium+ uptake into RPMI 8226 cells. RPMI 8226 cells
were preincubated at 37°C in the absence or presence of 100 nM AZ10606120 for 15
min (control), or in the absence or presence of 100 nM AZ10606120 for 15 min
followed by the absence (left) or presence (right) of 100 µM H2O2 for 15 min. Cells
were then incubated in the absence (basal) or presence of ATP at 37°C for 5 min.
Incubations were stopped by addition of MgCl2 medium and centrifugation and the MFI
of ethidium+ uptake determined by flow cytometry. Results are mean ± SD (n = 3);
**

P < 0.01 compared to corresponding basal control, and

††

P < 0.01 compared to

corresponding ATP in the absence of AZ10606120.

5.2.6 H2O2 does not enhance basal or ATP-induced soluble CD23
shedding from RPMI 8226 cells.
To determine whether H2O2 enhances ATP-induced soluble CD23 shedding,
RPMI 8226 cells were preincubated in the absence or presence 100 µM H2O2 and then
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with ATP, and the amount of soluble CD23 in cell-free supernatants measured by an
enzyme-linked immunosorbent assay (ELISA). As observed previously (Chapter 3),
incubation of cells with ATP resulted in significantly higher release of soluble CD23
compared to basal control cells (Figure 5.6). However, in the presence of H2O2, ATP
induced similar amounts of soluble CD23 release compared to cells incubated with ATP
in the absence of H2O2 (Figure 5.6). Basal soluble CD23 release was similar in the
absence or presence of H2O2 (Figure 5.6). This suggests that H2O2 does not enhance
ATP-induced soluble CD23 shedding from RPMI 8226 cells, but alters cell surface
CD23 by another mechanism.

Figure 5.6: H2O2 does not enhance basal or ATP-induced soluble CD23 shedding
from RPMI 8226 cells. RPMI 8226 cells in NaCl medium (1 x 106 cells/ml) were
preincubated in the absence (left) or presence (right) of 100 µM H2O2, and then in the
absence (basal) or presence of 1 mM ATP for 20 min. Incubations were stopped by
centrifugation and the amount of soluble CD23 in cell-free supernatants determined by
ELISA. Results are mean ± SD (n = 6);

**

P < 0.01 compared to corresponding basal

control.
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5.3 Discussion
This chapter demonstrates that H2O2 enhances ATP-induced cell surface loss of CD23
from RPMI 8226 cells in a rapid and time-dependent manner. However, H2O2 did not
enhance ATP-induced soluble CD23 release from RPMI 8226 cells. Therefore it is
possible the H2O2-induced enhancement of ATP-induced CD23 loss, from RPMI 8226
cells is an artefact due to H2O2 altering the binding of the CD23 mAb to cell surface
CD23. In this regard, it has been shown that H2O2 treatment reduces binding of some
mAb to their ligands (Ibsen 1996). However, if this explanation is true it is curious that
H2O2 generally reduces mAb binding to CD23 in the presence but not in the absence of
ATP. An alternate explanation is that H2O2 enhances internalisation of CD23 leading to
an increased loss of CD23 from the cell surface. H2O2 has been shown to induce the
internalisation of the keratinocyte growth factor receptor (Belleudi et al. 2006).
However, given that AZ10606120 did not completely impair the ATP-induced loss of
CD23 in the presence of H2O2, the potential internalisation of CD23 by H2O2 was not
examined further. The inability of AZ10606120 to completely prevent the ATP-induced
loss of cell surface CD23 in the presence of H2O2 was not due to an effect of H2O2 on
AZ10606120, as the P2X7 antagonist completely impaired ATP-induced ethidium+
uptake in the presence of H2O2. Furthermore, H2O2 did not increase ATP-induced
ethidium+ uptake excluding a direct effect of the ROS on P2X7 function. However,
ATP induced significant ROS formation in RPMI 8226 cells which was almost
completely impaired by AZ10606120 (results not shown). This suggests P2X7
activation plays a role in ROS formation in RPMI 8226 cells. It would be of interest to
determine the significance of P2X7-induced ROS formation in these cells, however it
was beyond the scope of this thesis.
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Foster and colleagues showed that DPI and rotenone enhanced ATP-induced CD62L
shedding from human T cells, and that this enhancement is due to P2X7 activation
(Foster et al. 2013). In contrast, DPI and rotenone did not significantly affect
ATP-induced CD23 loss, despite both compounds being able to induce ROS formation
in RPMI 8226 cells. The effect of DPI and rotenone on ATP-induced CD62L loss from
human T cells was not examined in the present study, but such a study would have also
served as a suitable positive control. Nevertheless, the reason for the difference between
the current study and that of Foster and colleagues, with DPI and rotenone on
ATP-induced shedding of cell surface molecules remains unknown. Foster and
colleagues treated human T cells with 3 mM ATP for an hour, whereas RPMI 8226
cells were treated with 1 mM ATP for 7 min, therefore it is possible that in the presence
of these compounds, treatment of RPMI 8226 cells with ATP for longer or at higher
concentrations may enhance ATP-induced CD23 loss. An alternate, but not mutually
exclusive reason for the differences between the two studies may relate to the ADAMs
mediating CD23 and CD62L shedding. ADAM17 is implicated in nucleotide-induced
CD62L shedding from murine B cells and T cells (Le Gall et al. 2009, Le Gall et al.
2010). Therefore it is likely that superoxide-enhancement of P2X7-induced CD62L loss
from human T cells involves ADAM17 (Foster et al. 2013). In contrast, ATP-induced
CD23 shedding from RPMI 8226 cells involves ADAM10 (Chapter 6). Finally, it
should be noted that it was not determined if the superoxide-induced enhancement of
P2X7-induced CD62L loss from T cells (Foster et al. 2013) was a result of CD62L
shedding or internalisation. Thus, further studies are also required in this model to better
understand the mechanisms involved.
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This chapter demonstrates that H2O2 does not enhance ATP-induced CD23 shedding
from RPMI 8226 cells but the possibility remains that H2O2 alters CD23 mAb binding
to CD23 or induces CD23 internalisation. However, given that this effect appeared to be
independent of P2X7 this was not investigated further. Furthermore, neither rotenone
nor DPI affected ATP-induced CD23 shedding from RPMI 8226 cells indicating that
ROS, along with several other signalling pathways (Chapter 4), do not play a significant
role in P2X7-induced CD23 shedding from these cells.
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CHAPTER 6
ADAM10 is involved in
P2X7-induced CD23 and
CXCL16 shedding from
RPMI 8226 cells
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6.1 Introduction
P2X7 activation induces the shedding of cell surface molecules including CD23 from
chronic lymphocytic leukaemia B cells (Gu et al. 1998), RPMI 8226 multiple myeloma
B cells (Farrell 2008; Chapters 3-5) and normal dendritic cells (Sluyter and Wiley 2002,
Georgiou et al. 2005), and the interleukin-6 receptor (IL-6R) from murine splenic
T cells, and P2X7/IL-6R co-transfected human embryonic kidney (HEK 293) cells and
murine NIH3T3 fibroblasts (Garbers et al. 2011). P2X7-induced IL-6R shedding is
mediated by a disintegrin and metalloprotease (ADAM) 10 (Garbers et al. 2011).
ADAM10 is also responsible for the constitutive, and ionomycin-induced shedding of
CD23 (Weskamp et al. 2006, Le Gall et al. 2009), and other molecules such as the
CXCR6 ligand and chemokine CXCL16 (Abel et al. 2004, Gough et al. 2004). Broad
spectrum metalloprotease inhibitors have implicated a role for metalloproteases in
P2X7-induced CD23 shedding from leukemic B cells (Gu et al. 1998) and RPMI 8226
cells (Sluyter and Wang, personal communication), but the identity of the
metalloprotease remains unknown. Given the role of ADAM10 in constitutive and
inducible CD23 shedding, it is a likely candidate in P2X7-induced CD23 shedding.
Therefore, using RPMI 8226 cells the aim of this chapter was to determine whether
ADAM10 is involved in P2X7-induced CD23 shedding.

6.2 Results
6.2.1 ADAM10 is expressed in RPMI 8226 cells
To determine if RPMI 8226 cells express ADAM10, RNA was isolated from
RPMI 8226 cells and examined by reverse transcriptase-polymerase chain reaction
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(RT-PCR). RT-PCR showed the expression of ADAM10 messenger RNA (509 base
pairs) in these cells (Figure 6.1). No PCR products were observed in the H2O controls
(Figure 6.1).

Figure 6.1: ADAM10 is expressed in RPMI 8226 cells. RNA was isolated from
RPMI 8226 cells, and then analysed by RT-PCR using primers for ADAM10. RNA
substituted with H2O was used as a negative control. PCR products were visualised
using ethidium bromide. A representative result from three experiments is shown.

6.2.2 The ADAM10 antagonist, GI254023X impairs P2X7-induced
CD23 shedding but not ethidium+ uptake into RPMI 8226 cells
To determine whether ADAM10 is involved in P2X7-induced CD23 shedding, RPMI
8226 cells were preincubated in the absence or presence of the ADAM10 antagonist
3 µM GI254023X (Ludwig et al. 2005a), and then with adenosine 5’-triphosphate
(ATP), and cell surface CD23 expression measured by flow cytometry. As previously
observed (Chapters 3-5), ATP induced the rapid shedding of CD23 from RPMI 8226
cells (Figure 6.2A). GI254023X impaired P2X7-induced CD23 shedding by 57 ± 11%
(Figure 6.2A). To exclude a direct inhibitory role of GI254023X on P2X7 itself, cells
were preincubated in the absence or presence of GI254023X for 15 min and ATPinduced ethidium+ uptake was measured by flow cytometry. GI254023X (3 µM) did not
affect ATP-induced ethidium+ uptake into cells (Figure 6.2B). In the absence of ATP,
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GI254023X did not significantly alter CD23 shedding or ethidium+ uptake compared
with cells incubated in dimethyl sulphoxide (DMSO) alone (Figure 6.2A, B).

Figure 6.2: The ADAM10 antagonist, GI254023X impairs P2X7-induced CD23
shedding but not ethidium+ uptake into RPMI 8226 cells. (A, B) RPMI 8226 cells in
NaCl medium were preincubated at 37°C for 15 min in the presence of DMSO or 3 μM
GI254023X, and then in the absence (basal) or presence of (A) 1 mM ATP at 37°C for 7
min or (B) 25 μM ethidium+ in the absence or presence of 1 mM ATP for 5 min at
37°C. Incubations were stopped by addition of MgCl2 medium and centrifugation. (A)
Cells were then labelled with phycoerythrin (PE)-conjugated anti-CD23 or isotype
control monoclonal antibody (mAb). The mean fluorescence intensity (MFI) of (A) cell
surface CD23 expression or (B) ethidium+ uptake was determined by flow cytometry.
Results are mean ± standard deviation (SD) (n = 3);
corresponding basal control, and

††

**

P < 0.01 compared to

P < 0.01 compared to corresponding ATP with

DMSO.
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6.2.3 CXCL16 is expressed on RPMI 8226 cells
To confirm a role for ADAM10 in P2X7-induced CD23 shedding, several attempts
were made to knockdown ADAM10 in RPMI 8226 cells using short inhibitory RNA.
However, this approach was unsuccessful due to poor transfection efficiency (results not
shown). Therefore to confirm that P2X7 activates ADAM10, the effect of P2X7
activation was examined on a second ADAM10 substrate, CXCL16. First, to determine
whether RPMI 8226 cells express CXCL16, cells were labelled with an anti-CXCL16 or
control IgG antibody (Ab) and fluorescence measured by flow cytometry. CXCL16 was
present on RPMI 8226 cells (MFI of 14 ± 1, Figure 6.3).

Figure 6.3: CXCL16 is expressed on RPMI 8226 cells. (A, B) RPMI 8226 cells in
NaCl medium were labelled with anti-CXCL16 (solid line) or isotype IgG control
(shaded) Ab, and then with a fluorescein isothiocyanate (FITC)-conjugated secondary
Ab. The MFI of CXCL16 cell surface expression was determined by flow cytometry.
(A) RPMI 8226 cells were gated by forward scatter (FSC) and side scatter (SSC) as
shown. (B) A representative result from three experiments is shown.
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6.2.4 ATP induces CXCL16 loss from RPMI 8226 cells in a timedependent manner
To determine if ATP induces CXCL16 shedding, cells were incubated with 1 mM ATP
which resulted in an 83 ± 8% (n = 3) loss of cell surface CXCL16 at 30 min, with a
similar loss of CXCL16 observed at 10 and 20 min (results not shown). ATP-induced
cell surface CXCL16 loss was then determined over shorter time points. ATP induced
the rapid loss of cell surface CXCL16 in a time-dependent fashion, with a t1/2 of
approximately 1 min (Figure 6.4).

6.2.5 ATP induces CXCL16 shedding from RPMI 8226 cells
To determine if ATP-induced loss of cell surface CXCL16 was due to CXCL16
shedding, RPMI 8226 cells were incubated in the absence or presence of 1 mM ATP,
and the amount of soluble CXCL16 in cell-free supernatants quantified by
enzyme-linked immunosorbent assay (ELISA). Incubation of cells with ATP resulted in
a significantly higher release of soluble CXCL16 compared with cells incubated in the
absence of ATP (Figure 6.5).

6.2.6 ATP and BzATP induce CXCL16 shedding from RPMI 8226 cells
To determine if the ATP-induced CXCL16 shedding was mediated by P2X7, cells were
incubated for 1 min (the t1/2) in the absence or presence of ATP, the most potent P2X7
agonist

2ʹ(3ʹ)-O-(4-benzoylbenzoyl)adenosine-5ʹ-triphosphate

(BzATP),

or

the

non-P2X7 agonists adenosine 5’-diphosphate (ADP) and uridine 5’-triphosphate (UTP)
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(all at 100 μM) and cell surface CXCL16 expression measured by flow cytometry. ATP
and BzATP induced a 62 ± 8% and 64 ± 1% loss of cell surface CXCL16 respectively,
while ADP and UTP had no effect compared to cells incubated in the absence of
nucleotide (Figure 6.6).

Figure 6.4: ATP induces CXCL16 loss from RPMI 8226 cells in a time-dependent
manner. RPMI 8226 cells in NaCl medium were incubated for up to 10 min (as
indicated) at 37°C in the absence or presence of 1 mM ATP. Incubations were stopped
by addition of MgCl2 medium and centrifugation. Cells were then labelled with
anti-CXCL16 or IgG control Ab, and then with a FITC-conjugated anti-rabbit IgG Ab.
The MFI of cell surface CXCL16 expression was determined by flow cytometry.
Results are mean ± SD (n = 3).
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Figure 6.5: ATP induces CXCL16 shedding from RPMI 8226 cells. RPMI 8226
cells in NaCl medium were incubated in the absence (basal) or presence of 1 mM ATP
at 37°C for 10 min. Incubations were stopped by centrifugation and amount of soluble
CXCL16 in cell-free supernatants determined by ELISA. Results are mean ± SD
(n = 3); **P < 0.01 compared to basal.

Figure 6.6: ATP and BzATP induce CXCL16 shedding from RPMI 8226 cells.
RPMI 8226 cells in NaCl medium were incubated in the absence (basal) or presence of
1 mM ATP, BzATP, ADP or UTP (all 100 μM) at 37°C for 1 min. Incubations were
stopped by addition of MgCl2 medium and centrifugation. Cells were then labelled with
anti-CXCL16 or IgG control Ab, and then with a FITC-conjugated anti-rabbit IgG Ab.
The MFI of cell surface CXCL16 expression was determined by flow cytometry.
Results are mean ± SD (n = 3); **P < 0.01 compared to basal.
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6.2.7 P2X7 antagonists impair ATP-induced CXCL16 shedding from
RPMI 8226 cells
To confirm that ATP-induced shedding of CXCL16 was mediated by P2X7, cells were
preincubated in the absence or presence of the P2X7 antagonists, AZ10606120 and
KN-62, and then with ATP, and cell surface CXCL16 expression measured by flow
cytometry. Both 100 nM AZ10606120 and 1 μM KN-62 impaired ATP-induced
CXCL16 shedding by 86 ± 24 % and 90 ± 9% respectively, compared to ATP-induced
CXCL16 shedding in the absence of P2X7 antagonists (Figure 6.7). In the absence of
ATP, neither antagonist significantly altered CXCL16 shedding (Figure 6.7).

Figure 6.7: P2X7 antagonists impair ATP-induced CXCL16 shedding from RPMI
8226 cells. (A, B) RPMI 8226 cells in NaCl medium were preincubated at 37°C for 15
min (A) in the absence (control) or presence of 100 nM AZ10606120, or (B) in the
presence of DMSO or 1 μM KN-62, and then in the absence (basal) or presence of
1 mM ATP for 1 min at 37°C. Incubations were stopped by addition of MgCl2 medium
and centrifugation. Cells were then labelled with anti-CXCL16 or IgG control Ab, and
then with a FITC-conjugated anti-rabbit IgG Ab. The MFI of cell surface CXCL16
expression was determined by flow cytometry. Results are mean ± SD (n = 3); *P < 0.05
compared with corresponding basal;

†

P < 0.05 or

††

P < 0.01 compared with

corresponding ATP without antagonist.
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6.2.8 Metalloprotease antagonists impair P2X7-induced CXCL16
shedding from RPMI 8226 cells
To determine a role for metalloproteases in P2X7-induced CXCL16 shedding, cells
were preincubated in the absence or presence of broad spectrum metalloprotease
antagonists BB-94 (Davies et al. 1993) and GM6001 (Grobelny et al. 1992), and then in
the absence or presence of ATP and cell surface CXCL16 expression measured by flow
cytometry. Both 1 μM BB-94 and 1 μM GM6001 impaired P2X7-induced CXCL16
shedding by 77 ± 20% and 52 ± 30 % respectively (Figure 6.8). In the absence of ATP,
neither antagonist significantly altered CXCL16 shedding (Figure 6.8).

Figure 6.8: Metalloprotease antagonists impair P2X7-induced CXCL16 shedding
from RPMI 8226 cells. (A, B) RPMI 8226 cells in NaCl medium were preincubated at
37°C for 15 min in the presence of (A, B,) DMSO, (A) 1 μM BB-94 or (B) 1 μM
GM6001, and then in the absence (basal) or presence of 1 mM ATP for 1 min at 37°C.
Incubations were stopped by addition of MgCl2 medium and centrifugation. Cells were
then labelled with anti-CXCL16 or IgG control Ab, and then with a FITC-conjugated
anti-rabbit IgG Ab. The MFI of cell surface CXCL16 expression was determined by
flow cytometry. Results are mean ± SD (n = 3);
corresponding basal DMSO;

††

**

P < 0.01 compared with

P < 0.01 compared with corresponding ATP with

DMSO.
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6.2.9 GI254023X impairs P2X7-induced CXCL16 shedding from
RPMI 8226 cells
To determine a role for ADAM10 in P2X7-induced CXCL16 shedding, cells were
preincubated in the absence or presence of the ADAM10 antagonist GI254023X, and
then with ATP and cell surface CXCL16 expression determined as above. GI254023X
(3 μM) impaired P2X7-induced CXCL16 shedding by 87 ± 15% (Figure 6.9). In the
absence of ATP, GI254023X did not significantly alter CXCL16 shedding compared
with cells incubated with DMSO alone (Figure 6.9).

Figure 6.9: GI254023X impairs P2X7-induced CXCL16 shedding from RPMI 8226
cells. RPMI 8226 cells in NaCl medium were preincubated at 37°C for 15 min in the
presence of DMSO or 3 μM GI254023X, and then in the absence (basal) or presence of
1 mM ATP for 1 min at 37°C. Incubations were stopped by addition of MgCl2 medium
and centrifugation. Cells were then labelled with anti-CXCL16 or IgG control Ab, and
then with a FITC-conjugated anti-rabbit IgG Ab. The MFI of cell surface CXCL16
expression was determined by flow cytometry. Results are mean ± SD (n = 3);
**

P < 0.01 compared with corresponding basal DMSO;

††

P < 0.01 compared with

corresponding ATP with DMSO.
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6.3 Discussion

Activation of P2X7 induces the shedding of CD23 from leukemic B cells (Gu et al.
1998) and normal dendritic cells (Sluyter and Wiley 2002, Georgiou et al. 2005). Data
from this chapter and previous chapters (Chapters 3-5) confirms that P2X7 activation
induces the rapid shedding of CD23 from RPMI 8226 cells. Broad spectrum
metalloprotease antagonists have implicated a role for metalloproteases in
P2X7-induced CD23 shedding from leukemic B cells (Gu et al. 1998) and RPMI 8226
(Wang and Sluyter, personal communication), but the identity of the metalloprotease
involved has remained inconclusive. Using the specific ADAM10 antagonist
GI254023X and RPMI 8226 cells, data from this chapter shows for the first time that
ADAM10 mediates P2X7-induced CD23 shedding. A role for ADAM10 in nucleotideinduced CD23 shedding was described for human leukaemic monocytic U937 cells
using an inhibitory prodomain construct of ADAM10, A10-(23-213) (Lemieux et al.
2007), and for CD23-transfected Chinese hamster ovary cells or murine B cells using
GI254023X (Le Gall et al. 2009, Le Gall et al. 2010). However, a direct role for P2X7
in this process was not established in any of these studies.

Data from this chapter also shows for the first time that P2X7 activation induces the
rapid shedding of CXCL16, and that this process is mediated by ADAM10. The P2X7
agonists ATP and BzATP induced the rapid cell surface loss of CXCL16 from
RPMI 8226 cells and measurements of soluble CXCL16 indicated that the ATP-induced
loss was a result of shedding. Specific P2X7 antagonists AZ10606120 (Michel et al.
2008) and KN-62 (Gargett and Wiley 1997) almost completely impaired ATP-induced
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CXCL16 shedding, while the non P2X7 agonists ADP and UTP had no effect on
CXCL16 expression. Moreover, P2X7-induced CXCL16 shedding could be impaired by
broad spectrum metalloprotease antagonists, BB-94 (Davies et al. 1993) and GM6001
(Grobelny et al. 1992), outlining a role for metalloproteases in this process. The
inhibition of these two metalloprotease inhibitors was not due to direct inhibition of
P2X7, as previous work in our laboratory has shown that neither BB-94 nor GM6001
impair ATP-induced ethidium+ uptake into RPMI 8226 cells (Wang and Sluyter,
personal communication). The specific involvement of ADAM10 in this process was
established by the ADAM10 antagonist GI254023X (Ludwig et al. 2005a), which like
BB-94 and GM6001 did not affect P2X7-induced ethidium+ uptake. Thus, the
P2X7-induced shedding of CXCL16 indicates that P2X7 activation stimulates
ADAM10. Of note, GI254023X impaired P2X7-induced CXCL16 and CD23 shedding
by ~87% and ~57%, respectively. This reduced capacity for GI254023X to block
P2X7-induced CD23 shedding may reflect differences in cell surface expression and/or
rates of shedding between CXCL16 and CD23.

P2X7 activation induces ADAM10-mediated CD23 and CXCL16 shedding from human
RPMI 8226 cells. The role of ADAM10 in this process is consistent with ADAM10
mediating P2X7-induced shedding of the interleukin-6 receptor from murine splenic
T cells, and from P2X7/interleukin-6 receptor co-transfected HEK 293 and NIH323
cells (Garbers et al. 2011). The possibility remains however, that other ADAMs may be
partly involved in P2X7-induced CD23 and CXCL16 shedding. ADAM8, 15, 28 and 33
(Fourie et al. 2003, Weskamp et al. 2006) have been associated with CD23 shedding
from CD23-transfected HEK 293 cells (Fourie et al. 2003) and primary murine
embryonic fibroblasts (Weskamp et al. 2006). Further, ADAM17 can mediate phorbol
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ester-induced CXCL16 shedding in CXCL16-transfected COS-7 cells (Abel et al. 2004,
Ludwig et al. 2005a, Hundhausen et al. 2007).

Chemokines and their receptors are important in human multiple myeloma plasma cell
migration and compartmentalisation in the bone marrow (Moller et al. 2003). CXCL16
induces chemotactic responses in human bone marrow plasma cells and directly adheres
to plasma cells expressing its receptor CXCR6 (Nakayama et al. 2003), suggesting these
molecules play a role in plasma cell tissue migration and localisation. A more recent
study showed that an anti-tumour molecule, comprised of snake venom and
nanoparticles, decreases the expression of CXCL16, and its receptor CXCR6 on murine
multiple myeloma cells (Al-Sadoon et al. 2013), suggesting that these molecules are
important in multiple myeloma survival. Despite these studies, there is a lack of
knowledge outlining a mechanistic role for CXCL16 in multiple myeloma. Therefore,
data from this chapter suggests P2X7-induced CXCL16 shedding is a novel pathway
that may be involved in multiple myeloma migration, localisation and survival.

In conclusion, data from this chapter demonstrates for the first time that human
P2X7-induced CD23 shedding is mediated by ADAM10 in RPMI 8226 cells. Also for
the first time, data from this chapter shows that P2X7 activation induces the rapid
shedding of CXCL16 from RPMI 8226 cells, and that this process is also mediated by
ADAM10.
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CHAPTER 7
P2X7 activation induces
rapid CD23 shedding from
primary human and
murine B cells
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7.1 Introduction
CD23 is a ‘low affinity’, transmembrane receptor for IgE that is expressed on B cells
and other leukocytes (Sarfati et al. 1992). Transmembrane CD23 can be released from
the cell surface to form soluble CD23, which also binds IgE, and exerts cytokine-like
activities on B cells and other leukocytes (Sarfati et al. 1992). Soluble CD23 sustains
growth of B cell precursors (Borland et al. 2007), promotes B and T cell differentiation
(Mossalayi et al. 1990a, Liu et al. 1991), and drives cytokine release from monocytes
(Hermann et al. 1999). The release of CD23 is mediated by membrane metalloproteases
of the ADAM (a disintegrin and metalloprotease) family. ADAM10 is principally
responsible for the constitutive and calcium-induced shedding of CD23 (Weskamp et al.
2006, Lemieux et al. 2007).

Activation of P2X7 by extracellular adenosine 5’-triphosphate (ATP) causes the uptake
of organic cations such as ethidium+ and YO-PRO-12+ (Cankurtaran-Sayar et al. 2009).
P2X7 activation induces a number of downstream effects including the shedding of
CD23 from chronic lymphocytic leukaemia B cells (Gu et al. 1998), RPMI 8226 human
multiple myeloma cells (chapters 3-6) and human monocyte-derived dendritic cells
(Sluyter and Wiley 2002, Georgiou et al. 2005). Data from chapter 6 demonstrates that
P2X7-induced CD23 shedding from RPMI 8226 cells is mediated by ADAM10.
2’ (3’)-O-(4-benzoylbenzoyl) ATP (BzATP)-induced CD23 shedding from murine
B cells is also mediated by ADAM10 (Le Gall et al. 2009, Le Gall et al. 2010), but a
direct role for P2X7 in this process was not established in these studies. Therefore, it
remains unknown if P2X7 activation induces CD23 shedding from primary murine
B cells or from primary human B cells. The aim of this chapter was to determine
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whether P2X7 activation induces the rapid shedding from primary human and murine
cells, and if so whether this process involves ADAM10.

7.2 Results
7.2.1 ATP induces CD23 loss from human B cells in a time-dependent
manner
To first determine if ATP induces CD23 loss from human B cells, peripheral blood
mononuclear cells (PBMCs) were incubated with ATP for up to 30 min and cell surface
CD23 expression measured by flow cytometry. ATP induced a rapid loss of cell surface
CD23 from B cells with a t1/2 of approximately 6 min (Figure 7.1).

7.2.2 ATP induces CD23 shedding from human B cells
To determine if the P2X7-induced loss of cell surface CD23 was due to CD23 shedding,
PBMCs were incubated in the absence or presence of 1 mM ATP, and the relative
amount of soluble CD23 in cell-free supernatants quantified by enzyme-linked
immunosorbent assay (ELISA). Incubation of PBMCs with ATP resulted in a
significantly higher release of soluble CD23 compared with cells incubated in the
absence of ATP (Figure 7.2).
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Figure 7.1: ATP induces CD23 loss from human B cells in a time-dependent
manner. (A-C) PBMCs in NaCl medium were incubated for up to 30 min at 37°C in the
absence (control) or presence of 1 mM ATP as indicated. Incubations were stopped by
addition of MgCl2 medium and centrifugation. PBMCs were labelled with
allophycocyanin

(APC)-conjugated

anti-CD19,

phycoerythrin

(PE)-conjugated

anti-CD23 or isotype control monoclonal antibody (mAb) and 7-aminoactinomycin D
(7AAD). The mean fluorescence intensity (MFI) of cell surface CD23 expression on
CD19+7AAD- B cells was determined by flow cytometry. (A) Basal or ATP-treated
lymphocytes (l) were gated by forward scatter (FSC) and side scatter (SSC) as shown
(top panel). CD19+7AAD- B cells (b) were gated as shown (bottom panel). (B)
Histograms (from one representative individual) show CD23 expression on (black or
grey fill) or isotype control mAb binding (black line) to CD19+7AAD- PBMCs
incubated in the absence (black fill or black line) or presence (grey fill) of 1 mM ATP
for 30 min; isotype control mAb binding to CD19+7AAD- PBMCs incubated in the
presence of ATP was similar to that of cells incubated in the absence of ATP (not
shown). (C) Results are mean ± standard deviation (SD) (n = 3 individuals).
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Figure 7.2: ATP induces CD23 shedding from human B cells. PBMCs in NaCl
medium were incubated in the absence (basal) or presence of 1 mM ATP at 37°C for 20
min, incubations were stopped by centrifugation and the amount of soluble CD23 in
cell-free supernatants determined by ELISA. Results are mean ± SD (n = 3 individuals);
*

P < 0.05 and **P < 0.01 compared to basal.

7.2.3 ATP and BzATP induce CD23 shedding from human B cells
To determine whether ATP-induced CD23 loss was mediated by P2X7, PBMCs were
incubated for 6 min (the t1/2) in the absence or presence of 1 mM ATP, the most potent
P2X7 agonist 0.3 mM BzATP, or the non-P2X7 agonists 1 mM adenosine diphosphate
(ADP) and uridine 5’-triphosphate (UTP), and cell surface CD23 expression measured
by flow cytometry. ATP and BzATP induced a 49 ± 9% and 60 ± 9% loss of cell
surface CD23, respectively, while ADP and UTP had no effect on CD23 expression
compared to cells incubated without nucleotide (Figure 7.3).
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Figure 7.3: ATP and BzATP induce CD23 shedding from human B cells. PBMCs in
NaCl medium were incubated in the absence (basal) or presence of 1 mM ATP, 0.3 mM
BzATP, 1 mM ADP or 1 mM UTP at 37°C for 6 min. Incubations were stopped by
addition of MgCl2 medium and centrifugation. PBMCs were labelled with
APC-conjugated anti-CD19, PE-conjugated anti-CD23 or isotype control mAb, and
7AAD. The MFI of cell surface CD23 expression on CD19+7AAD- B cells was
determined by flow cytometry. Results are mean ± SD (n = 3 individuals);

**

P < 0.01

compared to basal.

7.2.4 The P2X7 antagonist, AZ10606120 impairs ATP-induced CD23
shedding from human B cells
To confirm that ATP-induced loss of CD23 was mediated by P2X7, PBMCs were
preincubated in the absence or presence of 100 nM AZ10606120, and then with ATP,
and cell surface CD23 expression measured by flow cytometry. AZ10606120 impaired
ATP-induced CD23 loss by 89 ± 12% compare to ATP-induced loss of CD23 in the
absence of AZ10606120 (Figure 7.4). In the absence of ATP, AZ10606120 did not alter
CD23 expression (Figure 7.4).
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Figure 7.4: The P2X7 antagonist, AZ10606120 impairs ATP-induced CD23
shedding from human B cells. PBMCs in NaCl medium were preincubated at 37°C for
15 min in the absence or presence of 100 nM AZ10606120 and then in the absence
(basal) or presence of 1 mM ATP for 6 min at 37°C. Incubations were stopped by
addition of MgCl2 medium and centrifugation. PBMCs were labelled with APCconjugated anti-CD19, PE-conjugated anti-CD23 or isotype control mAb, and 7AAD.
The MFI of cell surface CD23 expression on CD19+7AAD- B cells was determined by
flow cytometry. Results are mean ± SD (n = 3 individuals);

**

P < 0.01 compared to

corresponding control basal and †P < 0.05 compared to corresponding ATP alone.

7.2.5 AZ10606120 impairs ATP-induced YO-PRO-12+ uptake into
murine B cells
The presence of functional P2X7 on primary human B cells is well-established (Gu et
al. 2000, Gu et al. 2001, Sluyter et al. 2001), but less well known for murine B cells.
Therefore, to first test whether functional P2X7 was present on murine B cells from
C57BL/6 and DBA/1 mice, splenic cells from these two strains were preincubated in the
absence or presence of 10 µM AZ10606120, and ATP-induced YO-PRO-12+ uptake
into B cells determined by flow cytometry. C57BL/6 mice were studied because of the
availability of the Pfizer P2X7 knockout mice (Solle et al. 2001), which had been
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backcrossed onto a C57BL/6 background (Tran et al. 2010). DBA/1 mice were also
studied, as this strain has been used to demonstrate a role for CD23 in rheumatoid
arthritis (Plater-Zyberk and Bonnefoy 1995), a disease in which P2X7 is also thought to
be involved (Labasi et al. 2002, Portales-Cervantes et al. 2012). ATP induced
significant YO-PRO-12+ uptake into murine B cells, from either C57BL/6 or DBA/1
mice, compared to YO-PRO-12+ uptake in the absence of ATP (Figure 7.5). Moreover,
10 µM AZ10606120 significantly impaired ATP-induced YO-PRO-12+ uptake in
B cells from C57BL/6 or DBA/1 mice, by 88 ± 14% or 95 ± 8%, respectively,
compared to ATP-induced YO-PRO-12+ uptake in the absence of AZ10606120 (Figure
7.5). In the absence of ATP, AZ10606120 did not alter YO-PRO-12+ uptake in B cells
from either mouse strain (Figure 7.5).

7.2.6 ATP induces CD23 loss from murine B cells in a time-dependent
manner
To determine if ATP induces CD23 loss from murine B cells, splenic cells were
incubated with ATP for up to 30 min and cell surface CD23 expression measured by
flow cytometry. ATP induced a rapid loss of cell surface CD23 from B cells of
C57BL/6 and DBA/1 mice with a t1/2 of approximately 7 min (Figure 7.6).
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Figure 7.5: AZ10606120 impairs ATP-induced YO-PRO-12+ uptake into murine B
cells. (A-C) Splenic cells in NaCl medium were preincubated in the absence or presence
of 10 µM AZ10606120 at 37°C for 15 min. Cells were then incubated with 1 µM
YO-PRO-12+ in the absence (basal) or presence of 1 mM ATP at 37°C for 15 min.
Incubations were stopped by the addition of MgCl2 medium and centrifugation. Cells
were labelled with APC-conjugated anti-CD19 mAb and 7AAD, and the MFI of
YO-PRO-12+ uptake in CD19+7AAD- B cells was determined by flow cytometry. (A)
Lymphocytes (l) were gated by FSC and SSC as shown. B cells (b) were gated as shown
(bottom panel). (B) Representative histograms show basal (grey fill) and ATP-induced
(solid line) YO-PRO-12+ uptake. (C) Results are mean ± SD (n = 3 mice (C57BL/6), or
duplicate values from 2 mice (DBA/1)); **P < 0.01 compared to corresponding control
basal and ††P < 0.01 compared to corresponding ATP alone.
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Figure 7.6: ATP induces CD23 loss from murine B cells in a time-dependent
manner. (A-C) Splenic cells in NaCl medium were incubated for up to 30 min at 37°C
in the absence or presence of 1 mM ATP as indicated. Incubations were stopped by
addition

of

MgCl2

medium

and

centrifugation.

Cells

were

labelled

with

APC-conjugated anti-CD19, FITC-conjugated anti-CD23, or isotype control mAb, and
7AAD. The MFI of cell surface CD23 expression on CD19+7AAD- B cells was
determined by flow cytometry. (A) Lymphocytes (l) were gated by FSC and SSC as
shown (top panel). B cells (b) were gated as shown (bottom panel). (B) Representative
histograms show CD23 expression on (black or grey fill) or isotype control mAb
binding (black line) to CD19+7AAD- PBMCs incubated in the absence (black fill or
black line) or presence (grey fill) of 1 mM ATP for 30 min; isotype control mAb
binding to CD19+7AAD- splenic cells incubated in the presence of ATP was similar to
that of cells incubated in the absence of ATP (not shown). (C) Results are mean ± SD (n
= triplicate values from 1 mouse).
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7.2.7 ATP and BzATP induce CD23 loss from murine B cells
To determine if ATP-induced CD23 loss was mediated by P2X7, cells from both mouse
strains were incubated for 7 min (the t1/2) in the absence or presence of 1 mM ATP,
0.3 mM BzATP, 1 mM ADP or 1 mM UTP, and cell surface CD23 expression
measured by flow cytometry. Similar to above (Figure 7.6), ATP induced a 37 ± 4% and
57 ± 4% loss of cell surface CD23 from B cells of C57BL/6 and DBA/1 mice,
respectively (Figure 7.7). BzATP induced a 33 ± 8% and 58 ± 5% loss of cell surface
CD23 from B cells of C57BL/6 and DBA/1 mice, respectively, while ADP and UTP
had no effect compared to cells incubated without nucleotide in either mouse strain
(Figure 7.7).

Figure 7.7: ATP and BzATP induce CD23 loss from murine B cells. (A, B) Splenic
cells in NaCl medium were incubated in the absence (basal) or presence of 1 mM ATP,
0.3 mM BzATP, 1 mM ADP or 1 mM UTP at 37°C for 7 min. Incubations were
stopped by addition of MgCl2 medium and centrifugation. Cells were labelled with
APC-conjugated anti-CD19, FITC-conjugated anti-CD23 or isotype control mAb, and
7AAD. The MFI of cell surface CD23 expression on CD19+7AAD- B cells was
determined by flow cytometry. Results are mean ± SD (n = 3 mice);

**

P < 0.01

compared to basal.
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7.2.8 AZ160606120 impairs ATP-induced CD23 loss from murine B
cells
To confirm that ATP-induced loss of CD23 was mediated by P2X7, cells were
preincubated in the absence or presence of 10 µM AZ10606120, and then with ATP,
and cell surface CD23 expression measured by flow cytometry. AZ10606120 impaired
ATP-induced CD23 loss by 95 ± 8% and 97 ± 6% from B cells of C57BL/6 and DBA/1,
mice respectively compared to ATP-induced CD23 shedding in the absence of
AZ10606120 (Figure 7.8). In the absence of ATP, AZ10606120 did not alter CD23
expression in B cells from either mouse strain (Figure 7.8).

Figure 7.8: AZ160606120 impairs ATP-induced CD23 loss from murine B cells. (A,
B) Splenic cells in NaCl medium were preincubated at 37°C for 15 min in the absence
or presence of 10 µM AZ10606120 and then in the absence (basal) or presence of 1 mM
ATP for 7 min at 37°C. Incubations were stopped by addition of MgCl2 medium and
centrifugation. Cells were labelled with APC-conjugated anti-CD19, FITC-conjugated
anti-CD23 or isotype control mAb, and 7AAD. The MFI of cell surface CD23
expression on CD19+7AAD- B cells was determined by flow cytometry. Results are
mean ± SD (n = (A) triplicate values from 1 mouse or (B) 3 mice). **P < 0.01 compared
to corresponding control basal and ††P < 0.01 compared to corresponding ATP alone.
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7.2.9 ATP-induced CD23 loss does not occur in P2X7 knockout mice
Finally, to further confirm a role for P2X7 in ATP-induced CD23 loss, P2X7 knockout
mice were used. Flow cytometric measurements demonstrated that the amount of CD23
expression between control-treated B cells from wild-type and P2X7 knockout mice
was similar (Figure 7.9). In contrast, incubation with 1 mM ATP induced a loss of cell
surface CD23 in B cells from wild-type mice (34 ± 10% loss), but ATP-induced CD23
loss from B cells from P2X7 knockout mice was minimal (8 ± 7% loss) (Figure 7.9).

Figure 7.9: ATP-induced CD23 loss does not occur in P2X7 knockout mice. Splenic
cells from wild-type (WT) or P2X7 knockout (KO) C57BL/6 mice in NaCl medium
were incubated in the absence (basal) or presence of 1 mM ATP for 20 min at 37°C.
Incubations were stopped by addition of MgCl2 medium and centrifugation. Cells were
labelled with APC-conjugated anti-CD19, FITC-conjugated anti-CD23 or isotype
control mAb, and 7AAD. The MFI of cell surface CD23 expression on CD19+7AADB cells was determined by flow cytometry. Results are mean ± SD (n = 3 mice); *P <
0.05 compared to basal control.
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7.2.10 P2X7 activation induces CD23 shedding from B cells of C57BL/6
mice
Staining of fixed and permeabilised cells can be used to assess internalisation of cell
surface receptors (Schmid et al. 1991, Turac et al. 2013). Therefore, to assess if cells are
permeabilised using the method of Schmid and colleagues (Schmid et al. 1991), the
presence of the intracellular molecule Toll-like receptor 9 (TLR-9) was examined in
RPMI 8226 cells. Fixed RPMI 8226 cells, or fixed and permeabilised RPMI 8226 cells
were labelled with an anti-TLR-9 or IgG control mAb and the fluorescence measured by
flow cytometry. TLR-9 was expressed in fixed and permeabilised RPMI 8226 cells but
was minimal on fixed RPMI 8226 cells (Figure 7.10).

Figure 7.10: TLR-9 is expressed in fixed and permeabilised RPMI 8226 cells. RPMI
8226 cells were fixed with paraformaldehyde and labelled with PE-conjugated
anti-TLR-9 or isotype control mAb in the absence (fixed, F) or presence (fixed and
permeabilised, F&P) of Tween-20. The MFI of TLR-9 expression was determined by
flow cytometry. Results are mean ± SD (n = 3); **P < 0.01 compared to control.
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Next, to indirectly assess if the ATP-induced loss of CD23 from murine B cells was a
result of CD23 shedding or internalisation, splenic cells from C57BL/6 mice were
incubated in the absence or presence of 1 mM ATP for 20 min and the expression of
cell surface CD23 on fixed cells, or total CD23 in fixed and permeabilised cells was
measured by flow cytometry. CD23 expression was similar in fixed cells compared to
fixed and permeabilised cells (Figure 7.11A) suggesting that the P2X7-induced loss of
CD23 was due to CD23 shedding rather than internalisation. To directly determine if
the P2X7-induced loss of cell surface CD23 was due to CD23 shedding, splenic cells
from C57BL/6 wild-type and P2X7 knockout mice were incubated in the absence or
presence of 1 mM ATP for 20 min, and the relative amount of soluble CD23 in cell-free
supernatants quantified by ELISA. Incubation of wild-type cells with ATP resulted in a
significantly higher release of soluble CD23 compared with P2X7 knockout cells
incubated with ATP, or cells of either strain incubated in the absence of ATP (Figure
7.11B). Moreover, the amount of soluble CD23 release from P2X7 knockout cells
incubated in the absence or presence of ATP was similar to that of wild-type cells
incubated in the absence of ATP (Figure 7.11B).

7.2.11 The broad spectrum metalloprotease antagonist, BB-94 impairs
P2X7-induced CD23 shedding from human and murine B cells
To determine a role for metalloproteases in P2X7-induced CD23 shedding, human
PBMCs or murine splenic cells were preincubated in the absence or presence of the
broad spectrum metalloprotease antagonist, 1 µM BB-94 (Davies et al. 1993) and then
with ATP, and cell surface CD23 expression measured by flow cytomtery. BB-94
impaired P2X7-induced CD23 shedding from B cells by 66 ± 10%, 100 ± 0% and
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96 ± 6% from human, C57BL/6 and DBA/1 mice, respectively (Figure 7.12). In the
absence of ATP, BB-94 did not alter basal CD23 expression in human and murine
B cells (Figure 7.12).

Figure 7.11: P2X7 activation induces CD23 shedding from B cells of C57BL/6
mice. Splenic cells from (A, B) wild-type (WT) or (B) P2X7 knockout (KO) C57BL/6
mice in NaCl medium were incubated for 20 min at 37°C in the absence (basal) or
presence of 1 mM ATP. (A) Incubations were stopped by addition of MgCl2 medium
and centrifugation. Cells were labelled with APC-conjugated anti-CD19 mAb and
7AAD, and fixed with paraformaldehyde. Fixed cells were then labelled with
FITC-conjugated anti-CD23 or isotype control mAb in the absence (fixed, F) or
presence (fixed and permeabilised, F & P) of Tween-20. The MFI of CD23 expression
in CD19+7AAD- B cells was determined by flow cytometry. (B) Incubations were
stopped by centrifugation and the amount of soluble CD23 in cell-free supernatants
determined by ELISA. Results are mean ± SD (n = (A) 3 or (B) 4 mice);

**

P < 0.01

††

compared to basal control and P < 0.01 compared to ATP.
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Figure 7.12: The broad spectrum metalloprotease antagonist, BB-94 impairs
P2X7-induced CD23 shedding from human and murine B cells. (A) Human PBMCs
and (B) C57BL/6 or (C) DBA/1 murine splenic cells were preincubated in the presence
of (A-C) dimethyl sulphoxide (DMSO) or 1 µM BB-94 and then in the absence (basal)
or presence of 1 mM ATP at 37°C for (A) 6 min or (B, C) 7 min. Incubations were
stopped by addition of MgCl2 medium and centrifugation. Cells were labelled with
APC-conjugated anti-CD19 mAb, PE- or FITC-conjugated anti-CD23 or isotype control
mAb, and 7AAD. The MFI of cell surface CD23 expression on CD19+7AAD- B cells
was determined by flow cytometry. Results are mean ± SD (n = (A) 4 individuals, or
(B, C) 3 mice); *P < 0.05 and **P < 0.01 compared to corresponding basal DMSO, and
††

P < 0.01 compared to corresponding ATP in the presence of DMSO.

7.2.12 The ADAM10 antagonist, GI254023X impairs P2X7-induced
CD23 shedding from human and murine B cells
To determine a role for ADAM10 in P2X7-induced CD23 shedding, human PBMCs or
murine splenic cells were preincubated in the absence or presence of ADAM10
antagonist, 3 µM GI254023X (Ludwig et al. 2005a), and then with ATP, and CD23
expression measured by flow cytometry. GI254023X impaired P2X7-induced CD23
shedding from B cells by 77 ± 20%, 83 ± 29% and 100 ± 0% from human, C57BL/6
and DBA/1 mice, respectively (Figure 7.13). GI254023X did not alter basal CD23
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expression in human or DBA/1 B cells (Figure 7.13A, C). In contrast, GI254023X
significantly increased basal CD23 expression on C57BL/6 B cells (Figure 7.13B).

Figure 7.13: The ADAM10 antagonist, GI254023X impairs P2X7-induced CD23
shedding from human and murine B cells. (A) Human PBMCs, and (B) C57BL/6 or
(C) DBA/1 murine splenic cells were preincubated in the presence of (A-C) DMSO or
3 µM GI254023X and then in the absence (basal) or presence of 1 mM ATP at 37°C for
(A) 6 min or (B, C) 7 min. Incubations were stopped by addition of MgCl2 medium and
centrifugation. Cells were labelled with APC-conjugated anti-CD19 mAb, PE- or
FITC-conjugated anti-CD23 or isotype control mAb, and 7AAD. The MFI of cell
surface CD23 expression on CD19+7AAD- B cells was determined by flow cytometry.
Results are mean ± SD (n = (A) 3 individuals, or (B, C) 3 mice); *P < 0.05 and
**

P < 0.01 compared to corresponding basal DMSO, and

††

P < 0.01 compared to

corresponding ATP in the presence of DMSO.

7.3 Discussion
Data from this chapter shows for the first time that P2X7 activation induces the rapid
shedding of CD23 from primary human and murine B cells. This was confirmed by a
series of experiments. First, ATP induced the rapid loss of cell surface CD23 shedding
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with a t1/2 of approximately 6 and 7 min from human and murine B cells, respectively.
Second, the most potent P2X7 agonist BzATP also induced the rapid loss of cell surface
CD23, whereas the non-agonists ADP and UTP had no effect. Third, a specific P2X7
antagonist, AZ10606120 (Michel et al. 2008), almost completely impaired the
ATP-induced cell surface CD23 loss from both human and murine B cells. Fourth, ATP
failed to induce CD23 loss from B cells from C57BL/6 P2X7 knockout mice. Finally,
measurements of soluble CD23 (as well as total CD23 expression for murine B cells)
indicated that cell surface loss of CD23 was due to shedding from both human and
murine B cells.

Using the ADAM10 inhibitor, GI254023X (Ludwig et al. 2005a), data from this chapter
shows that P2X7-induced CD23 shedding from human and murine B cells is mediated
by ADAM10. This finding is consistent with a role for ADAM10 in P2X7-induced
CD23 shedding from RPMI 8226 cells (Chapter 6). A potential role for ADAM10 in
P2X7-induced CD23 shedding from primary B cells is indirectly supported by other
studies. ATP-induced CD23 shedding from human leukaemic monocytic U937 cells
(Lemieux et al. 2007), and BzATP-induced CD23 shedding from Chinese hamster
ovary cells (Le Gall et al. 2009) and murine B cells (Le Gall et al. 2010), are also
mediated by ADAM10. Like with P2X7-induced CD23 shedding from RPMI 8226 cells
(Chapter 6), the possibility remains that other metalloproteases may also be involved in
P2X7-induced CD23 shedding from human and murine B cells. ADAM 8, 15, 28 and
33 have been associated with constitutive CD23 shedding from CD23-transfected
HEK 293 cells (Fourie et al. 2003) and primary murine embryonic fibroblasts
(Weskamp et al. 2006), although ADAM10 was identified as the principal sheddase of
CD23 (Weskamp et al. 2006).
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The current chapter also demonstrates the presence of functional P2X7 on murine B
cells from both C57BL/6 and DBA/1 mice. Although the presence of functional P2X7
on human B cells is well established (Gu et al. 2000, Gu et al. 2001, Sluyter et al. 2001),
reports of functional P2X7 on murine B cells are limited, with some studies indicating
murine B cells do not respond to ATP (Chused et al. 1996, Tsukimoto et al. 2006) nor
express P2X7 (Chused et al. 1996, Taylor et al. 2009a). In the current chapter, P2X7
activation induced CD23 shedding from murine B cells. Moreover, ATP was shown to
induce YO-PRO-12+ uptake into murine B cells, and that the process was impaired by
AZ10606120. Consistent with this result, ATP fails to induce YO-PRO-12+ uptake into
B cells from P2X7 knockout mice (Geraghty and Sluyter, personal communication). Of
note, the relative amounts of P2X7-mediated YO-PRO-12+ uptake and rates of
P2X7-mediated CD23 shedding were similar between C57BL/6 and DBA/1 mice. This
similar amount of relative P2X7 function most likely reflects the presence of the partial
loss-of-function mutation P451L in both of these strains (Adriouch et al. 2002, Syberg
et al. 2012).

Fixation and permeabilisation of murine splenic cells was used to show that
P2X7-induced CD23 loss from murine B cells was due to shedding rather than
internalisation. This was assessed using the method published by Schmid and
colleagues (Schmid et al. 1991), due to the initial unavailability of an ELISA for murine
soluble CD23. TLR-9 is expressed intracellularly in RPMI 8226 cells (Takeshita et al.
2004) and was used to validate this method. This method showed that P2X7 activation
induces the shedding, rather than internalisation of CD23 from splenic murine B cells.
During the course of this investigation, a murine CD23 ELISA became available and

170

was used to confirm that P2X7 activation induces the shedding of CD23 from splenic
cells.
In conclusion, data from this chapter demonstrates human and murine P2X7 activation
induces the rapid shedding of CD23 from B cells. Moreover, the data indicates a role for
ADAM10 in this process.
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CHAPTER 8
Conclusions and
significance
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8.1 Conclusions and significance
Purinergic signalling induces an array of cellular processes and physiological responses,
including inflammation and other pathological conditions (Lazarowski et al. 2003,
Burnstock 2007). Purinergic signalling is mediated by extracellular nucleotides and
nucleosides that activate P2 receptors (Lazarowski et al. 2003, Burnstock 2007). The
P2X7 receptor is a ligand-gated cation channel, which is expressed on a variety of cell
types, including B cells (Lenertz et al. 2011, Wiley et al. 2011). Adenosine
5’-triphosphate (ATP) activation of P2X7 allows a flux of cations across the cell
membrane (Surprenant et al. 1996, Rassendren et al. 1997, Chessell et al. 1998b).
Prolonged ATP activation induces cell permeabilisation or pore formation, which
allows the uptake of large cations including ethidium+ and YO-PRO-12+ (Jiang et al.
2005, Cankurtaran-Sayar et al. 2009). P2X7 activation also induces a variety of
downstream events including interleukin (IL)-1 secretion (section 1.4.5.1), cell death
and proliferation (section 1.4.5.2), transcription factor activation (section 1.4.5.3),
reactive oxygen species (ROS) formation (section 1.4.5.4) and membrane-related
changes (section 1.4.5.5), including the shedding of cell surface molecule, CD23
(section 1.5). Prior to the commencement of this thesis it was known that a disintegrin
and metalloprotease (ADAM) 10 constitutively sheds CD23 from the surface of cells
(Weskamp et al. 2006, Lemieux et al. 2007), however it was unknown if P2X7-induced
CD23 shedding involved ADAM10. Also, prior to this thesis, P2X7 was recognised to
play a role in ATP-induced CD23 shedding from malignant B cells (Gu et al. 1998) and
cultured dendritic cells (Sluyter and Wiley 2002), but whether this process occurred in
primary B cells was unknown.
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Previous preliminary data from our laboratory indicated that the RPMI 8226 multiple
myeloma B cell line express P2X7 and CD23, and that P2X7 activation induced CD23
shedding from these cells (Farrell 2008). Data from Chapter 3 of this thesis confirmed
the presence of functional P2X7 on RPMI 8226 cells and also confirmed that P2X7
activation induces CD23 shedding from these cells. Moreover, data from this chapter
revealed that P2X7 function in RPMI 8226 cells is sensitive to extracellular cations, and
is increased in both KCl and sucrose medium. This modulation of P2X7 function
corresponds with published studies, which showed that extracellular cations impair
P2X7 function (Wiley et al. 1992, Michel et al. 1999), while KCl and sucrose medium
(due to an absence of Na+) increases P2X7 function (Michel et al. 1999). This chapter
also showed that the new generation P2X7 antagonists A-438079 (Nelson et al. 2006),
AZ10606120 (Michel et al. 2008) and AZ11645373 (Stokes et al. 2006), which were
well-characterised using recombinant P2X7, are also potent antagonists of endogenous
P2X7 in RPMI 8226 cells. In particular, AZ10606120 near-completely impaired both
ATP-induced ethidium+ uptake (pore formation) and CD23 shedding (Chapter 3). In
summary, results from this chapter validated the use of the RPMI 8226 cell line as a
suitable model to study the molecules and processes involved in P2X7-induced CD23
shedding.

Using a candidate approach (Chapter 4), it was shown that several signalling pathways
involved in P2X7-induced responses, as well as changes in intracellular cation
concentrations, which affect P2X7-induced responses, were not involved in
P2X7-induced CD23 shedding from RPMI 8226 cells. Future studies, using large
antagonist libraries and a high throughput assay may prove a more useful approach to
identify potential signalling pathways in P2X7-induced CD23 shedding. During this
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thesis, the ROS, mitochondrial superoxide, was shown to enhance P2X7-induced
CD62L shedding from T cells (Foster et al. 2013), suggesting that ROS may also play a
role in P2X7-induced CD23 shedding. However, ROS-inducing compounds did not
affect P2X7-induced CD23 shedding from RPMI 8226 cells (Chapter 5). Although ROS
produced as a result of these compounds did not seem to play a role in P2X7-induced
CD23 shedding, P2X7 activation induced significant ROS formation in RPMI 8226
cells (Chapter 5). ROS formation after ATP treatment is involved in the ATP-induced
shedding of transforming growth factor-α (Myers et al. 2009), and therefore it is
possible that ROS formation after P2X7 activation influences CD23 shedding.
However, in this case, it is unlikely, as the ROS inducing compounds
diphenyleneiodonium and rotenone (Foster et al. 2013), which have also been used as
ROS inhibitors (Seil et al. 2008, Wang and Sluyter 2013) did not alter P2X7-induced
CD23 shedding from RPMI 8226 cells (Chapter 5). Thus neither this line of
investigation nor the source of ROS formed downstream of P2X7 activation was
examined further. There is also a lack of data showing a role for P2X7-induced ROS
formation in primary B cells, thus it would be of interest to determine whether P2X7
activation induces ROS formation in primary B cells, and if so to determine the origins
and biological significance of P2X7-induced ROS formation in these cells.

The phospholipase D (PLD) antagonists halopemide, CAY10593 (VU0155069) and
CAY10594 significantly impaired CD23 shedding from RPMI 8226 cells by blocking
P2X7 directly (Chapter 4). CAY10593 and CAY10594 impaired P2X7 at
concentrations higher than previously used to directly target PLD (Scott et al. 2009).
The PLD1 antagonist CAY10593, was particularly potent, impairing P2X7
independently of PLD1, with a half maximal inhibitory concentration (IC50) of
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approximately 2 µM (Chapter 4), which is similar, or lower to the IC50 values of the
non-selective P2 receptor antagonists pyridoxal phosphate-6-azophenyl-2-4-disulphonic
acid (PPADs) and suramin, respectively (Chessell et al. 1998a). This suggests that the
CAY10593 scaffold may be useful in the future design of new P2X7 antagonists.
Several potent P2X7 compounds have been created in this manner, including MRS 2540
which was based on the KN-62 scaffold (Lee et al. 2008, Hu et al. 2010). Furthermore,
this data also indicates that it is becoming increasingly important to ensure that
antagonists used in signalling studies do not directly affect P2X7. A growing list of
compounds that target signalling molecules downstream of P2X7 have been shown to
impair P2X7, including the protein kinase C antagonists, chelerythrine (Shemon et al.
2004) and Ro 31-8220 (Shemon et al. 2007), and the mitogen activated protein kinase
antagonists, SB203580 and SB202190 (Michel et al. 2006).

Data from this thesis also showed that the pannexin-1 antagonist, probenecid
(Silverman et al. 2009), impaired ATP-induced ethidium+ uptake (Chapter 3), but not
ATP-induced CD23 shedding from RPMI 8226 cells (Chapter 4). The reason for this
remains unknown, however probenecid impaired ATP-induced ethidium+ uptake by less
than 50% (Chapter 3) and may be less effective at impairing events downstream of
P2X7 activation such as ATP-induced CD23 shedding. Consistent with this, CAY10593
is a more potent blocker of ATP-induced ethidium+ uptake than ATP-induced CD23
shedding (Chapter 4). However, CAY10594 and halopemide, which weakly impaired
ATP-induced ethidium+ uptake, also weakly impaired ATP-induced CD23 shedding
(Chapter 4). An alternate explanation for the observations with probenecid, is that this
compound may impair P2X7-mediated events dependent on ion fluxes but not those
independent of ion fluxes, such as ATP-induced CD23 shedding. Recent data indicates
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that probenecid impairs both P2X7-induced channel activity and dye uptake
independently of pannexin-1 in P2X7-transfected HEK 293 cells (Bhaskaracharya et al.
2014). Further, probenecid also impairs P2X7-mediated IL-1β release (Bhaskaracharya
et al. 2014), a process dependent on K+ efflux (Perregaux and Gabel 1994). If this is the
case, probenecid may be a useful tool to segregate P2X7-mediated events dependent on
ion fluxes from those not dependent on ion fluxes.

For the first time, data from this thesis showed that ADAM10 mediates P2X7-induced
CD23 shedding from RPMI 8226 cells (Chapter 6), and from primary murine and
human B cells (Chapter 7). Remarkably, the rate of P2X7-induced CD23 shedding from
human and murine B cells was similar to that observed for RPMI 8226 cells
(t1/2 of ~7 min) (Chapters 3 and 7). This indirectly supports the involvement of a
common mechanism. Also for the first time, data from this thesis showed that P2X7
activation induces the shedding of CXCL16 (Chapter 6), another ADAM10 substrate
(Abel et al. 2004, Gough et al. 2004, Ludwig et al. 2005b, Hundhausen et al. 2007),
confirming that P2X7 activates ADAM10. To further confirm a role for ADAM10 in
P2X7-induced CD23 shedding, several attempts were made to knockdown ADAM10
using short inhibitory RNA (siRNA) in RPMI 8226 cells. These however, were
unsuccessful due to the difficulty of transient transfection of these cells (results not
shown). A recent study outlines a more efficient way of transiently transfecting siRNA
into multiple myeloma cells using electroporation (Steinbrunn et al. 2014), which will
be of use for future experiments.
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The possibility remains that other metalloproteases may also be involved in
P2X7-induced CD23 shedding from human and murine B cells. ADAM 8, 15, 28 and
33 have been associated with constitutive CD23 shedding from CD23-transfected
HEK 293 cells (Fourie et al. 2003) and primary murine embryonic fibroblasts
(Weskamp et al. 2006), although ADAM10 was identified as the principal sheddase of
CD23 (Weskamp et al. 2006). To assess whether any of these metalloproteases affect
P2X7-induced CD23 shedding, future experiments should determine whether these are
expressed in RPMI 8226 cells, and using siRNA knockdown (with electroporation),
assess the effects of these ADAMs on P2X7-induced CD23 shedding. The involvement
of these metalloproteases downstream of P2X7 activation is also further complicated by
their ability to induce the shedding of ADAM10 from cells (Tousseyn et al. 2009).
Currently, there is no indication that P2X7 activation induces the shedding of
ADAM10, however, an enzyme-linked immunosorbent assay or immunoblotting could
be used to examine this.

As noted above, the candidate approach used in Chapter 4 failed to identify potential
intracellular signalling molecules involved in P2X7-induced CD23 shedding. Thus, the
possibility remains that P2X7 activation induces cell surface CD23 shedding through
the colocalisation of ADAM10 and CD23, rather than by directly stimulating ADAM10.
ADAM10 has been shown to colocalise with CD44, the hyaluronic acid receptor
(Anderegg et al. 2009), a molecule that is also shed after P2X7 activation (Lin et al.
2012). Confocal microscopy could be used in future studies to determine whether
ADAM10 colocalises with CD23 following P2X7 activation.
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Data from this thesis also showed for the first time the presence of three
non-synonymous P2X7 single nucleotide polymorphisms (SNPs) in RPMI 8226 cells;
the A348T gain-of-function SNP (Cabrini et al. 2005, Roger et al. 2010, Stokes et al.
2010), the A433V SNP, which may be an additional gain-of-function SNP (Roger et al.
2010, Stokes et al. 2010) and the H521Q SNP, which partly impairs P2X7 channel
activity (Roger et al. 2010). The presence of these gain-of-function SNPs may account
for the large amount of ATP-induced ethidium+ uptake in RPMI 8226 cells relative to
other cell lines (Farrell 2008, Pupovac 2009, Gadeock 2010). It would be of interest to
assess whether P2X7 SNPs affect P2X7-induced CD23 or CXCL16 shedding. Studies
have shown that the P2X7 loss-of-function SNP, G496A is associated with a slower
ATP-induced loss of CD23 from human monocyte-derived dendritic cells (Sluyter and
Wiley 2002), and CD62L from human CD4+ and CD8+ T cells (Sluyter and Wiley
2014), while the gain-of-function SNP A348T, is associated with increased IL-1β
secretion from lipopolysaccharide (LPS)-primed human monocytes (Stokes et al. 2010).
Furthermore, it would also be of future interest to determine if P2X7 splice variants
(Cheewatrakoolpong et al. 2005, Adinolfi et al. 2010) mediate ATP-induced CD23 or
CXCL16 shedding.

A previous study has shown that LPS can induce CD23 shedding from human and
murine B cells, and that this process is mediated by Toll-like receptor 4 (TLR4) and
matrix metalloprotease 9 (Jackson et al. 2009). However it remains unlikely that LPS,
potentially present in the reagents used, was responsible for the ATP-induced CD23
shedding observed in the current study. First, ATP induced the rapid (< 30 min)
shedding of CD23 (Chapters 3 and 7); in contrast LPS induces the slow (24 h) shedding
of CD23 (Jackson et al. 2009). Second, ADP and UTP (prepared in the same solution as
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those for ATP) failed to induce CD23 shedding (Chapter 7). Third, ATP-induced CD23
shedding was impaired by P2X7 antagonists from both RPMI 8226 cells (Chapter 3)
and primary B cells (Chapter 7), as well as in B cells from P2X7 knockout mice
(Chapter 7). Nevertheless, future studies using B cells from either C3H/HeJ mice, which
are hyporesponsive to LPS due to single point mutation in the TLR4 gene (Hoshino et
al. 1999), or TLR4 knockout mice will be of value to address this potential issue further.

There is a possibility that ATP-induced CD23 shedding is an early event of
P2X7-mediated apoptosis. In the current study, 30 min incubation with ATP caused a
small but significant amount of apoptosis, determined by forward scatter (cell
shrinkage) and 7AAD uptake (loss of membrane integrity) (Philpott et al. 1996), in
primary murine but not primary human B cells compared to respective B cells incubated
in the absence of ATP (results not shown). In contrast, human and murine B cell
apoptosis was not increased following 6-7 min treatment with either ATP or BzATP
compared to control treatment, nor was B cell apoptosis increased following incubation
with AZ10606120 in the absence or presence of ATP (results not shown). Furthermore,
control and ATP-treated RPMI 8226 cells showed similar gated percentages
continuously throughout experiments. Nevertheless, given that P2X7 activation can
induce apoptosis at 24h in human peripheral blood mononuclear cells (Gu et al. 2001),
murine splenic cells (Tsukimoto et al. 2006) and RPMI 8226 cells (Farrell 2008), the
possibility remains that ATP-induced CD23 shedding is an early upstream event in
P2X7-mediated apoptosis of B cells.
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Human genetic (Portales-Cervantes et al. 2012, Lester et al. 2013) and murine model
studies (Labasi et al. 2002, Woods et al. 2012) suggest a role for P2X7 in rheumatoid
arthritis and Sjogren’s syndrome. The role of P2X7 in these disorders has largely been
attributed to the release of the proinflammatory cytokines, IL-1β and IL-18 (Labasi et
al. 2002, Baldini et al. 2013). However, synovial soluble CD23 (Huissoon et al. 2000,
Ribbens et al. 2000) and CXCL16 (Ribbens et al. 2000, Nanki et al. 2005) are elevated
in patients with rheumatoid arthritis, and circulating soluble CD23 is elevated in
Sjogren’s syndrome (Bansal et al. 1992). Moreover, B cells also play major roles in the
pathogenesis of these disorders (Bendaoud et al. 1991, Schellekens et al. 1998). Thus,
the possibility remains that P2X7-induced shedding of proinflammatory soluble CD23
and CXCL16 from B cells may also be involved in rheumatoid arthritis, Sjogren’s
syndrome or other disorders. However, evidence directly linking B cells, P2X7, CD23
and CXCL16 in inflammatory and autoimmune disease is lacking.

Overall, this study shows, for the first time that ADAM10 mediates P2X7-induced
CD23 and CXCL16 shedding from RPMI 8226 cells, as well as CD23 from primary
human and murine B cells (Figure 8.1). Moreover, this study excludes a potential role
for various signalling molecules including ROS and the flux of various cations in
P2X7-induced CD23 shedding. Finally, this study shows that the PLD1 antagonist,
CAY10593 (VU0155069), impairs P2X7 independently of PLD1 (Figure 8.1).
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Figure 8.1: Summary schematic of the main findings in this thesis. ADAM10
mediates P2X7-induced CD23 and CXCL16 shedding from RPMI 8226 B cells, as well
as CD23 from primary human and murine B cells. RPMI 8226 cells express P2X1,
P2X4, P2X5, PLD2 and ADAM10 mRNA. The PLD1 antagonist, CAY10593
(VU0155069), impairs P2X7-induced CD23 shedding, P2X7 channel and pore
formation independently of PLD1. Abbreviations: ATP, adenosine 5’-triphosphate; ADAM, a
disintegrin and metalloprotease, Eth+, Ethidium+, PLD, phospholipase D; sCD23, soluble CD23;
sCXCL16, soluble CXCL16.
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